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Abstract 
The ability of bacteria to constantly evolve new methods of resistance to antibacterial 
therapies represents a constant challenge in medicine. Emergence of strains of 
enterococci and S. Aureus that show resistance to vancomycin is an alarming 
phenomenon, as vancomycin represents the last line of defence against pathogens with a 
significant level of resistance to all other available therapies, methicillin resistant S. 
Aureius (MRSA) being a prime example of such a pathogen. 
Vancomycin has a number of significant advantages as a drug therapy. It exploits a 
target that is not found in the host cells, the cell wall. It does this by inhibiting 
transpeptidation, which blocks murein biosynthesis, destabilising the cell wall and 
allowing the internal osmotic pressure of the cell to cause the cell membrane to rupture, 
killing the cell. The target of vancomycin is on the outside of the cell, so it is not 
affected by the membrane bound efflux pumps that induce multi-drug resistance. 
Therefore the only mechanism of resistance available is alteration of the target. Two 
such resistance mechanisms exist and if these can be overcome, the analogues of 
vancomycin that achieve this should be less prone to drug resistance than any other 
existing therapy. 
This work represents the first step towards such a goal, and is the first example of the 
application of rational drug design to complex natural product drugs, like vancomycin. 
This project used an X-ray crystal structure of vancomycin complexed to a mimic of the 
cell wall peptide. This structure was used in conjunction with the de notvo design 
program SPROUT as the basis for molecular design, in order to create analogues of 
vancomycin that were predicted to offer increased affinity for the tripeptide cell wall 
mimic. Five such designed molecular templates were created and assessed for synthetic 
feasibility. One of these templates was selected and synthesised. This analogue 
prompted a second design phase which produced a further three molecular templates, 
two of which were also synthesised. The efficiency of these modified vancomycins to 
bind the target tripeptide was assessed using nanoelectrospray ionisation - mass 
spectrometry. It was found that all the analogues produced offered increased binding 
efficiency as compared to vancomycin tested under the same conditions. This work 
paves the way to exploring the use semi-synthetic derivatives of vancomycin as novel 
therapeutic agents. 
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Chapter One 
Project Introduction 
1.1 Introduction 
In order to design good drug treatments, it is important to understand the nature of the 
disease processes involved. This is as true in the field of antibiotics, as it is in any other 
area of medicinal chemistry. Therefore an understanding of the structure of bacteria and 
their biochemistry is a crucial tool in antibacterial drug design. In particular. knowledge 
of the inherent differences between pathogenic bacterial cells and cells of their 
mammalian hosts is invaluable when attempting to produce drugs that are able to 
selectively damage bacterial cells, whilst minimising disruption to the host cell's 
biochemistry. 
1.2 Bacteria 
Bacteria are probably the most abundant form of life on the planet and billions live on 
the skin and in the intestinal track of every animal. Most of these are benign and even 
beneficial, helping in digestion. Occasionally, they are pathogenic and infection 
causing. This may be the result of bacteria normally present growing out of control, like 
the enterococci in Pseucloniembr-czous colitis, or by introduction of a pathogenic 
species such as E. coli, which causes food poisoning or S. aureits, which infects 
wounds. Bacteria are prokaryotic and all share a similar cell construction. Shown below 
is a depiction of a typical bacterial cell (Figure 1.1 ). 
Cap 
Cell 
Cyt 
Mei 
R 
Figure I. I. A typical cell. 
Some of these features are highly variable like the pili and flagella. but most are highly 
conserved. The more conserved structures are of more interest as antibacterial targets. 
The most highly conserved portions are: 
The nucleoid, this is the condensed form of the bacterial chromosome. It is a single 
double helix of DNA, that codes for all the major structures of the bacteria. There are 
secondary DNA elements called plasmids, which are present in most bacteria, which 
code for extra features and are very important in bacterial resistance. This is 
significantly different to humans who have 46 chromosomes and cannot make plasmids. 
Ribosomes, these freely-floating structures are responsible for protein synthesis. 
Cytoplasm, this is predominantly water and contains nutrients and additional 
components. 
The cell membrane encloses the cytoplasm and controls movement of material in and 
out of the cell. There maybe one or two of these depending on the type of bacteria. 
The cell wall, provides mechanical stability to the cell, preventing lysis by osmotic 
pressure when the cell is in a solution that is more dilute than the cytoplasm (a 
hypotonic solution). ' 
The least conserved portions: 
The capsule, also termed the slime layer, is a gelatinous polysaccharide layer that 
encases the cell and provides a defence against the immune response of higher 
organisms. 
Pili, are used in cell-to-cell recognition, allowing conjugation, a simplified from of 
sexual interaction where DNA is transferred but reproduction does not occur. They also 
allow invading bacteria to attach to the host cells. 
Flagella, these whip-like appendages facilitate motion and more than one maybe 
present on the cell. ' 
3 
1.3 Potential targets and existing therapies 
1.3.1 Nucleic acid synthesis 
The nucleic acid structure is significantly different in bacteria and mammalian cells. 
However, the genetic information needed to code for cell structures is stored as DNA 
and utilises transcription to RNA and translation to proteins as in eukaryotic cells. 
Although the processes are similar in both cell types, there are considerable differences 
as prokaryotic bacterial cells have different enzymes to construct and manipulate their 
DNA and RNA. 
These differences can be exploited in order to target pathogenic bacterial cells whilst 
having a minimal effect on the eukaryotic cells of the host. The two major opportunities 
for interfering with the nucleic acid synthesis in bacteria utilise these enzymatic 
differences between prokaryotic and eukaryotic cells. The first is direct interference 
with the enzymes responsible for RNA and DNA synthesis. The second involves 
indirectly interfering with nucleic acid synthesis by inhibition of folic acid production. 
Folic acid is an important co-factor in nucleic acid synthesis, but it is also important in 
many other cell functions and is therefore discussed in detail later. 
1.3.1.1 DNA replication2'3 
DNA replication occurs during mitotic cell division, where one bacterial cell copies its 
chromosome and divides into two daughter cells. It also takes place during plasmid 
replication whilst in conjugation to a second bacterial cell. Both of these processes rely 
on a large number of enzymes, but are subtly different and as conjugation is not vital for 
cell viability, only the effects on chromosome replication are considered here. 
Of the many enzymes involved in DNA replication, two can be exploited as targets for 
inhibition of nucleic acid synthesis, they are: Topoisomerase II (also known as DNA 
gyrase, T-II) and Topoisomerase IV (T-IV). 4-7 
T-II is responsible for the negative supercoiling of DNA within the chromosome during 
replication. 4 6 This is an ATP dependent process, where one strand of the DNA helices 
4 
being produced is broken transiently to allow the other double helical strand to be 
passed through it, the helix i, then rejoined without disruption to its genetic sequence. 
This relieves the strain produced in the newly formed DNA chains, a strain that arises 
due to the action of helicases, which unwind the double stranded helix into single 
stranded DNA allowing base pairing for replication. Once fully replicated, the 
intertwined DNA intermediates are freed from the enzyme and are described as 
catenated, this means that the two daughter DNA chromosomes are physically 
interlocked. 
T-IV is responsible for decatenation, ' which is also an ATP dependent process where 
one double strained helix is transiently cleaved and the other double stranded DNA 
helix is passed through the gap. The first strand is then rejoined and the two 
chromosomes are entirely separate. They can then be moved apart into the forming 
daughter cells, thus allowing the completion of cell replication. 
1.3.1.2 Inhibitors of DNA replication 
Novobiocin is an antibiotic derived from Streptomvices nit'errs. It binds to T-II and 
prevents hydrolysis of ATP. As ATP hydrolysis is a crucial step in the enzymatic 
pathway providing the energy for the enzyme to perform its function, this inhibits T-[I 
blocking enzyme activity and terminating DNA replication (Figure 12). 
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Figure 1.2. Novobiocin. 
Another important class of drugs are the fluoroquinolones, which act by inhibiting 
either T-II or T-IV. Their specific activity depends on their structure and on the 
bacterial species, two members of this drug family are ciprofloxacin and sparfloxacin 
(Figure 1.3). Ciprofloxacin's primary mode of action is inhibition of T-II in Gram- 
negative pathogens and T-IV in Gram-positive pathogens, yet sparfloxacin, which is 
only slightly different in structure, inhibits T-IV as its primary mode of action in Gram- 
positive bacteria. 5 In all cases these drugs work by stabilising the complex betvv een the 
enzyme and the cleaved DNA strand, enhancing their ability to cleave DNA and thus 
turning the enzyme into a physiological poison. 
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Figure 1.3. Fluoroquinolone antibacterials! 
1.3.1.3 RNA synthesis8'9 
RNA synthesis is a fundamental step in the cell cycle. It is intimately involved in the 
production of proteins and inhibition of RNA synthesis leads to rapid cell death by 
depletion of critical cell proteins. There are three predominant types of bacterial RNA: 
ribosomal RNA (rRNA), transfer RNA (tRNA) and messenger RNA (mRNA). These 
are also utilised in mammals and in both cases they are vital in the processes of 
transcription and translation, converting DNA into RNA and then RNA into proteins. 
However there are again enzymatic differences that can be exploited. In eukaryotic cells 
there are at least three RNA polymerases, for example human cells produce five, 
whereas bacterial cells posses only one. RNA polymerases are the enzymes responsible 
for joining one RNA base to the next to produce an RNA chain. The single RNA 
polymerase (RNAp) of bacteria is structurally similar to RNA polymerase I (RNAp-I) 
of eukaryotes. They have similar functions, as they are both DNA dependant RNA 
polymerises. Despite this, there are sufficient differences in their structures, which 
means that drug therapies which inhibit one have a minimal effect on the other. 
1.3.1.4 Inhibitors of RNA synthesis 
One inhibitor of the bacterial RNAp is rifampicin (Figure 1.4). Rifampicin works by 
blocking the channel that the elongating RNA proceeds along in the enzyme active site, 
thus preventing the elongation stage of RNA synthesis. This forces the release of the 
RNA strand after only two RNA bases have been joined. 10 This effectively terminates 
RNA synthesis and as a result protein production. 
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Figure 1.4. Rifampicin. " 
1.3.2 Protein synthesis 
Protein synthesis is one of the most significant aspects of the bacterial life cycle and in 
fact the life cycle of any cell, prokaryotic or eukaryotic. However this is significantly 
accentuated by the rapid growth of bacteria and the consequential high demand for 
protein production. In addition to their involvement in the cell structure, enzymes are 
proteins that catalyse essentially all cellular reactions and they are associated with the 
cell membranes to allow the uptake of nutrients, the expulsion of wastes and cell-to-cell 
interactions. Therefore any interruption to their production is highly damaging to cell 
growth. 12,13 
1.3.2.1 Ribosomes 
Protein synthesis is facilitated by ribosomes, which are structure,, that are freely-floating 
in the bacterial cytoplasm and are composed of two subunits, each of which is a 
combination of ribosomal RNA and polypeptide chains. The significance of protein 
synthesis can be demonstrated by the prevalence of these structures in the bacterial cell. 
E. coli typically contain some 15 to 20 thousand of these structures, approximately 15ýý 
of the cell mass. 1 2.13 
The subunits are described as 30S and 50S and associate to give the complete ribosome, 
which is 70S. In this instance S stands for Svedberg unit, which is a measure of 
sedimentary velocity and is an expression of the particles density. It describes how fast 
a given particle will precipitate by centrifugation. ' 2.13 
The 30S subunit is smaller than the 50S component and contains one strand of rRNA, 
16S, and 21 peptide chains. The 50S subunit contains two strands of rRNA, one 5S and 
7 
one 23S, and has 34 peptide chains. In both cases these components arrange in a highly 
organised way to produce the specific shape of each type of sub-unit. The distinct 3D 
shape of each sub-unit is highly conserved. This is crucial as the active site for 
translation is formed at the interface of these two subunits when they associate 
(Figure 1.5). 12'13 
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Figure 1.5. The 70S ribosome and its constituents. ' 
1.3.2.2 The synthetic sequence 
The sequence of protein synthesis can be described as a three step series. It begins with 
initiation, the assembly of mRNA, the ribosome and an initiator. It then progresses 
through elongation, where the codon sequence is read sequentially and the 
corresponding amino acid assembled, and finishes with termination where the 
assembled protein is released and the mRNA and ribosome disengage from each other. 
However, before these sequences can be explained it is necessary to describe some 
important features of tRNA and mRNA. 1 2' '3 
mRNA is essentially the blue-print of a protein, describing the linear structure of a 
protein. It works via codons, which are specific sequences of three adjacent base pairs 
that code for a single amino acid. They are read from the 5' end of the mRNA and code 
the protein from the N-terminus to the C-terminus. Three bases are necessary for each 
8 
L. 
codon as this leads to 64 possible combinations of base sequences (2 bases would gi\ e 
only 16 possibilities), this allows the system to code for the twenty different amino 
acids with some remaining codes to start and stop the process. Each of the amino acids 
have at least one distinct codon that codes for it in mRNA. but some are encoded by 
multiple codons. However any codon will only ever code for one amino acid. There is 
one codon for initiation (AUG), which also codes for methionine. All proteins begin 
with methionine although this maybe removed by post-translational protein 
modification. There are three codons that do not code for amino acids, these are 
described as stop and cause termination of peptide synthesis. 12.13 
tRNA is responsible for the positioning of amino acids in conjunction with mRNA. To 
facilitate this, tRNA possesses an anti-codon which is the reciprocal code to that of the 
codon on mRNA. Again, each anti-codon codes for only one amino acid. The 
arrangement of the anti-codon of tRNA, so that it base pairs with the codon of the 
mRNA, ensures the correct orientation of amino acids in peptide synthesis. The tRNA 
helps activate the amino acid, as they are acylated onto the 3'-hydroxy position of the 
ribose sugar of the terminal adenine base of the tRNA (all tRNA finish in adenine), to 
produce an aminoacyl-tRNA. This positions the ester bond that couples the amino acid 
to the tRNA in the correct position to fit into the peptidyl transferase domain of the 
ribosome, where it is activated and the tRNA can easily be displaced. 12.13 
Initiation 
Initiation (shown in Figure 1.6) begins with the 30S sub-unit binding N- 
formylmethionyl-tRNA (tMet-tRNA), the interface of this complex presents the anti- 
codon of the tRNA and the 3' end of the 16S rRNA, together these form a binding site 
for the mRNA, the first codon pairs with the anti-codon of the tRNA. This pairing is 
usually AUG for the codon and gives UAC as the corresponding anti-codon on the 
tRNA, but it can also be GUG giving CAC as the anti-codon. The 50S subunit then 
binds to this to form the active ribosome-mRNA complex. ' 2,13 There are extra proteins 
involved in this sequence called initiation factors (IF) and these help to control the 
sequence of binding, in prokaryotes there are three of these, in eukaryotes there are 
more. They are numbered 1-3 in prokaryotes; IF-3 prevents binding of the 50S and 30S 
subunits before mRNA binding and promotes correct binding of the mRNA. IF-2 binds 
guanidine tri-phosphate (GTP) and fMet-tRNA directing the attachment of the tMet- 
tRNA to the 30S sub-unit and displacing IF-3. IF-1 appears to direct the addition of the 
9 
50S sub-unit, which results in the hydrolysis of GTP to guanidine di-phosphate (GDP) 
IF- I then permits the loss of IF-2 and GDP to from the complete 70S ribosome-mRNA 
complex. ' 2,13 
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Figure 1.6. The initiation of protein synthesis. " 
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Elongation 
Elongation is a cyclic process consisting of three steps, aminoacyl-tRNA binding, 
transpeptidation and translocation, which are repeated until every amino acid of the 
peptide has been added, as shown in Figure 1.7. These steps also rely on protein co- 
factors which are referred to as elongation factors (EF). 1-. 1- 
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Aminoacyl-tRNAs can be bound in three sites on the ribosome-mRNA complex. they 
are described as the peptidyl site (P site), the aminoacyl site (A site) and the exit site (E 
site) respectively. The tRNA carrying the growing peptide chain is alwaý s in the P site 
at the beginning of any elongation cycle (or fMet-tRNA if it's directly after initiation), 
the A site then takes the incoming aminoacyl-tRNA. For all cases the anti-codon of the 
tRNA must be complementary to the codon on the mRNA, ensuring the correct amino 
acid is delivered to the peptidyl transferase domain. The E site is unoccupied at this 
stage. 
The binding of an aminoacyl-tRNA to the ribosome is made possible by EF-Tu, this co- 
factor binds GTP and an aminoacyl-tRNA and delivers them to the A site, where the 
aminoacyl-tRNA base pairs to the mRNA. This results in hydrolysis of the GTP to GDP 
and releases the EF-Tu GDP complex. The EF-Tu GDP complex is then regenerated to 
EF-Tu GTP by a second co-factor EF-Ts and binds another aminoacyl-tRN. A ready for 
the next cycle. 12,13 
The appropriate tRNA now occupies both the P and the A sites of the ribosome and the 
second step of the elongation cycle begins. This stage is a tranpeptidation reaction 
catalysed by the peptidyl transferase domain found on the 50S Subunit. This catalytic 
site activates the (x-carboxyl group of the amino acid that is forming the acyl link to the 
tRNA in the P site. This is then attacked by the a-amine group of the amino acid on the 
tRNA in the A site. This displaces the 3'-hydroxy of the ribose sugar, breaking the ester 
bond and forming a new peptide bond. This results in the peptide being one amino acid 
longer, and attached to the tRNA in the A . site. 
The tRNA in the P site has no bound 
12.13 
amino acids. 
Translocation is the final step in the elongation cycle. This step moves the ribosome one 
codon along the mRNA in the 3' direction. The tRNA that was in the P site now moves 
to the E site and leaves the ribosome, the tRNA bound to the peptide chain is transferred 
from the A site to the P site and this leaves the A site free for the next aminoacyl-tRNA. 
This complicated process is reliant on the co-factor EF-G, which is bound to another 
GTP and again the energy required is derived from the cleavage of an inorganic 
phosphate from the GTP to give GDP. 1 2,13 
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Figure 1.7. The elongation cycle. '2 
Termination (Figure 1.8) occurs when all the codons have been read, all the amino acids 
added and a nonsense codon enters the A site, these are UAA, UAG or UGA. At this 
point further protein co-factors are involved. These are the release factors I to 3 (RF-l, 
RF-2 and RF-3). These help recognise the stop codon and stimulate the cleavage of the 
12 
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peptide from the tRNA in the P site by the peptidyl transferase domain. At this point the 
peptide is free and folds into the final tertiary structure of the protein and the tRNA is 
moved from the P site to the E site and released. The 50S and 30S subunits then 
dissociate and release the rnRNA. At this point IF-3 binds again to the 30S subunit to 
block its association with the 50S sub-unit until another rnRNA is in place. ' '' 
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Figure 1.8. Termination of protein synthesis. 
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1.3.2.3 Selectivity 
As described at the beginning of this section, proteins are highly significant to all 
aspects of the cell and disruption to their production inhibits cell growth. The processes 
of translation are similar in both eukaryotes and prokaryotes and both are reliant upon 
mRNA, aminoacyl-tRNA and ribosomes. This introduces the possibility of toxicity if 
the host protein synthesis is inhibited by the antibacterial therapy. However, at the 
ribosome level differences can be observed. Prokaryotes have a single type of ribosome 
whereas eukaryotes have three types, cytosolic ribosomes which are 80S, membrane 
bound ribosome, which are also 80S but are attached to the endoplasmic reticulum and 
mitochondrial ribosomes, which are 55S. The cytosolic and membrane bound ribosome 
are identical in composition and can therefore be consider as one class of the 80S 
ribosomes (Table I. 1). '2 14 
Comparison of ribosome structure in prokaryotes, 
eukaryotes, and mitochondria 
Bacterial (70S) Eukaryotic (80S) Mitochondrial (55S) 
Large Subunit 50S 60S 39S 
23S 2904 nts 28S 4700 nts 16S 1560 nts 
rRNAs 
SS 120 nts 5S 120 nts 
(1 of each) 
5.8S 160 nts 
Proteins 33 -49 48 
Small Subunit 30S 40S 28S 
rRNA 16S 1542 nts 18S 1900 nts 12S 950 nts 
Proteins 21 -33 29 
Table 1.1. Ribosomes types and their properties. 
(nts = nucleotides; - indicates these are typical values for peptides - variable upon species)" 
Table 1.1 highlights potentially exploitable differences between these three ribosome 
types and these are sufficient enough to offer a high degree of selectivity. This 
selectivity is vital in order to minimise disruption to the host's protein synthesis. The 
bacterial ribosomes and the mitochondrial ribosomes show the greatest similarity, which 
is the origin of the most side-effects displayed by protein synthesis inhibitors. These 
side-effects are produced by inhibition of both the ribosomes of the pathogen and those 
of the host's mitochondria. ' 2-'4 
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1.3.2.4 Inhibitors of protein synthesis 
There are a large number of drugs that inhibit protein synthesis. There are four main 
classes; the aminoglycosides, the macrolides, the tetracyclines and the oxazolidinone . 
There are also a number of individual compounds that also inhibit protein synthesis. 
The most significant of these is chloramphenicol. Of these only the aminoglycoside' are 
bactericidal drugs, the others are bacteriostatic at therapeutic concentrations. 
The aminoglycoside antibiotics are structurally related polycationic compounds 
containing at least two amino sugars. There is more than one binding site for these 
drugs in the 70S ribosomes. Streptomycin was one of the first drugs of this class to be 
discovered and hence is the most well studied. Streptomycin binds to the 30S sub-unit, 
whereas kanamycin has binding sites on both the 50S and the 30S subunit (Figure 1.9). 
The streptomycin binding site on the 30S ribosome appears to be unique, as there is no 
competition between streptomycin and the other aminoglycosides for this binding site. 
In addition, mutations of the 30S ribosome that offer resistance to streptomycin do not 
confer resistance to the other aminoglycosides, which reinforces the idea of different 
binding sites. 13 
Regardless of the binding site, the aminoglycosides all cause the misreading of the 
mRNA codons and induce the introduction of incorrect amino acids into the proteins 
that are synthesised whilst these drugs are bound to the ribosome. This produces 
proteins that have altered actions or are completely without function. It appears that 
many of these miscoded proteins become embedded in the cell membrane and change 
its permeability which maybe a significant contribution to the bactericidal activity of 
this class of compounds. 13 
It has also been noted that high concentrations of streptomycin can induce complete 
inhibition of protein synthesis by binding to the mRNA-70S ribosome complex either 
during or just after initiation and thus preventing the elongation cycle from 
occurring. 13'15 
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Figure 1.9. Some aminoglycoside antibacterials. 
The macrolides are macrocyclic lactones which inhibit protein synthesis by binding to 
the 50S ribosome near the peptidyl transferase site in the entrance of a tunnel that 
allows the egress of the newly formed peptide from the ribosome. This prevents the 
progress of the peptide through the tunnel and causes the premature release of the 
peptidyl-tRNA complex and terminates peptide synthesis. There are both natural and 
semi-synthetic macrolides, erythromycin is probably the most extensively used natural 
macrolide. However, many of the semi-synthetic macrolides exhibit greater activity, the 
semi-synthetic macrolide azithromycin is 2-8 fold more active (Figure 1.10). 1 6 
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Figure 1.10. Some macrolide antibacterials. 
The tetracyclines are a series of compounds based around a linear fused ring system that 
incorporates both aromatic and non-aromatic rings. Tetracycline was the first 
discovered and lends its name to the whole class, 6-deoxy-demethyltetracycline is not a 
clinically significant antibiotic, but it possesses the minimum pharmacophore necessary 
for antibacterial activity (Figure 1.1 1). These compounds bind to the 30S ribosome sub- 
16 
unit and in the 70S ribosome, thus blocking the A site and preventing the binding of 
aminoacyl-tRNA, which terminates peptide synthesis. '? 
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Figure 1.11. Some tetracycline antibacterials. 
The oxazolidinones are unique in that they are totally synthetic drugs. unlike most other 
antibacterials. They bind to the 50S ribosome near to the peptide l transferase domain 
but do not inhibit its action. They do however block the formation of the 70S ribosome, 
if they bind before the association of the 50S and 30S subunits. Alternatively, if binding 
occurs after association, they prevent the translocation of the peptidyl-tRNA from the A 
site to the P site. They posses relatively simple structures. Linezolid was the first of this 
class of drugs and is effective primarily against Gram-positive bacteria. ranbezolid is a 
newer oxazolidinone and shows activity against both Gram-positive and Gram-negative 
bacteria (Figure 1.12). '8'19 
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Figure 1.12. Some oxazolidinones antibacterials. 
Chloramphenicol is also produced synthetically but was originally isolated from 
Streptomnvces vene.. uelae, it has a very simple structure and yet has a very broad range 
of activity (Figure 1.13). It prevents peptidyl transferase from linking the aminoacyl- 
tRNA in the A site to the nascent peptide on the tRNA in the P site by binding close to 
the peptidyl transferase domain on the 50S sub-unit and disrupting the binding of the 
aminoacyl portion of the aminoacyl-tRNA. It has no effect on the codon - anti-codon 
interaction. 13 
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Figure 1.13. Chloramphenicol. 
1.3.3 Folic acid synthesis 
Reduced forms of folic acid are a crucial co-factor in a multitude of enzymes that are 
vital to cell growth. These enzymes rely on transfer of a single carbon and reduced folic 
acids act as the source of this carbon. Both RNA and DNA synthesis are reliant upon 
this co-factor, as the purine bases and thymidine are synthesised using reduced folic 
acid as a source of carbon. It is also a co-factor in the synthesis of glycine and 
methionine and therefore has a double impact upon protein synthesis as it is crucial for 
both access to amino acids and to the template (mRNA) from which the protein is 
synthesised. ' 3,20,21 
Bacteria must synthesise folic acid as they do not have the active transport proteins 
necessary to import it into their cells, in contrast mammals can not synthesise folic acid 
and must gain it from their diet. 
Bacteria synthesise reduced folic acids in three steps from p-aminobenzoic acid, 
pteridine and glutamate. The first step is the addition of p-aminobenzoic acid (pABA) 
and the pteridine, 7,8-di hydropteri n-pyropho sph ate (DHPPP). to give dihydropteroic 
acid (DHP). This is catalysed by dihydropteroate synthase (DHPS). The next step is 
addition of glutamate to give dihydrofolic acid (DHF) and this is catalysed by 
dihydrofolate synthase (DHFS). The final step is catalysed by dihydrofolate reductase 
(DHFR) and converts dihydrofolic acid to tetrahydrofolic acid (THFA) (Figure 
1.14). 13,20.21 
18 
/(: 
)C02H 
H2N 
0 aC02H pABA 0 
HN 
NOPP 
HN 
Nr 
N 
H2NN DHPS H NýN 
INH 
2 ri 
DHPPP DHP 
Glutamate DHFS 
C02H O CO2H NADP NADPH 0 
0INH0 
IN HH 
Hy NrN C02H DHFR HN 
N 
CO2H 
H2N J\ýNI 
Fi 
H2NN N 
Fi 
THFA DHF 
Figure 1.14. Synthesis of reduced folates. 
1.3.3.1 Inhibitors of folic acid synthesis 
Neither DHPS nor DHFS are present in mammalian cells and are therefore excellent 
targets for inhibition. However there are no clinically significant DHFS inhibitors. 
DHPS is inhibited by the sulfonamides, which are clinically significant drugs, used to 
treat urinary tract infections. They are mimics of pABA and act by competitive 
inhibition of dHPS. Sulfamethoxazole is the major antibiotic of this type (Figure 
5ý 13.20.21 
Trimethoprim (Figure 1.15) inhibits DHFR and mimics the structure of the pteridine 
fragment of dihydrofolate. It also acts as a competitive inhibitor. It has a 60,000-fold 
selectivity for bacterial DHFR and is therefore selectively toxic, inhibiting only the 
bacterial enzyme at therapeutic levels. 
Inhibition of either of these enzymes is sufficient to block DNA, RNA and protein 
synthesis, but this could only produce a bacteriostatic effect. Trimethoprim and 
sulfamethoxazole are routinely prescribed together and have a synergistic action, 
usually producing a bactericidal effect. 13 20.21 
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1.3.4 The cell membrane 
The cell membrane of bacterial cells is a bi-layer of phospholipids. it follows the fluid 
mosaic model that is the standard arrangement in all cell membranes. This means that 
the polar phosphate heads of the phospholipids point toward the cell cytoplasm on one 
face of the bi-layer and toward the aqueous environment of the exterior of the cell on 
the other. This arrangement places the hydrophobic fatty acid tails of the phospholipids 
in a central layer and excludes water. The combined effects of the polar layers 
sandwiching the lipophilic layer creates a semi-permeable membrane, which is effective 
in controlling the movement of solutes in and out of the cell. Proteins, glycoproteins and 
cholesterol are incorporated into the bi-layer. Proteins control the uptake of desired 
solutes and facilitate the removal of cellular by-products and wastes, glycoproteins are 
involved in cellular recognition and cholesterol help,, to maintain the fluidity of the 
membrane (Figure 1.16). 
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Figure 1.16.. A depiction of the cell membrane. " 
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1.3.4.1 Membrane disruption therapies 
Despite its complexity the cell membrane offers a challenging target for antibacterial 
therapies, as it is common to all organisms. There are differences in the proteins and 
glycoproteins present, but so far there are no clinically significant therapies that offer 
selective disruption of bacterial membranes without damage to the host organism. There 
are however a number of compounds that are clinically used despite their apparent lack 
of selectivity. They are effective with limited toxicity by virtue of being applied 
topically. By administering to the surface of the skin, compounds that would be highly 
toxic if taken internally are useful as antiseptics and they have few side effects, as the 
outer layers of the skin are already dead. 
Two typical members of this antibacterial class are polymyxin B and gramicidin A. they 
both work by disrupting the bi-layer of the cell membrane, increasing its permeability to 
polar molecules and thus allowing vital nutrients to escape from the cells resulting in 
cell death. They are used topically to prevent wound infections and to treat infections of 
the eye (Figure 1.17 ). ' 3.2 3. 
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1.3.5 The cell wa1125_28 
The cell wall prevents osmotic lysis of the cell membrane whilst the bacteria are in a 
hypotonic environment. There are two distinct organisations of the cell wall structure 
and these have been traditionally used to subdivide bacteria into two classes dependent 
upon their response to a staining agent developed by Christian Gram in 1884. '9 These 
are termed Gram-positive and Gram-negative. Gram-positive cells are stained by crystal 
violet and once fixed by the mordent, iodine, are not decolourised by ethanol, staving 
blue or purple. Whereas Gram-negative bacteria initially stain but are decolourised 
when washed with ethanol. An adaptation of this technique utilises sarfranin as a 
counter stain. This dyes the Gram-negative cells pink or red. As the cell wall structure', 
of each cell type were elucidated, the understanding of these observations increased and 
the reasons for the differential staining became obvious (Figure 1.18). 
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Figure 1.18. A stained bacterial sample, pink cell are Gram-negative and blue cells are Gram- 
positive. 30 
Gram-positive cells have a cell membrane surrounded by a layer of peptidoglycan 
(murein) between 20 and 80 nm in thickness. Gram-negative bacteria again have a cell 
membrane but this is surrounded by a thinner peptidoglycan layer only 7 to 8 nm thick, 
this is then surrounded by a further outer membrane. Both cell walls provide rigidity to 
the cell but the extra membrane of the Gram-negative bacteria prevents access to the 
peptidoýglycan layer by a range of external compounds, such as crystal violet stain. The 
dye sticks to the surface of the membrane initially staining the cell but is then washed 
off, but in the Gram-positive cells it diffuses into the peptidoglycan and once treated 
with iodine becomes insoluble and stains the cell even after washing with ethanol. This 
demonstrates the effect of the outer membrane of Gram-negative cells as a molecular 
barrier and this has significant impact upon the effect of certain antibiotics (Figure 
l. l9). 
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Figure 1.19. The cell wall arrangements in Gram-positive and negative species; 
In both cases the cell wall is complex and contains a multitude of compounds, but 
peptidoglycan has offered the most significant targets for antibacterial therapy to date. 
The basic structure of peptidoglycan is the same throughout all bacterial species and is 
comprised of a series of -lycosidic chains cross-linked by short peptides (Figure 1.20). 
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23 
Peptidoglycan synthesis is a multi-step process, which is carried out by an extensive 
array of enzymes, in a synthetic sequence that spans the cell membrane of the bacteria. 
Steps occur in the cell cytoplasm, the cell membrane and also outside the cell. This can 
be used as a basis to subdivide this sequence into three phases, they are; the cytoplasmic 
synthesis, membrane associated synthesis and extra cellular polymerisation and 
tailoring. 
1.3.5.1 Cytoplasmic synthesis26 28 32"z4 
There are several crucial reactions that take place in the cytoplasm, they are; the 
synthesis of N-acylglucosamine uridine diphosphate (UDP-NAG), the synthesis of N- 
acetylmuramic acid uridine diphosphate (UDP-NAM), the synthesis of the D-amino 
acids, glutamate and alanine and the synthesis of ineso-diaminopimelic acid or lysine. 
Finally these substrates are assembled into the UDP-NAM pentapeptide. 
Substrate synthesis 26,28 
UDP-NAG is synthesised in four successive steps beginning from D-fructose-6- 
phosphate. The first reaction is catalysed by G1mS transferase (L-Blutamine: D-fructose- 
6-phosphate amidotransferase), this enzyme catalyses the hydrolysis of glutamine to 
glutamate and utilises the released ammonia to convert D-fructose-6-phosphate to 
glucosamine-6-phosphate. The second step utilises phosphoglucosamine mutase, which 
converts glucosamine-6-phosphate to glucosamine- l -phosphate. The bi-functional 
enzyme G1mU synthase catalyses the last two steps, acylation of the amine on the sugar 
and then the transfer of uridine diphosphate (UDP) to the 1 position of the sugar to give 
UDP-NAG. 26ýs'3''3436 
UDP-NAM is synthesised in two steps from UDP-NAG. The first stage adds 
enolpyruvate to the 3 position of UDP-NAG; this is catalysed by MurA transferase. 
MurB reductase then catalyses the reduction of the pyruvate double bond, using 
NADPH as a co-factor. Overall, this involves addition of lactic acid to the 3 position of 
UDP-NAG (Figure 1.21). 32 34 
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Figure 1.21. Synthesis of UDP-NAG and C'DP-NA. 
D-alanine is produced by the epimerisation of L-alanine, which is catalysed by alanine 
racemase. There is evidence that there maybe two distinct forms of alanine racemase, 
however both have the same responses to alanine, both rely on pyridoxal-5-phosphate as 
a co-factor and are inhibited by the same antibiotiCS. 30-32 
D-Alanine is then utilised by a further enzyme in the cytoplasm, D-ala-D-ala ligase. 
This takes two alanine molecules and activates the carboxyl group of one as the mixed 
phosphate anhydride using ATP as the source of the phosphate and producing ADP as a 
by-product. Then the amino group of the second alanine displaces the phosphate to form 
a D-ala-D-ala dipeptide (Figure 1.22). 334 
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Figure 1.22. The mechanism of D-ala-D-ala ligase. 34 
D-Glutamic acid is produced by the action of D-amino acid aminotransferase in the 
majority of bacteria. This enzyme removes the amino group from D-alanine and 
transfers it to a-keto-glutarate. This yields D-glutamic acid and pyruvate. In many of 
25 
the lactic acid bacteria, D-glutamic acid is also produced by the action of glutamate 
racemase on L-glutamic acid. 32'34 
Meso-diaminopimelic acid (DL-DAP) is synthesised by the action of diaminopimelate 
epimerase on LL-diaminopimelic acid. Diaminopimelic acid may then be converted to 
lysine by diaminopimelate decarboxylase or it maybe incorporated into the UDP-NANl 
pentapeptide, this depends on the bacterial species (Figure 123). 34 
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Figure 1.23. The synthesis of, L1eso-diaminopimelic acid and L-lysine. 34 
UDP-NAM pentapeptide synthesis 
This stage of cell wall synthesis involves the sequential addition of five amino acids to 
the carboxyl terminus of the lactic acid of UDP-NAM. This is an unusual occurrence as 
it involves peptide synthesis removed from the ribosome and without the involvement 
of mRNA. This process is controlled by the Mur synthase enzymes, which activate the 
carboxyl group as a phosphate mixed anhydride, whilst hydrolysing ATP to ADP. The 
carbonyl group of the mixed anhydride is then attacked by the amine of the amino acid 
being added to give a tetrahedral intermediate. This intermediate then collapses to 
release the newly generated amide and an inorganic phosphate Figure 1.24). 28, 
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Figure 1.24. A general mechanism for the addition of amino acids as catalysed by the 
Mur synthase enzymes. 32 
MurC synthase is the first enzyme in this sequence and is responsible for the addition 
of L-alanine to the carboxyl of the lactic acid of UDP-NAM. In some species it can add 
either glycine or L-serine but these are much less common. 3 . 
34.37 
MurD adds D-glutamic acid and is a highly specific enzyme as little variation has been 
observed in this position. Some bacteria show that the a-carboxylic acid can be 
'6 
converted into a primary amide. However it is not clear whether this is due to addition 
of an altered monomer or whether this occurs after the pentapeptide is formed. 32.34 37 
MurE is responsible for the addition of the diamino acid to the third position of' the 
peptide chain; this is the least specific enzyme in the sequence as the third position 
shows the largest variation in the amino acid. The amino acid added is always added to 
the y-position of the glutamic acid, a motif not normally seen in peptides synthesised on 
ribosomes. 
The only observed residue in Gram-negative bacteria is meso-diaminopimelic acid (in- 
DAP) 
'27 
in Gram-positive bacteria the predominant amino acids are mm-DAP or L-lysine. 
In all cases the nn-DAP is incorporated by addition of the amine of the L-stereocentre, as 
apposed to the D-stereocentre and therefore mirrors the addition of L-lysine. 
However, there are numerous other possibilities for this residue at this position in 
Gram-positive bacteria, L-ornithine, LL-diaminopimelic acid, , ne, so-2,6-diamino-3- 
hydroxy-(3-pimelic acid and L-hydroxy-lysine have all been observed. There are also 
amino acids found in this position that have the distant amine acetylated or only have 
one amine group; 4-acetylamino-2-amino-butyric acid, L-homoserine, L-alanine or L- 
glutamate. This leads to the conclusion that there must be a second mode of cross- 
linking in the bacteria that does not involve the distant amine of the amino acid in the 
third position and this is indeed the case. In a limited number of bacteria the cross- 
linking (discussed in detail below) is between the glutamate in the 2 position and the 
alanine in the 4 position. 3''34'37 
MurF is the last enzyme in this sequence and is responsible for the addition of the two 
remaining amino acids of the pentapeptide as a dipeptide. This dipeptide is normally the 
D-ala-D-ala produced by D-alanine ligase, although there are a number of variations 
observed here as well. In some cases the terminal D-alanine is replaced by D-serine and 
may also be replaced by D-lactate to give a depsipeptide that is incorporated into the 
pentapeptide. In both these cases the D-alanine in the fourth position is conserved and 
there appears to be very little variation in that position. These variations of the ultimate 
amino acid are important resistance mechanisms to the glycopeptide antibiotics. 
particularly the D-lactate presenting mutant and are discussed below in greater 
detail32.34.37 
. 
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Figure 1.25.: summary of UDP-NAM pentapeptide synthesis. '' 
1.3.5.2 Inhibitors of cytoplasmic synthesis13'26 
Fosfomycin inhibits the transfer of enolpyruvate, the first step in the synthesis of UDP- 
NAM from UDP-NAG, the reaction catalysed by MurA synthase. It mimics 
phosphoenol-pyruvate, the natural substrate of the enzyme, and is able to enter the 
active site. One of the catalytic cysteine residues of the active site then ring opens the 
epoxide. This results in a stable covalent bond between the enzyme and the antibiotic, 
preventing enzymatic catalysis and therefore depleting UDP-NAM, thus preventing the 
synthesis of the cell wall. 
D-Cycloserine inhibits alanine racemase and D-ala-D-ala lipase. It acts as a mimic of D- 
alanine and binds competitively to the active site of the effected enzymes thus 
preventing synthesis of D-ala-D-ala and therefore preventing cell wall synthesis. 
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Figure 1.26. Inhibitors of cytoplasmic cell wall synthesis. 13.26 
1.3.5.3 Membrane associated synthesis 38 41 
There are two reactions on the inner surface of the cell membrane and these produce a 
monomer (lipid II), which is transported across the membrane to the outside of the cell, 
where it can be polymerised into the peptidoglycan cell wall. Neither of the enzymes 
seem to have a great degree of specificity in regard to the pentapeptide chain, as there is 
little evidence for mutants of these enzymes in bacteria that present altered amino acid 
sequences. Heijenoort and co-workers42 report that MraY transferase will accept 
peptides with altered length (dipeptides to heptapeptides). pentapeptides with altered 
sequences and pentapeptides with dansyl or acetyl substitutents. Ha et al. 43 , Iio %k that 
MurG is slightly more specific than MraY, it requires that the pentapeptide be present, 
but it is known that this enzyme will tolerate modification of the pentapeptide, as the D- 
serine or D-lactate presenting mutants that are resistant to glycopeptides do not contain 
altered versions of this enzyme. 
Lipid I synthesis 38-41 
Lipid I (undecaprenyl diphospho-NAM-pentapeptide) is synthesised by the enzyme 
MraY transferase. This enzyme is a phospho-N-acetylmuramoyl-pentapeptide 
transferase. This means that it catalyses the cleavage of the pyrophosphate between 
UDP and NAM whilst catalysing the formation of a second pyrophosphate between 
NAM and undecaprenyl phosphate with UMP as a side product. Undecaprenol is a 55- 
carbon molecule that is highly unsaturated and linear in shape, this makes it ideal for 
embedding in the phospholipid bi-layer of the cell membrane. It acts to anchor the 
amino-sugar and its pentapeptide substitutent to the membrane, both initially on the 
inner face and then after it has been transferred to the cell exterior. 
Lipid 11 synthesis 38-41 
In the second step of the membrane bound sequence MurG transferase (N- 
acetylglucosamine transferase) catalyses the transfer of NAG to NAM with release of 
UDP, thus forming the (3-1, -I-alycosidic linkage observed in cell walls. 
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In some bacterial species the distant amine of the diamino acid in position 3 of the 
pentapeptide is extended at this point. This is accomplished by the sequential addition 
of amino acids to the amine terminus; the amino acids added are activated as they are 
bound to tRNA. The amine terminus therefore reacts with the tRNA-activated amino 
acid and forms an amide bond whilst releasing tRNA. The number and type of amino 
acid added depends on the bacterial species. 
1.3.5.4 Inhibitors of lipid I synthesis' 3,26 
Bacitracin inhibits the dephosphorylation of undecaprenol pyrophosphate by stabilising 
the complex it forms with the membrane bound phosphatase that cleaves it. This is on 
the cell exterior but has a considerable impact on these internal processes as it prevents 
the recycling of the undecaprenol and therefore prevents the formation of lipid I. 
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Figure 1.28. Bacitracin. 
30 
Tunicamycin also inhibits the synthesis of lipid I. but it acts by inhibition of phospho-N- 
acetylmuramoyl-pentapeptide transferase, preventing it from catalysing the transfer of 
NAM-pentapeptide to undecaprenol phosphate. 
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Figure 1.29. Tunicamycin. 
1.3.5.5 Extra-cellular polymerisation 38-41 
The lipid II monomer is inverted in the membrane, transferring the NAG-NAM 
pentapeptide to the outer surface of the membrane. The mechanism for this and the 
protein responsible for this action are as yet unknown. After this transfer the monomeric 
units are exposed to two further enzymatically-catalysed reactions that convert a series 
of these monomers into the characteristic polymeric glycopeptide cell wall. 
There is a range of enzymes that are membrane associated and described as penicillin 
binding proteins (PBP's). These enzymes affect the polymerisation steps. Their nature 
and functions vary greatly as does their size and degree of expression across bacterial 
species. They are split into two groups, high molecular weight PBP's and low molecular 
weight PBP's. 
High molecular weight PBP's4' 
High molecular weight PBP's control transglycosylation and transpeptidation. There is 
a wide range of these PBP's and they are all multi-modular, largely consisting of a 
lipophilic anchor that embeds in the cell membrane, a non-penicillin binding domain 
that is usually a transglycosylase and then a penicillin binding domain that is a 
penicilloyl serine transferase, which catalyses transpeptidation. 
Transglycosylation is a reaction where the NAG-NAM pentapeptide from lipid II is 
transferred to the extending cell wall. Depending on the bacterial species this is either 
by the displacement of the pyrophosphate from lipid II with 4-hydroxy group of the N- 
acetylglucosamine of the elongating glycan chain (arrow 2, Figure 1.30) or the inverse 
the 4-hydroxy group of the N-acetylglucosamine displaces the pyrophosphate of the 
31 
elongating glycan chain (arrow 1, Figure 1.30). Either way, undecaprenol is released as 
the pyrophosphate, which is dephosphorylated and re-absorbed into the bacteria to be 
re-used. Little else is known about this enzymes mechanism, particularly the key 
interactions between the enzyme and the substrate, although steps have been taken to 
attempt to identify which PBP's are critical to cell function using knockout studies. 41 
Class A PBP 
Figure 1.30. Transhlycusylation one of the extra-cellular steps in glvcopeptide synthesis. -" 
Transpeptidation is the cross-linking step between the peptide side-chains of adjacent 
glycan strands. There are a number of different types of cross-links possible, the 
majority of these are formed by displacement of the terminal D-amino acid residue with 
either the distant amine of the diamino acid in the third position of the pentapeptide, or 
by displacement with an inter-peptide bridge extending from the distant amine. This 
inter-peptide bridge is yet another source of diversity in the cell wall structure, the 
number of residues and the amino acid composition is highly variable and dependent 
upon the bacterial species. The simplest form of transpeptidation is shown in Figure 
1.31 AandB. 
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Figure 1.31. Simple transpeptidation: A) shown in an extra-cellular context. 4' B) shown as it 
synthetic scheme. 
As mentioned above a limited number of bacteria display cross-linking between the 
glutamate in the 2 position and the alanine in the 4 position, this necessitates the 
inclusion of a diamino acid in the inter-peptide bridge. This is linked to the a-carbonyl 
of the glutamate residue by its a-amine and then displaces the terminal D-alanine of the 
adjacent chain with its distant amine or the N-terminus of an extending residue attached 
to that amine. 
This variation in the mode of linking and the nature of the inter-peptide bridge may go 
some way to explaining why there are multiple copies of the PBP's in the bacterial 
world, yet this does not explain why multiple copies should be expressed in a single 
organism, a trait that is very common. It is likely that they are more deeply involved in 
the life cycle of the bacteria than just the initial synthesis of peptidoglycan. There is 
already a large body of evidence that shows that these enzymes are critical in the 
division to daughter cell during reproduction and that they are crucial in determining 
cell morphology. However, it is only as more is becoming clearly understood about 
these enzymes, that it may be possible to show exactly which particular enzyme is 
responsible for peptidoglycan synthesis in each part of the bacterial cells life cycle. 
33 
Low molecular weight PBP's41 
The low molecular weight PBP's are smaller enzymes, which have been shown to have 
peptidase activities. There are two types of low molecular weight PBP's, DD- 
carboxypeptidases and DD-endopeptidases, both are involved in further tailoring of the 
exposed chemical functionality on the peptidoglycan. The DD-carboxypeptidases 
remove D-alanine terminal residues and so limit the amount of cross-linking. The DD- 
endopeptidases cleave internal DD-dipeptide bonds in the peptidoglycan layer. for 
example, those in between the D-centre of diaminopimelic acid and D-alanine of the 
cross-links between the peptide side chains. This opens up the peptidoglycan layer and 
allows the growth of the cell. DD-endopeptidases are also involved in the recycling of 
the cell wall fragments that were cleaved to allow cell expansion. 
The number and type of PBP present is dependant upon the species of bacteria, but all 
the enzymes that have a penicillin-binding domain are serine transferases and share a 
common mechanism of action, that was described by Ghuysen and co-workers. 
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Figure 1.32.: depiction of the active site and the reaction mechanism of the serine transferases. 
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The carbonyl donor is bound into the active site and the carbonyl group activated by H- 
bonding to two amines, the water molecule (shown in red in Figure 1.32) acts as a 
proton transfer agent removing a proton from the serine residue allowing it to attack the 
carbonyl group. The water accepts a proton from serine and also donates a proton that is 
accepted by R'X, forming R'XH which diffuses from the active site to be replaced by 
R"YH. The process is then reversed. Water accepts a proton from R"YH which attacks 
the carbonyl displacing the serine residue which extracts a proton from the water. Thus 
giving RC(O)YR" which is released from the active site. X can be 0 or NH depending 
on the species of bacteria. For peptidases R"YH is water and for transpeptidase R"YH is 
an amino acid. 
1.3.5.6 Inhibition of transglycosylation and transpeptidation13,26,38,4' 
As yet there are no effective inhibitors available for clinical use that specifically target 
transglycosylation. However a natural product, moenomycin (Figure 1.33), is a potent 
inhibitor of the transglycosylase (non-penicillin binding) domain of PBP'. s, thus 
preventing addition of the NAG-NAM sugars to the growing cell wall. Although 
moenomycin is too toxic for clinical use, it is hoped that it can be used to gain a greater 
understanding of the mechanism of transglycosylation and thus allow the production of 
4 clinically significant inhibitors .ý 
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Figure 1.33. Meonomycin. " 
Glycopeptides, like vancomycin or ristocetin, do inhibit transglycosylation, but also 
inhibit transpeptidation. They are discussed below in detail (section 4). 
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The foremost class of antibacterials to date has been the 1i-lactams. There are many 
groups of molecules which posses this structure, including penicillins. cephalosporim. 
carbapenems and monobactams (aztreonam is the only monobactam in use). They are 
all clinically useful antibiotics that inhibit the transpeptidase (penicillin binding) domain 
of PBP's (Figure 1.34). 
RHRH 
ÖNSÖNS 
ýN PN 
O0 R' 
CO2H CO2H 
Penicillin core Celphalosporin core 
H2N 
OH Sý 
N 
N- H N/ 
R' 
ON 
O 
C02H 
ýO 
0 SOgH CO2H 
Carbapenem core Aztreonam (monobactam) 
Figure 1.34. The core structures of the (3-lactam containing antibiotics. " 
All (3-lactams work by mimicking the structure of the D-ala-D-ala terminus of the 
pentapeptide and in so doing, they act as a competitive inhibitor for the active site of 
transpeptidase. They have a significant advantage as they are already locked in the 
appropriate conformation to bind into the active site. In comparison, the D-ala-D-ala 
terminus is freely rotating and therefore must adopt the correct conformation to bind, 
thus slowing binding and incurring an entropic penalty for the loss of free rotation. This 
overall means (3-lactams have a higher affinity for transpeptidase than D-ala-D-ala. 
Once in the active site, the amide of the (3-lactam is cleaved, this is analogous to the 
cleavage of the D-ala-D-ala amide that frees one of the D-alanines. However. the 1- 
lactam ring is cyclic, therefore cleavage of the amide does not release the remainder of 
the structure, and this acts as a steric block preventing access of a nucleophile (R"YH) 
to the acetylated serine of the enzyme. This means that hydrolysis of the acylated 
enzyme is very slow, it has a turn over rate of one or less per hour and the enzyme is 
effectively inhibited by covalent irreversible inhibition (Figure 1.35). 
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Figure 1.35. Inhibition of serine transferases by P-Iaetams, penicillin shown as an example! 
1.4 Glycopeptide antibiotics, structure and mode of action 
1.4.1 The glycopeptide antibiotics 
Vancomycin was the first of the glycopeptides to be discovered in 1956.44 Since then, 
many more have been discovered. They are derived from actinomycetes found in soil 
samples. ' Only two of the glycopeptides, vancomycin and teicoplanin, are currently in 
clinical use in humans. Both are antibacterials used to treat Gram-positive bacterial 
infections. They are not transported across the outer membrane of Gram-negative 
bacteria and therefore cannot reach their site of action in the cell wall and thus have no 
effect on Gram-negative pathogens. 4 Vancomycin is the last resort treatment for post- 
surgical infections with methicillin resistant Staphylococcus aureus (MRSA). 4 
1.4.2 Structure of the glycopeptide antibiotics 
Glycopeptides share the common construction suggested by their name, i. e. they are 
composed of both glycosides (sugars) and a peptide. The sugars are highly variable and 
some are unique to these antibiotics. However, the aglycones, the peptide portion of the 
drug available after removal of the sugars, show much less variation. The first attempt at 
the characterisation of these structures involved the use of chemical methods. Marshal147 
was the first to publish the combustion analysis of vancomycin in 1965. Quoted as C, 
54.01, H, 5.68, Cl, 4.71, N. 8.88,0,27.13, which is remarkably close to the predicted 
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values for vancomycin, which are C, 54.70: H. 5.22: Cl, 4.89; N, 8.70; 0.26.50. 
However, the derivation of the empirical formula was incorrect, Ci48His; C14N, 10c, was 
suggested, whereas C66H75CI2N9O24 is now known to be the formula. 4949 This paper 
also describes the preparation of two crystalline degradation products, CPD-l and II. 
CPD-I is discussed below. Marshall's work 47 began the task of uncovering the complete 
structure by identifying a number of phenolic residues and identifying the presence of 
N-methyl-D-leucine. However, the complete structure was not proposed. 
Further chemical studies were undertaken, 50-5.1 but the next significant breakthrough 
came from Williams et al. and NMR studies of vancomycin in 1977.54 In this work, all 
the elements of the vancomycin structure were accounted for and evidence was 
presented from assignment of the 270 MHz H'NMR spectrm, and the use of nuclear 
Overhauser effects. The nature of the backbone (the presence of secondary amides) and 
the stereochemistry of the sugars were elucidated. Although the total carbon skeleton 
was accounted for, the total structure was not assigned at this point. The work of 
Sheldrick and Williams in the following year, was the first to offer a complete structural 
assignment. 
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Figure 1.36. Structure as determined by Sheldrick et al. " 
Further work by Williams et al. in 1981 refined this total structure by comparison of 
the nuclear Overhauser effect difference spectra of vancomycin and crystalline 
degradation product I (CDP-I), and the X-ray crystal structure of CDP-I. Marshall`' 
was the first to produce CPD-I by heating vancomycin in aqueous HCI (pH 
4.2) for 40 
38 
hrs at 60 - 70 T. This produced a brown crystalline solid but Marshall did not suggest a 
structure for the compound produced. The work of Williams allowed the assignment of 
the stereo-configuration of the chlorine substitutent of the ring that is highlighted in 
Figure 1.36 to be revised. It was shown to be pointing backwards in vancomycin 
(Figure 1.37), whereas it is pointing forward in CDP-I. 56 
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Figure 1.37. The proposed structure of vancomycin, the highlighted area indicates the 
arrangement of residue 3. '6 
This structure was then refined by Harris and Harris (1982-1983). 
4"'-9 They postulated 
that the Unusual arrangement of residue 3, as an iso-asparagine (highlighted in Figure 
I. 37), was unlikely and that it was probable that the iso-aspartic acid present in the 
crystalline degradation product was derived via the cleavage and re-arrangement of an 
asparagine present in the vancomycin structure. The presence of the asparagine residue 
was then confirmed through a series of chemical tests on vancomycin. This lead to an 
amendment to the proposed structure of vancomycin, to give the structure below. This is 
the final structure of vancomycin (Figure 1.38). 
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Although most of the work carried out to elucidate the structures of the glycopeptidc,, 
was preformed on vancomycin itself, or it,, derivatives, it was obvious at the time that 
vancomycin did not share its aglycone with most of the other glycopeptides that had 
been discovered. 57 There are two possible variations of the aglycone in the 
glycopeptides, one is displayed by vancomycin and the other by ristocetin. Ristocetin is 
not used clinically, as it causes aggregation of platelets in the blood. 
The determination of the structure of ristocetin (Figure 1.40) was also quite involved 
and took a number of years and the input of many research groups. However the 
complete assignment of vancomycin accelerated this process. 58-63 
Following the elucidation of both the vancomycin and ristocetin structure, it was 
observed that all the glycopeptides are heptapeptides (seven residue) which display 
identical stereo-configuration along the peptide backbone, which is D-D-L-D-D-L-L. 31 
45 They all have either the aglycone displayed by vancomycin or ristocetin. Complestatin 
is an exception to these rules and its structure is shown below (Figure 1.39). 
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Figure 1.39. Complestatin. '' 
Chloreremomycin, balhimycin and orienticin C share the vancomycin aglycone. Five 
out of the seven amino acid bear aromatic residues (residue 2 and residues 4-7). These 
aromatic residues are cross-linked, residue 2 linked to 4, which is also linked to 6, and 
residue 5 is linked to 7. The remaining two amino acids bear aliphatic residues, 
asparagine at position 3 and N-methyl-D-leucine at position 1, and these are not cro-"- 
linked. These structural elements combine to give three fused rings that form a bowl 
shaped cradle that is distinctive in all glycopeptides. 
Teicoplanin, avoparcin, actaplanin and A47934 share the ristocetin aglycone. This has 
all seven amino acids with aromatic side chains and in addition to the cros,, -links 
displayed in the vancomycin aglycone, has a further cross-link between the aromatic 
residues 1 and 3. Thus there are four fused rings and these also fold into the 
characteristic glycopeptide cradle. 31 
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Figure 1.40. Vancomycin and ristocetin, exemplifying the two peptide cores of glycopeptides. 31 
1.4.3 Mode of action 
The cradle-like structure adopted by the peptide portion of the glycopeptides is crucial 
to their mode of action. 4- ý The cleft this conformation creates allows the binding of the 
terminal D-alanyl-D-alanine portion of the intermediates used to synthesise the cell 
wall. Both lipid II and immature cell walls display these D-ala dipeptide termini and are 
therefore sequestered by vancomycin. When vancomycin binds to lipid II it prevents 
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access of both the transglycosylase and the transpeptidase. This stops the formation of 
new cell wall. When vancomycin binds to the immature peptide that has already 
undergone transglycosylation, transpeptidation is blocked, thus preventing the cross- 
linking of the amino acid side chains. The result of this is that the balance between the 
hydrolysis of the cell wall and the addition of new cell wall is destroyed and the cell 
wall loses its mechanical stability. The bacterial cell is then lysed by osmotic pressure if 
45 it enters a hypotonic solution. 
The molecular basis for the ability of vancomycin to sequester the D-ala-D-ala dipeptide 
terminus was determined by Williams et tit. 64 It was shown that a dipeptide, acetyl-D- 
ala-D-ala fits into the cleft in the surface of vancomycin, so that its carboxyl terminus 
points at the N-terminus of vancomycin. This allows the formation of a hydrogen 
bonding network between the amide backbones of the dipeptide and vancomycin. as 
well as a salt bridge between the C-terminal carboxylate of the dipeptide and the 
cationic nitrogen of the N-methyl-D-leucine. This binding model was then refined in a 
later paper, 65 where the isobutyl group of the terminal N-methyl-D-leucine was shown 
to wrap over the dipeptide and exclude water from the binding pocket, thus re-enforcing 
the hydrogen bonding. These investigations allowed the production of a model of the 
binding site for the dipeptide and the antibiotic, shown below in Figure 1.41. 
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' network. 
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Williams et al. 66 then went on to consider the energetics of complex formation, which 
led to the conclusion that the mobility of residues one and three was an advantage in 
binding. Movement of these residues allow the partial association of the dipeptide and 
the antibiotic. This is followed by a re-arrangement that displaces solvent from the 
reminder of the structure and allows the completion of the binding interactions. 66 
Further work advanced the binding model using diacetyl-L-lys-D-ala-D-ala and other 
D-ala-D-ala containing peptides. The aglycone and some semi-synthetic analogues of 
vancomycin were also considered in these studies. These studies helped to define the 
role of the chlorine substituents and the N-terminal amino acid in the binding of the 
dipeptide containing cell wall analogues. 67-70 
A further development in the understanding of the binding process came from the 
observation that the dimerisation of these antibiotics is significant in the mode of action 
and this is discussed in detail in Section 1.5. 
In addition to antibiotic action brought about by inhibition of transpeptidation, a number 
of studies have provided evidence that there is an additional mechanism for antibiotic 
activity in some glycopeptides. Kahne and co-workers 71 developed a series of 
compounds that showed binding of the cell wall peptide is not actually necessary to 
produce biological activity. They produced disaccharides (glucose and vancosamine) 
which had been alkylated on the amino sugar with a lipophilic chlorobiphenyl chain. 
This moiety produced a measurable minimum inhibitory concentration (MIC) against 
both sensitive and resistant strains of E. faecium and E. faecalis and thus they concluded 
that there must be an alternative mode of action for this compound, as it lacked the 
binding pocket needed to bind D-ala-D-ala or D-ala-D-lac based cell wall peptides. It 
was suggested that this inhibition was mediated through a direct interaction between the 
disaccharide and some of the enzymes involved in cell wall biosynthesis. The 
compounds are shown in Figure 1.42 and the MICs for one of them and vancomycin are 
shown in Table 1.2 (N. B. Van A and Van B are phenotypes of resistance, see 
Section 1.6). 
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Figure 1.42. Two disaccharides produced by Kahne and co-workers. 71 
NIIC ( ml) 
Compound E. faecium E. faecalis 
Sensitive Resistant (Van A) Sensitive Resistant (\'an B) 
vancomycin 1 -048 
4 
-1048 
chlorobiphenyl 
disaccharide 
128 128 1-18 18 
Table 1.2. \I IC's for the chlorobiphens I disaccharide and v ancomy cin 
from Kahne and co-workers7' 
Kahne and co-workers72 also produced a number of compounds with variations of the 
sugars seen in vancomycin, where hydrophobic chains had been added to the , Lwars and 
alternative links to the peptide portion of vancomycin were also employed. Bý 
comparing the differences these novel sugar,, had when coupled to either the 
hexapeptide, which cannot effectively bind the cell wall peptide, or to the heptapeptide 
which can bind the cell wall peptide, they were able to confirm that alternate binding 
mode and were able to understand it more fully. The first series has sugar variations 
coupled to the 4th amino acid residue, as shown in Figure 1.43 and their MIC data are 
shown in Table 1.3. 
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This series showed both sugars are important for binding (compare 4/-la to 2/2a) and 
that the activity produced by binding D-ala-D-ala containing cell wall intermediates iI 
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Figure 1.43. Kahne and co-workers compounds with altered sugars. '' 
d C MIC ( ml) E. 
faeciani 
ompoun Sensitive Resistant (Van A) 
Vancomycin (1) ? 2048 
2 <0.025 1-. 5 
3 <0.03 16 
4 0.8 63 
2a 10 40 
3a 64 1024 
4a 50 >200 
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more important than the activity produced by the novel binding mechanism (compare 
compounds 2-4 to compounds 2a-4a). It does however show that there is a significant 
level of activity retained in compound 2a which can not effectively bind D-ala-D-ala 
containing cell wall intermediates and thus this secondary binding mode has some 
importance in the search for compounds active against resistant strains of bacteria. The 
marked loss of activity of 3a compared to 2a shows that the placement of the 
hydrophobic chain is crucial in the activity of these compounds. 
Kahne and co-workers72 also produced a pair of compounds where the position at which 
the sugars were attached was altered, these are shown in Figure 1.44 and their NIIC data 
is shown in Table 1.4. 
C d MIC ( ml) E. aeciuni ompoun Sensitive Resistant (Van A) 
Vancomycin 2 2 l8 
Residue 4 linked <0.01 63 
Residue 7 linked 0.16 16 
Table 1.4. MIC data for compounds with altered point of sugar attachment produced by Kahne 
and co-workers. '2 
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Figure 1.44. Compounds with altered point of sugar attachment produced 
by Kahne and co-workers. 72 
A comparison of MIC data for these compounds showed that the compound with the 
sugars linked through residue 7 had the best activity against the resistant strain, though 
both compounds had good activity. Kahne and co-workers? conclude that the altered 
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binding found in these kinds of compounds are probably the result of inhibition of 
transglycosylation, but they did not feel that the data generated was sufficient to be 
certain that this was their mode of action. 
Kahne and co-workers73 further strengthened the hypothesis that there is a secondary 
mode of action for some glycopeptides by producing and comparing a series of 
glycopeptides with and without the damaged binding pockets. They used vancomycin, 
chlorobiphenyl vancomycin, teicoplanin and dalbavancin. They showed that while the 
parent compounds with intact binding pockets have similar values for both MIC and 
IC50 in a transglycosylase assay with penicillin binding protein 2 (PBP2 ). there is a 
marked difference in the activities of the compounds with damaged pockets (Table 1.5). 
The chlorobiphenyl vancomycin and dalbavancin analogues were still able to produce 
measurable MIC's and IC50's (transglycosylase), but the vancomvcin and teicoplanin 
analogues could not. Kahne and co-workers73 reasoned that this could only occur if 
these compounds exhibited a second mode of action that wa,, independent of binding the 
cell wall peptide. 
Compound MIC (µg/ml) IC50 (µm) 
S. aureus 29213 S. aureus PBP2 
vancomycin 3.2 1.7 
teicoplanin 3.? 1.2 
chlorobiphenyl vancomycin 0.1 17 
dalbavancin 0.1 1.1 
vancomycin damaged pocket >264 >500 
teico lapin damaged pocket >100 >500 
chlorobiphenyl vancomycin damaged pocket 4.8 3.5 
dalbavancin damaged pocket 50 70 
Table 1.5. NIIC's and IC50's for a range of compounds studied by Kahne and co-workers. 
Roy et al. 74 built on this hypothesis by producing affinity columns with lipophilic 
glycopeptide anchored to solid supports, which were then used to chromatograph 
solubilised E. coli membranes. This produced very interesting results as it showed that a 
number of cell wall biosynthetic enzymes were bound to the column and could be 
isolated and characterised. They also carried-out similar experiments with glycopeptides 
that had no lipophilic side chains anchored to solid supports and found that they had no 
specific binding interactions with the membrane enzymes. Thus this supported the 
hypothesis of Kahne and co-workers7' that there was a further mode of action for 
glycopeptides with hydrophobic side chains. 
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1.5 Dimerisation 
Dimerisation, an important phenomenon in the glycopeptide antibiotics, i', the 
spontaneous association of two molecules of glycopeptide into a complex that is 
stabilised by a network of hydrogen bonds. It is most often observed in the presence of 
an appropriate ligand but the more strongly dimerising glycopeptides will associate 
even when a ligand is not present. 75 
This phenomenon was first reported by Waltho and Williams'` when they observed and 
quantified the dimerisation of complexes formed by ristocetin A and its pseudoaglycone 
in the presence of diacetyl-L-lys-D-ala-D-ala. They calculated that the dimerisation 
constant for ristocetin-diacetyl-L-lys-D-ala-D-ala dinier was --2000 M-1. 
Further work by Williams and co-workers" went on to measure the dimerisation 
constants of a range of glycopeptides, including vancomycin (700 M-1), and gave a 
greater understanding of the mechanism of dimerisation and its effects. They showed 
that the dimerisation in ristocetin is a hack-to-back, head-to-tail arrangement as shown 
in Figure 1.45. 
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Figure 1.45. A representation of the dimer formed between two ristocetin tripeptide complexes. 
" 
The red dashed bonds indicate the hydrogen bonding normally observed 
in complex formation and 
the blue dashed bonds show the hydrogen bonds of the dimer. 
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Williams and co-workers77 explained that dimerisation is favourable because it is a 
cooperative process, which strengthens and shortens the hydrogen bonds between both 
the two glycopeptides and also between the glycopeptides and the tripeptide that mimic,, 
the cell wall. 
There are a number of ways that dimerisation may help improve the antibacterial 
properties of these compounds in vivo. Firstly, because of its cooperative nature, once 
the dimer is formed and binds to two cell wall intermediates each set of hydrogen 
bonding interactions are re-enforced. Therefore, it becomes less likely that either one of 
the cell wall intermediates would dissociate or that the glycopeptides would dissociate 
from each other, thus the complex formed should be longer lived than that of the 
monomeric form. In addition, once one cell wall peptide is bound it becomes more 
likely that a second cell wall peptide will be bound. This is because the dimer is held in 
close association with the bacterial cell wall and thus the dimer is effectively tethered by 
the first complex (between the cell wall peptide and glvcopeptide), the formation of the 
second complex is effectively an intramolecular process, and thus is favoured over the 
analogous process where a monomeric glycopeptide approaches the cell wall and has to 
bind in an intermolecular process. The formation of the second complex is also 
preferred because the unoccupied binding site is already pre-organised into the correct 
conformation by the hydrogen bonds to the occupied glycopeptide and therefore has 
already paid the entropic plenty for this part of the binding event, thus further favouring 
binding of a second cell wall intermediate. 
The amino-sugar extending from residue 6 of ristocetin adds an extra stability to the 
complex dimer, as it hydrogen bonds to the carbonyl group of the backbone amide in 
residue 2 in the other ristocetin (shown in Figure 1.45). This sugar is also present in 
another of the glycopeptides studied in this work, eremomycin, which also exhibits a 
high dimerisation constant > 10000 M-'. Ristocetin, eremomycin and vancomycin all 
exhibit the same back-to-back dimer arrangement, yet vancomycin has a lower 
dimerisation constant. Williams and co-workers77 suggest thtat the absence of this 
particular sugar in vancomycin provides an explanation for the lower dimerisation 
constant observed in vancomycin. 
Williams and co-workers78 carried out further experiments to assess the importance of 
dimerisation in the antibacterial activity of glycopeptides. The antibacterial properties of 
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three antibiotics with a range of dimerisation constants, teicoplanin A; -I (which does 
not dimerise), vancomycin (which dimerises weakly), and eremomycin (strongly 
dimerising) were tested by measuring the inhibition of growth of B. subtilis with 
varying amounts of diacetyl-L-lys-D-ala-D-ala as an exogenous antagonist. In these 
experiments the antibiotics which dimerised most strongly were expected to be the most 
difficult to antagonize with exogenous ligand. This is because their binding would be 
initially bimolecular (intermolecular) and thus strongly effected by the exogenous 
ligand, but then unimolecular (intramolecular) and thus weakly effected by the 
exogenous ligand. Whereas, the weakly dimerising glycopeptide would always hind by 
a bimolecular (intermolecular) fashion and thus be strongly effected by the exogenous 
ligand. Their experiments proved this to be true, as 1 µg teicoplanin Az-1 needed only 
5 µg of ligand to prevent a zone of inhibition forming, I µg of vancomycin took 50 pa 
to prevent a zone of inhibition forming and eremomycin still showed inhibition despite 
the presence of 50 µg of ligand. This strengthens the hypothesis that the more strongly a 
-lycopeptide antibiotic dimerises, the more likely it is to have good antibacterial 
activity. Figure 1.46 gives a simple schematic that illustrates why a dimeric form is 
more strongly bound. However this is a simplification as there are numerous factors that 
contribute to the antibacterial properties of these compounds. 
A 
growing 
monomer cell wall : , -ý \ 
B 
membrane 
Figure 1.46. A) Shows the weakly hound monomeric glycopeptide. B) Shows the more strongly 
hound dimeric glycopeptide. Adapted from Williams and co-, vorkers. 
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Sheldrick and co-workers79 solved a crystal structure for vancomycin where the dirner 
had bound an acetate ion. This displayed the back-to-back dimerisation that had been 
suggested from the NMR data of earlier studies and confirmed this hypothesis. 
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Try et aL75 examined the effect that dimerisation has upon binding when the complex of 
the glycopeptide is in close association with a surface. They used micelles of sodium 
dodecyl sulphate (SDS) or vesicles of phosphatidylcholine (PC) which had a range of 
cell wall mimic peptides bound into them with deconvl chains. They found that the PC 
vesicles with a deconyl pentapeptide gave a system that was qualitatively similar to 
binding near the surface of the bacteria and that they observed an approximate 100-fold 
enhancement of binding compared to the unanchored system. 
Loll et a!. 80 also solved a crystal structure for vancomycin, again with a bound acetate 
ligand, that shed further light on its dimerisation. They were able to measure the bond 
length and angles for the hydrogen bonds of the dimer interface (shown in Table 1.6). 
From this data they concluded that the increase in affinity for the bound ligand was due 
to increased polarisation in the amide bonds of the backbone residues that form the 
dimer interface. They also , uggest that the reason why ristocetin, eremomycin and other 
compounds that contain an amino-sugar attached to the 6 `h amino acid residue have 
greater dimerisation constants, is that the amino-su`aar is charged and forms a further 
hydrogen bond at each end of the dimer interface. This not only increases the number of 
hydrogen bonds, but since the amine on the amino-sugar is a cation, the polarisation 
induced by its hydrogen bonding is greater than that of the hydrogen bonds of the 
backbone amides. This agrees with the observations of Williams and co-workers77 
mentioned above. 
Donor Acceptor O---H Distance (A) C=O---H Angle (deg) 
V2: 6 VI: 3 2.29 170 
V1: 5 V2: 5 2.14 149 
V2: 5 V 1: 5 2.03 163 
V1: 6 V2: 3 2.22 164 
Table 1.6. Hydrogen bonding in the dimer interface. 10 
Where V2: 6 indicates that the donor or acceptor is on the 6 `h amino acid of the second monomer. 
Further work by Loll and co-workers81 showed that the sugar residues of vancomycin 
play a significant role in the formation of the dimer, in that they provide a steric 
constraint which reduces the motility of the peptide portion of the compound. They 
compared crystal structures of vancomycin and aglucovancomycin and found that there 
was a greater degree of conformational heterogeneity in the crystal structure of the 
aglucovancomycin as four distinct conformations were obser\ ed in the crystal structure. 
;I 
Lehman et al. 82 solved four crystal structures for balhimycin and degluco-balhimycin. 
Balhimycin is a closely related glycopeptide and differs in structure to vancomycin by 
having only glucose attached to the residue of amino acid 4 and an amino-sugar 
attached to the residue of amino acid 6. In these structures they again observed the 
characteristic back-to-back dimer, but they also observed a face-to-face dimerisation. 
They postulated that this form of dimerisation may be significant in binding e%ents in 
vim because this dimer traps the two peptides within the complex. However, this face- 
to-face dimerisation has not been observed in solution studies. so may not be 
particularly important. 
Williams and co-workers`3 effectively combined many aspects from the studies of 
dimerisation by examining the data generated by solution NMR studies and the 
published crystal structures of a range of glycopeptides that covered the spectrum of 
dimerisation strength. They found that there was a correlation between the interfacial 
distance of the dimer measured in the crystal structures, the shift of the X4 proton 
(Figure 1.47), measured by NMR, and the dimerisation constants observed for each 
glycopeptide. They found that when a compound has a high dimerisation constant, the 
interfacial distance measured in the crystal structure was smaller, and the X4 proton was 
shifted further downfield in the NMR spectra. From this, Williams and co-workers83 
reasoned that the stronger the dimerisation, the shorter (and thus stronger) the hydrogen 
bonds between the dimer pairs and the more rigidly held the dimer is. The shift of 
proton X4 is dependent upon the dimer strength because the tightening of the dimer 
interface shortens the hydrogen bonds and brings this proton into close association with 
two of the backbone carbonyl groups that form part of the hydrogen bond network 
between the two glycopeptides of the dimer, shown in Figure 1.47. 
HO 
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H Rr, H R5 
Figure 1.47. Section of the dimer interface of two glycopeptides of the vancomycin family showing 
the proximity of X4 to two amide carbonyls that results from the formation of the dimer hydrogen 
bond network. 83 
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1.5.1 Synthetic variants which exploit dimerisation 
The observed dimerisation of glycopeptides opened up new wavy for improving the 
antibacterial properties of these compounds. A number of groups have attempted to 
make synthetic analogues where two glycopeptides are covalently linked and could 
exploit the favourable cooperative binding which results from dimerisation. 
Rao and Whitesides54 produced a dimer where two vancomycin molecules were linked 
through their C-terminus to each other using p-xylenediamine as a linking fragment 
(Figure 1.48). They used p-xylenediamine because it was rigid and thus would not 
introduce an entropic penalty, through loss of bond rotations, when the synthetic dimer 
bound to ligands. They decided to link through the C-terminus as previous studies 
showed that modification here had minimal effects on the binding characteristics of the 
compound. Rao and Whiteside, 54 also produced a covalently linked dimer of the 
tripeptide cell wall mimic (Figure 1.48). To do this they linked two a-acetyl-L-lys-D- 
ala-D-ala tripeptides through there e-amines of lysine using succinic acid as the linking 
fragment. They examined these in competitive fluorescence and affinity capillary 
electrophoresis assays and determined the dissociation constant for the divalent 
complex. These results indicated that the divalent complex had an enhancement of 
-1000-fold relative to the corresponding monomeric complex. 
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Figure 1.48. The vancomycin and ligand covalently linked dimers of Rao and ý1 hitesides. 'ý' 
Staroske and Williams5-5 produced covalently bound dimers of vancomycin that ýý cre 
linked from the N-terminus of one vancomycin to the C-terminus of the other, called a 
head-to-tail dimer. They produced two variations of this type of dimer. one that used ß- 
alanine as a linking fragment and a second that used 6-aminohexanoic acid as the 
linking fragment. Staroske and Williams"' reasoned that these dimers would be more 
active than the head-to-head (C-terminus to C-terminus) compounds produced Rao and 
Whitesides84 because they would more effectively form a tetrameric arrangement that 
utilises the back-to-back dimerisation seen in the monomeric form of vancomycin. They 
believed that the cooperative strengthening of the complex, that would be expected with 
dimerisation should lead to an improvement in the compounds activity against 
vancomycin-resistant enterococci. Figure 1.49 shows a schematic that demonstrates the 
differences in the tetrameric arrangements of the head-to-head and the head-to-tail 
dimers. 
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a) b) 
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Figure 1.49. a) shows tetrameric complex as postulated for the head-to-tail covalent dinier, 
b) shows the tetrameric complex as postulated for the head-to-head covalent dinier. 
As can be seen in Figure 1.49, the tetrameric form postulated for the head-to-tail 
covalent dimer (a) places all four vancomycins in such a way that they can form two 
hack-to-back dimers and thus strongly bind four ligands. The tetrameric form of the 
head-to-head covalent dimer (b) allows only one back-to-back dinier to form and 
therefore would result in two strongly hound ligands and two more weakly bound 
ligands. 
Nicolaou et a/. Sh, 57 made as series of covalently linked dimers through a process of 
target-accelerated combinatorial synthesis. To achieve this a selection of vancomycin 
analogues were made, these analogues were alkylated on the amine of the vancosamine 
sugar with varying chain lengths of fragments that terminated in either a double bond or 
a sulphide. These compounds were then mixed and dimerised in sitii with the ligand 
present and because olefin metathesis and disulphide formations are both reversible an 
equilibria was formed between all the possible complexes of dimers that the mixed 
chain length monomers could produce. 
The compounds that formed the most stable complexes were favoured in these 
circumstances because they would be bound to the ligands and pre-organised to react 
with each other. Thus, pairs of analogues that were able to form dimers would be 
rapidly reacted to form covalent dimers and would then also be much more likely to 
stay bound to a ligand. Whereas, pairs of analogues that formed weakly associated 
dimers would not be in stable complexes and thus would not be cross-linked and could 
freely dissociate to form better pairs and thus be converted to more strong associated 
dimers. The process would thus, in theory, equilibrate to a distribution of covalent 
dieters with a chain lengths that are ideal to orientate them to form stable back-to-back 
dimers. As strong dimerisation correlates to good antibacterial activity, it was thought 
that this process should select for potent compounds with good activity against resistant 
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strains of bacteria. This technique was both successful and prolific, producing a %ast 
number of compounds, most of which had activities that were equal to or greater than 
vancomycin in all the strains of bacteria that were evaluated in the NIIC studies. Figure 
1.50 shows the common structure for this sequence of compounds. 
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Figure 1.50. The covalent dimers produced by Nicolaou et al. Where V -V' is S-S or C=(' 
and a and h are 1-8. `''"' x 
1.6 Resistance to glycopeptides 
As the use of glycopeptides slowly increased during the 1980s, it became inevitable that 
resistance would eventually occur. 88 This was finally observed in 1986 in Enteruc occus 
faecium. 89 The molecular basis for this resistance was elucidated by Walsh and co- 
workers9° who showed that it is the result of replacement of the terminal D-alanine 
residue on the cell wall intermediate lipid II that confers resistance. They showed that 
Enterococcus faecium mediated this change through the use of two enzymes, VanH and 
VanA, which reduce pyruvate to D-lactic acid (Vanes) and then form a depsipeptide wk with 
D-alanine and the D-lactate (VanA ). Further work by Walsh et al. 9' showed three further 
proteins were necessary to mediate this action; VanX a zinc dependant D, D dipeptidase, 
that selectively cleaves D-ala-D-ala dipeptides, showing a 1010 fold preference for the 
dipeptide over the depsipeptide9 and VanS and VanR, which form a two-component 
regulatory system, where VanS is a sensor protein and embeds in the cell membrane and 
VanR is a cytoplasmic response regulator that activates transcription of the DNA 
encoding VanA. VanH and VanX. 91 
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Following this, more evidence of resistance was observed in enterococci and there are 
now at least six known phenotypes of resistance to glycopeptides. 92 These are classified 
depending upon the breadth and level of resistance and whether the resistance is 
inducible, i. e. presence of the drug triggers the resistance mechanism, or constitutive, 
present whether drug is present or not. However, the mechanisms all rely on the 
replacement of the terminal D-alanine residue of the peptidoglycan building block with 
an alternate residue. The mechanism described by Walsh is now known as the VanA 
phenotype, the remainder are listed below in Table 1.7. 
Phenotype 
Peptidoglycan 
Tenninus 
Resistance 
(MIC in 
tg/mL) 
Source Induction Organism 
Vanc (? 64) E. /aertunt 
VanA D-ala-D-lac Acquired Inducible 
Teic (>_16) E. faecalis 
E. lUC'('ll(/11 
VanB D-ala-D-lac Vanc (>_4) Acquired Inducible 
E. faecalik 
Constitutive E. gallinariwn 
VanC D-ala-D-ser Vanc (? 2) Intrinsic 
& Inducible E. casseliflavus 
Vanc (>_16) 
VanD D-ala-D-lac Intrinsic Constitutive E.. /uieciuni 
Teic (>_? ) 
VanE D-ala-D-ser Vanc (16) Acquired Inducible E. faecalis 
VanG D-ala-D-ser'? Vane (16) E. faecalis 
Table 1.7. Phenotypes of givcopeptide resistance. "' 
These six resistance paths can be divided into two subtypes based on the nature of the 
residue that replaces the terminal alanine. The first type of resistance involves the 
replacement of the terminal alanine by a D-lactate (phenotypes VanA, VanB and 
VanD). VanA encodes two further proteins VanY and VanZ, VanY is a membrane hound 
carboxypeptidase that can cleave both D-ala-D-ala dipeptides and D-ala-D-lac 
depsipeptides, and is analogous to the low molecular weight PBP's discussed above. 
VanZ's purpose is as yet unknown but it is also membrane bound and appears to be 
significant in teicoplanin resistance. VanB resistance phenotype also relies on VannH, 
VanA and VanX enzymes and the two-component regulatory system of VanS and VanR. 
however these sensor proteins have a low homology with the VanA phenotype, which 
may explain why VanB is sensitive to teicoplanin but VanA is not. Kahne and co- 
57 
workers93 offered a further explanation of this fact, by demonstrating that the aglycones 
of either vancomycin or teicoplanin would induce resistance in bacteria with the VanB 
phenotype. However if either of the aglycones were glycosylated with the sugar from 
teicoplanin that carries a lipophilic residue the resistance mechanism is not induced and 
the drugs are able to inhibit cell wall synthesis. This suggests that the sugar is in 
someway countering the effect of the resistance by preventing the recognition of 
teicoplanin by VanS. 
VanD phenotype presents the D-lactate precursor whether glycopeptides are present or 
not and is therefore resistant to both vancomycin and teicoplanin. Consequently t anS 
and VanR are unimportant in this phenotype as the production of the lactate 
intermediate does not need to be induced. 92 
The affect on the molecular interactions between the cell wall intermediate and the 
glycopeptides is profound, altering the two terminating residue', so that they are now 
linked by an ester where there would be an amide linkage in the wild type. This 
produces a 1000 fold drop in the binding affinity. 92 When the ester presenting cell wall 
intermediate is placed in the same binding position as the wild type intermediate there 
would be an unfavourable interaction between the carbonyl of the amide that connect,, 
amino acids 3 and 4 of vancomycin and the oxygen of the ester in the depsipeptide. 
There is an electrostatic repulsion between the lone pairs on the oxygen, where 
originally there would have been a hydrogen bond (Figure 1.51). 92 
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Figure 1.51. Comparison of binding, in the wild type versus lactate containing intermediate. 94 
The effects of both the loss of the hydrogen bond and of the electrostatic repulsion 
combine to produce such a dramatic loss in activity. Recent work by Boger and co- 
workers 4 quantified the relative effects of each of these phenomena, by using a 
tripeptide mimic where the nitrogen of the amide joining the two terminal amino acids 
had been substituted fora methylene group to give the structure shown in Figure 1.52. 
HO=O 
Ac' NO 
Ac'NH 
O 
Figure 1.52. Boger's novel binding probe. 94 
This novel compound was used to quantify the loss of a hydrogen bond by comparing, 
the binding affinities of vancomycin and aglucovancomycin to this and to the natural 
cell wall mimic D-ala-D-ala. It was found that in both cases the binding affinity was ten 
times lower for the novel binding probe than D-ala-D-ala. `'4 The process was then 
repeated, but this time comparing the binding of the binding probe and D-ala-D-Iac to 
both glycopeptides, here the binding affinity of D-ala-D-lac was found to be a 100 fold 
lower than that of the binding probe. It was therefore reasoned that the repulsive effect 
contributed a 100 fold reduction to the binding of D-ala-D-lac and the loss of the 
H- 
bond contributed a ten fold reduction in the binding afflnity,. 
04 This was confirmed by a 
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further compound where the carbonyl on the backbone of vancomycin was removed. 
which is discussed later in Section 1.7.2. 
The second category of resistance relies upon the bacteria replacing the terminal D- 
alanine with D-serine, as seen in the phenotypes: VanC, VanE and VanG. All three 
phenotypes rely on three enzymes to produce the resistant cell wall intermediates, 
similar to the lactate presenting phenotypes. 92 The first is Van XY is a D-ala-D-ala 
dipeptidase and it functions as VanX does, however it can also act as a 
carboxypeptidase, like VanY, and shows the same specificity. This means it can cleave 
UDP-NAM D-ala-D-ala pentapeptide, but it cannot cleave t'DP-NANI D-ala-D-ser 
pentapeptide. The second enzyme, VanT is a membrane-bound racemase, which takes 
the naturally occurring L-serine and converts it to the D-isomer. The third, l'anC, VanE 
or VanG, depending on the phenotype, is similar to the natural ligase, but has altered 
specificity, in order to promote the formation of D-ala-D-ser dipeptides. VanE, VanG 
and some VanC phenotypes are inducible and have the two-component VanR and fans 
sensor kinases, the constitutive VanC phenotypes do not require these. 
VanC is exceptionally selective in its ability to synthesise dipeptides of the D-ala-D-ser 
95 form, it shows a 400 fold selectivity in the selection of D-ser in the terminal position. 
Alteration of the terminal D-ala to D-ser confers resistance because serine has a CH2OH 
as its side chain, whereas alanine has a CH3 (Figure 1.53). As a result this altered cell 
wall intermediate has increased steric bulk close to the crucial C-terminus and this 
prevents it from binding in the same way as the wild type. 
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Figure 1.53.: A comparison of C-terminus of D-ala-D-ala and D-ala-D-ser presenting cell wall 
intermediates. 
In addition, the OH group makes serine a hydrophilic residue and will therefore not 
satisfy the hydrophobic binding of this area, further decreasing the 
binding affinity. This 
is quite important because the entropic effects of this hydrophobic 
interaction make a 
substantial contribution to the overall binding energy. 
Cristofaro et a1.70 quantified the 
effect of loss of this hydrophobic interaction by, measuring the association constants 
between diacetyl-L-lys-D-ala-D-ala and a vancomycin derivative that ýtias missing the 
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isobutyl side-chain from the terminal amino acid. They found that the lo's of this group 
reduced the association constant from 1.6 x 106 to 7.7 x 104. The combined effects of 
the increase in steric bulk and the loss of the hydrophobic interaction mean vancom`cin 
has a binding affinity 6 times lower for this substrate than for the natural substrate. `', 
1.7 Previous modifications of vancomycin 
There have been numerous attempts to modify vancomycin and other related 
glycopeptides. Many of the papers referenced above in the elucidation of the 
vancomycin or ristocetin structures (Section 1.4.2), which were the basis for the study 
and classification of glycopeptides, used modifications of the natural drug to help 
discover the structure and mode of action. Most of these modifications do not increase 
the binding of the modified drug, and so will not be discussed in detail here. 
There have been numerous studies which have attempted to modify the structure of 
vancomycin in order to increase its ability to bind to the cell wall intermediates and 
ultimately its efficacy as a drug. Three groups of these modification,, are discus"cdi 
below; hydrophobic derivatives, derivatives including internal modifications of the 
binding pocket and derivatives modified at the N-terminus. 
1.7.1 Hydrophobic derivatives 
There are a number of reported naturally occurring glycopeptides which have lipophilic 
chains attached. Some of these exhibited increased antibacterial activity as compared to 
vancomycin. 46'96 The discovery of these has prompted many research groups to 
investigate semi-synthetic derivatives that incorporate similar hydrophobic chains. 
Nagarajan and co-workers 46,97-99 produced over a hundred such synthetic derivatives by 
varying the position of attachment of the hydrophobic chain (either on the amine of the 
amino sugar or the N-terminal amine or both) and the nature of the hydrophobic chain 
(both aryl and aliphatic chains were used). These studies showed that mono alkvlation 
of the amino sugars with benzyl and benzyl derivatives substituted in the para position 
produced the greatest increase in antibacterial activity when measured in vitro. 
97 The 
two compounds with the lowest MIC's are shown in Figure 1.54. The MIC data for the 
compounds and some reference glycopeptides are shown in Table 1.8. 
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Figure 1.54. The two analogues produced by Nagarajan and co-workers with the linsest \IIC. " 
Compound MIC (µg/nil) 
vancomycin 128,256,, 512.1,024 
teicoplanin 16,64,1284 
ristocetin 5144,1024, -1048 
-octylbenzyl 1,, ?,, 4,8 
p-octyloxybenzyl 0.5,2,4,, 8-,, 
Table 1.8. MIC data for the compounds of Nagarajan and co-workers with some reference 
glycopeptides against 4 E. faeciurn and 2 E. faecalis isolates 
(the subscripts indicate the number of times a value was observed). 9' 
Allen et al. 100-102 reported a series of compounds that are hydrophobic derivatives of a 
glycopeptide that is closely related to vancomycin, bearing an additional epi- 
vancosamine sugar on the sixth residue of the peptide and where the vancosamine of 
vancomycin was replaced with epi-vancosamine. They were produced by alkylating on 
the amine of the epi-vancosamine sugar (the one on residue 4, Figure 1.55, the residues 
are numbered from the N-termnus) with chains containing one or two phenyl rings. The 
analogues show that there is good agreement between the clogP of the compound, its 
propensity to dimerise or become membrane bound and antibacterial activity. They 
showed that as clogP increased for a compound, so did its propensity to dimerise. the 
likelihood of it becoming membrane bound and the antibacterial activity as measured by 
MIC. The two compounds with the lowest MIC's are shown in Figure 1.55. The \IIC 
data and binding constant to diacetyl-L-lys-D-ala-D-ala (Ac-2KAA) and diacetyl-L-1ys- 
D-ala-D-lactate (Ac2KAIac) are shown in Table 1.9 for the compounds and 
vancomycin. 
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Figure 1.55. LY333328 and LY377502, the two most potent analogues produced In AIlen et al. 101 
Compound MIC (. t /ml) M. luteus 
(ATCC9341) 
Kb Ac2K; A. 1 Kb . 1c, KAlac 
vancomycin 0.26 4.1 x 102' 0.41 x 103 
LY333328 0.0011 2.6x 105 0. -1 4x 10 LY377502 0.00072 4.4x 105 - 0.37x 10 
Table 1.9. MIC and binding constants for vancomycin, Ll'333328 and LY377502 
from Allen et al. 101 
In one of the papers Allen et al. 102 reiterate an argument put fort and by William, et 
ul. 78'103 that suggested an explanation for the increased affinity seen in these 
hydrophobic derivatives. The explanation states that the increase was the result of a 
combination of cooperativity of binding produced by dimerisation of the glycopeptide 
and from membrane anchoring via the lipophilic side chain. 
The dimerisation offers an increased binding affinity to the cell wall peptides by 
forming homo-dimers of the glycopeptide, where the hydrogen-bonding network that i, 
formed in dimerisation re-enforces the hydrogen-bonding network that forms on 
complexation with the ligand. 
The lipophilic chains acting as membrane anchors fix the glycopeptide to the surface of 
the bacterial cell. This means that ligand complexation is in-effect an intramolecular 
process as both the glycopeptide and glycan strands are anchored to the membrane, as 
opposed to an intermolecular process, as in un-substituted glycopeptides that do not 
LY333328 
R =\ 
/ 
ýI/ 
LY377502 
pIý 
i 
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possess a lipophilic membrane anchor. The intramolecular process is energetically 
favoured over the intermolecular process and this re-enforces the effect of the 
dimerisation. Allen et at. confirmed this theory by testing two compounds LY264826 
and an analogue produced by alkylating LY264826 on the amine of one of the epi- 
vancosamine sugars with para-chlorobenzylaldehyde to give LY191145. They found 
that the alkylated compound LY191145 had a lower MIC, dimerised more stronLly and 
had a greater inhibition of transglycosylation. The two compounds are shown in 
Figure 1.56. The MIC data and binding constant to Ac2KAA and Ac7KAlac are shown 
in Table 1.10 for the compounds and vancomycin. 
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Ta 
Compound 
MIC (. tg/m1) 
M. luteus 
(ATCC9341) 
Kb Ac2KAA Kb Ac2K. Alac 
Vancomycin 0.26 4.1 x 10' 5.1 x 10 
LY264826 0.063 1.5x10' 1.4x10' 
LY191145 0.023 4. Ox10' 1.8x10 
ble 1.10. MIC and binding constants for vancomvcin. L1'264826 and L1' 1911 
from Allen et al. 102 
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1.7.2 Derivatives including internal modifications of the binding pocket 
There have been limited attempts to modify the binding pocket of glycopeptides like 
vancomycin. The aim of these efforts was to re-engineer the binding pocket in order to 
remove the repulsive interaction that occurs when glycopeptides try to bind the lactate 
presenting resistant cell wall peptide and thus increasing the spectrum of actin ity for 
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these compounds. However, these undertakings were limited because the glycopeptide 
core is composed of interlinked peptide macro-cycles, which make modification to the 
deep seated peptide residues very challenging. 
Malabarba et at. 104 produced two analogues of the teicoplanin aglycone where the first 
and third residues were replaced, one had L-lysine at position 3 and D-1vsinc at position 
1, the other had L-phenylalanine at position 3 and D-lysine at position I (Again, the 
residues are numbered from the N-termnus). Both of these compounds show a marginal 
increase in antibacterial activity, as compared to vancomycin, over a range of sensiti\c 
and resistant species. This is a surprising result as the aglycones of all of the 
glycopeptides are significantly less active than their parent compounds. 
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Figure 1.57. Two analogues of the teicoplanin aglycone produced by Nlalabarba et A'04 
NIIC ( ml) 
Compound S. aureus S. haemolyticus S. pyogenes E. faecalis E. faecalis 
(Tour) (L602) (C203) (TCC7080) (L526 (Van. k) ) 
teicoplanin 0.125 8 0.125 0.125 >128 
vancomycin 0.25 1 0.25 0.5 > 128 
MDL MDL 0.125 0.25 0.25 0.5 16 
63166 
MDL 0.063 0.063 0.5 0.5 >1 -18 64945 
Table 1.11. Comparison of MIC data for teicoplanin, vancomycin and the two compounds 
produced by Malabarba et a1.104 
Boger and co-workers 1 05 produced a series of vancomycin analogues that varied in the 
presence or absence of sugar and the degree of methylation, but contained a L-(3- 
cyanoalanine at the 3 position, and compared them to the equivalent vancomycin vv ith 
the original L-asparagine at the three position. They found that these tended to have 
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lower MIC's than vancomycin for a range of both resistant and susceptible bacteria. 
However, one analogue was as good or better than the equivalent vancomycin analogue 
and better than vancomycin itself against all the tested strains. 
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Figure 1.58. The most potent cyanoalanine analogue produced by Boger and co-workers. 1° 
MIC ( ml) Ka 
S. E. aecium E. fae 
Compound aureus Van B Ac2KAA Ac2KAIac 
ATCC 
ATCC vancomycin Van A 1I CC (t 10ý') (x 10 
25923 
35667 resistant B. N[4166 51299 
vancomycin 1.25 2.5 500 2000 125 23- 3.9 3.3 
aglucovancomycin 0.625 2.5 160 640 80 5.8 3.1 
cyanoalanine 0.625 1.25 40 40 2.5 9. O 3.3 
analogue 
Table 1.12. Comparison of K. and 311C data for vancums cin, aglucovancomycin and the 
cyanoalanine analogue produced by Boger and co-workers. 1° 
Crowley and Boger106 re-engineered the vancomycin binding pocket at the critical 
location of the repulsive interaction with the altered lactate presenting cell wall 
precursor. However, to effect such a deep seated modification of the pocket it was 
necessary to resort to the total synthesis of the molecule. They succe`sfully synthesised 
the aglycone of vancomycin where the amide carbonyl between residue, 4 and 5 of the 
heptapeptide had been replaced by a methylene group, to leave an amine joining the two 
residues instead of an amide. This resulted in a 35-fold drop in affinity to the D-ala-D- 
ala cell wall mimic, but an increase in affinity of 40-fold against D-ala-D-lac cell wall 
mimic. This produced an analogue with balanced affinities against both the lactate and 
the alanine presenting cell wall mimics and showed increased antibacterial activity 
against VanA resistant E. fnecalis, when compared to vancomycin, as measured by 
MIC. 
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Figure 1.59. Vancomycin analogue with re-engineered portion highlighted in red. ""' 
NIIC ( ml) Ka 
Compound E. faec"alis 
6.14166 Ac, KAA Ac, K 11ac 
vancomycin >500 2.0 x 10-' 1.8 \I (- 
a`lucovancomycin >500 1.7 x 1V 1. -, x 
10- 
re-engineered 31 4.8 x I0ý 5 2x 10 analogue . 
Table 1.13. Comparison of K;, and NIIC data For vancums cin, atilucovancomv cin and the rc- 
engineered analogue produced by Crowley and Boger. '"`' 
1.7.3 Derivatives modified at the N-terminus 
There are a small number of reports of modification at the ; V-terminw, of v ancomvcin 
with limited success. 
Williams and co-workers"' attempted to introduce sp centres at the N-ternminus by 
replacing the terminal amine of N-demethylvancomycin with a ketone and then reacting 
this with hydroxylamine, benzyl hydroxylamine or malononitrile to produce an oxime. a 
benzyl oxime and a malononitrile derivative. They also reduced the ketone to yield asp` 
alcohol, effectively replacing the amine of N-demethylvancomycin with an alcohol. 
However, all of these derivatives had a lower affinity for diacetyl-L-lys-D-ala-D-ala. 
This loss in affinity is attributed to the sp- centre forcing a conformation where the 
hydrophobic side chain that remains of the terminal leucine residue points away from 
the tripeptide losing a crucial hydrophobic interaction. The alcohol also had a lower 
affinity for diacetyl-L-lys-D-ala-D-ala, but the loss of activity was not as severe. This 
reduction probably results from a loss of the Coulumbic interaction between the amine 
and the C-terminus of the tripeptide, because the amine would he positively charged at 
physiological pH. whereas the alcohol would not. 
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Figure 1.60. The compounds produced by Williams and co-workers. 107 
Compound Ka (ICI") Ac2 KA: A 
vancomycin 8±? x 10' 
N-desmethyl vancomycin 1.7 ± 0.7 x 10 
ketone -L2 0.3 x ± 10- 
alcohol 1.6 ± 0.1 x 104 
malonitrile N/A 
oxime 1.0 ± 0.6 x 10 
benzyl oxime ?. 0 ± 0.4 x 10 
Table 1.14. Binding constant of vancomycin, ; V-desmethyl vancomycin and the compounds 
produced Williams and co-workers. 107 
Further work by Williams and co-workers108 attempted to introduce a fourth amide into 
the binding pocket by acetylating N-demethylvancomycin and by replacing the N- 
methyl-D-leucine of vancomycin with N-acetyl-L-leucine, thus producing two N-acetyl- 
leucine derivatives, one D isomer and one L isomer. However, both of these showed 
reduced affinity to the tripeptide cell wall mimic. Again this is likely to be through loss 
of the Coulumbic interaction between the charged amine and the C-terminus of the 
tripeptide, since the acetamide will not protonate at physiological pH. Further analogues 
were created by producing the vancomycin ketone (Figure 1.60) and converting it to an 
acetylhydrazone, a tosyl-hydrazone and a semicarbazone (Figure 1.61). All three 
analogues showed reduced affinity to the tripeptide cell wall mimic. Again this can 
be 
explained by the introduction of a sp- centre replacing the amine of the leucine residue 
and forcing unfavourable conformational changes. 
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Figure 1.61. Further compounds produced by Williams and co-workers. 108 
Table 1.15. Bind: 
Compound Ka (NI-) Ac2K: A 
vancomycin 8x 1W 
N-desmethyl vancomycin 1.7 x 10 
N-acetyl-L-leucine 
derivative 3.6 x 104 
N-acetyl-D-leucine 
derivative 1.0 x 104 
acetyl hydrazone N/A 
semicarbazone N/A 
tosyl hydrazone ?. 0 x 104 
ine constant of vancomvcin. N-desmethvl vancomvcin an( 
produced Williams and co-workers. 108 
I the compounds 
Nicolaou et al. ' 09 produced a series of analogues where vancomycin was alkylated on 
the vancosamine sugar with substituted benzyl groups, then the terminal 
N-methylleucine was removed and an amino acid added to both the N-terminus and the 
C-terminus. All of the resultant analogues showed lower antibacterial activity compared 
to vancomycin against the three susceptible bacteria tested, but two compounds showed 
higher antibacterial activity against all the resistant bacteria tested, as measured by NIIC. 
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Figure 1.62. The two analogues active against resistant strains of bacteria 
produced by Nicolaou et al. 109 
MIC ( ml) 
E. faecalis 
Compound VISA vanc. 
sensitive vancomycin resistant (\"an A) 
MU50 133 4002 1528 2689 2741 2781 2805 
vancomycin 3.13 0.39 0.39 >100 50 >100 100 25 
L-val 2 1 2 8 >16 2 16 8 
L-cha 8 4 4 16 >16 16 16 16 
MIC ( ml) 
Com ound 
E. faecium 
p Van A Van A& synercid (Sat G) Van :. & synercid (Sat A) 
4001 1669 2671 2823 1803 1924 1944 
vancomycin >100 100 50 100 50 25 50 
L-val 8 8 8 8 8 8 8 
L-cha 16 16 16 8 16 8 8 
Table 1.16. MIC data for vancomycin and the two analogues produced by `icolaou et at. --- 
These results suggest that increasing the affinity to the tripeptide mimic of the cell wall 
by alterations to the N-terminus will be quite challenging. To produce a compound that 
shows not only increased binding to the cell wall mimic, but also improved biological 
activity against the whole organism observed in the MIC, would be a significant 
achievement. To extend the spectrum of action of vancomycin by restoring it: activity 
against resistant strains would be an even greater challenge. However, it is believed that 
the use of the powerful computational tools available in Leeds should allow the design 
of an appropriate modification to the N-terminus in order to increase the number of 
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interactions between the tripeptide and the glycopeptide and thus increase the affinitv 
and this is the basis of this project. 
1.8 Project outline 
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Figure 1.63.: ßn exploded view of vancomvcin binding a cell wall mimic. ' 07 
Figure 1.63 shows an exploded diagram of vancomycin bound to the tripeptide cell wall 
mimic, which is a tripeptide diacetyl-L-lys-D-ala-D-ala. As discussed earlier, 
vancomycin is bowl shaped and binds the tripeptide via a series of hydrogen bonds 
between the backbone amides of each moiety. Vancomycin attaches along the bottom of 
the tripeptide and wraps up along the sides. This leaves the top exposed to solvent and 
the available hydrogen bonding sites of this surface unutilised (Figure 1.64). 
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H-bond 
vancomycin backbone 
Figure 1.64.: schematic representation of vancomycin binding pocket. 
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The amino acid that completes the vancomycin heptapeptide is N-methyl D-leucine. The 
conformation this residue adopts is unfavourable for extension of the peptide, as shown 
by the compounds produced by Williams and co-workers. 10 There is also a further 
problem presented by this residue, the N-methyl substitutent means that the amide that 
results from acylation of this residue would have a methyl substitutent. The presence of 
the methyl on this resultant amide would prevent any interaction with the tripeptide, as 
it would have no hydrogens to hydrogen bond with and would no longer be charged at 
physiological pH. This makes this N-methyl D-leucine residue doubly unfavourable. 
However, it is possible to remove this terminal amino acid to give a hexapeptide, which 
terminates in a free amine eliminating this problem. This has been accomplished in the 
past by performing an Edman degradation, the conditions for which have been 
established by Booth et a!. 1 "' It is envisaged that vancomycin hexapeptide could be 
alkylated on the newly freed amine in such a way that allows the formation of an amide 
that can offer a hydrogen bond to the carboxylic acid terminus of the tripeptide. If this 
hydrogen bond forms it should orientate the remainder of the modifying fragment along 
the top surface of the tripeptide and thus offer hydrogen bonds to the unsatisfied sites on 
that surface (Figure 1.65). 
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Figure 1.65. A schematic of project concept. 
The increase in the number hydrogen bonds between the two molecules will increa"e 
the stability of the complex. This should not only increase the resulting compounds 
affinity to the tripeptide ligand and thus its effectiveness against the susceptible 
bacteria, but also should hopefully compensate for the effect of the replacement of the 
terminal D-alanine by either a lactate or a serine and thus reverse the resistance, making 
the new vancomycin analogue active against VRE or MRSA. 
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The modified vancomycin analogues will be designed using SPROUT. SPROUT is a 
de-novo design program that allows a user to take a 3D model of a structure and design 
a complimentary molecule that will offer binding interactions that satisfy the target. The 
best compounds that are designed will then be synthesised in the lab. In this sense 'best' 
includes both a consideration of what is most likely to improve the binding, but also 
whether it is possible to synthesise the compound. Therefore early in each SPROUT 
run, attempts will be made to prune out structures that are not going to be chemically 
stable, regardless of how highly they score in terms of binding affinity. 
1.9 References 
(1) Voet, D.; Voet, J. G. Prokaryotes. Biochemistry; 2nd ed.; John NVI ley and Sons, 
Inc.: New York, 1995; pp 2-6. 
(2) Prescott, L. M.; Harley, J. P.; Klein, D. A. DNA Replication. Microbiology, 4th 
ed.; The McGraw-Hill Companies. Inc., 1999; pp 216-221. 
(3) Nicklin, N.; Graeme-Cook, K.; Paget, T.; Killington, R. A. DNA Replication. 
Instant Notes in Microbiology; BIOS Scientific Publishers Ltd: Oxford, 1999; pp 
32-37. 
(4) Voet, D.; Voet, J. G. Type II Topoisomerase Supercoil DNA at the Expense of 
ATP Hydrolysis. Biochemistry; 2nd ed.; John Wiley and Sons, Inc.: New York, 
1995; pp 880-882. 
(5) Fisher, L. M.; Pan, X. -S. Targeting of DNA Gyrase in Streptococcus 
Pneumoniae by Sparfloxcin: Selective Targeting of Gyrase or Topoisomera, e IV 
by Quinolones. Antimicrob. Agents Chernother. 1997,41, (2), 471--1.74. 
(6) Osheroff, N.; Corbett, A. H.: Hong, D. Exploiting Mechanistic Differences 
between Drug Classes to Define Functional Drug Interaction Domains of 
Topoisomerase II. J. Biol. Chefin. 1993,268, (5), 14394-14398. 
(7) Cozzarelli, N. R.; Zechiedrich, E. L.; Khodursky, A. B. Topoisomerase IV, not 
Gyrase, Decatenates Products of Site-specific Recombination in Escherichia 
Coli. Genes Dev. 1997, ? 580-2592. 
(8) Voet, D.; Voet, J. G. Transcription. Biochemistry; 2nd ed.; John Wiley and Sons. 
Inc.: New York, 1995; pp 915-958. 
(9) Nicklin, N.: Graeme-Cook, K.; Paget, T.. Killington, R. A. Transcription. 
Instant Notes in Microbiology: BIOS Scientific Publishers Ltd: Oxford. 1999: pp 
40-45. 
73 
(10) Darst, S. A.; Campbell, E. A.: Korzheva, N., Mustaev, A.: %Jurakami. K.: Nair. 
S.; Goldfarb, A. Structural Mechanism for Rifampicin Inhibition of Bacterial 
RNA Polymerase. Cell 2001,104,901-912. 
(11) Chatterji, D.; Balakrishnan, V.. Varma, S. Piperine Augments Transcription 
Inhibitory Activity of Rimfampicin by Severalfold in Mycobacterium 
Smegmatis. Curr. Sci. 2001,80, (10), 1302-1305. 
(12) Prescott, L. M.; Harley, J. P.; Klein, D. A. Protein Synthesis. Microbiology: 4th 
ed.: The McGraw-Hill Companies, Inc., 1999; pp 226-233. 
(13) Scholar, E. M.; Pratt, W. B. The Antimicrobial Drugs; 2nd ed.; Oxford 
University Press: Oxford, 2000. 
(14) Kimball, J. W. Biology: 6th ed.: Wm. C. Brown Publishers: Dubuque, 1994. 
(15) Luzzatto, L.; Apirion, D.. Schlesinger, D. Polyribosome Depletion and 
Blockage of the Ribosome Cycle by Streptomycin in E. cherirhia coll. J. . 1/o/. 
Biol. 1969,42,315. 
(16) Fu, W.; Retsema, J. Macrolides: structures and microbial targets. Int. J. 
Antun icrob. Ag. 2001,18, S3-S 10. 
(17) Roberts, M.; Chopra, I. Tetracycline Antibiotics: Mode of Action, ; Application,,, 
Molecular Biology and Epidemiology of Bacterial Resistance. , 11i rohiol. t/O/. 
Biol. Rev. 2001,65, (2), 232-260. 
(18) Appelbaum, P. C.; Ednie, L. M.; Rattan, A.; Jacobs, M. R. Antianaerobic 
Activity of RBX 7644 (Ranbezolid), a New Oxazolidinone, Compared with 
Those of Eight Other Agents. Antimicrob. Agents Chernother. 2003,47, (3). 
1143-1147. 
(19) Appelbaum, P. C.; Bozdogan, B. Oxazolidinones: Activity, Mode of Action and 
Mechanism of Resistance. Int. J. c%ntimicrob. Ag. 2004,23,113-119. 
(20) Prescott, L. M.: Harley, J. P.; Klein, D. A. Antibacterial Drugs. Microbiology. 
4th ed.; The McGraw-Hill Companies, Inc., 1999; pp 684-690. 
(21) Achari, A.; Somers, D. O.: Champness, J. N.; Bryant, P. K.; Rosemond, J. 
Crystal Structure of the Anti-Bacterial Sulfonamide Drug Target 
Dihydropteroate Synthase. Nat. Struct. Biol. 1997,4, (6), 490-497. 
(22) Chiras, D. Human biology : health, homeostasis, and the environment; 2nd ed.; 
West Publishing Company: Minneapolis, 1995. 
(23) Bosscha, M. I.; van Dissel, J. T.: Kuijper. E. J.. Swart, W.. Jager, M. J. The 
Efficacy and Safety of Topical Polymyxin B, Neomycin and Gramicidin for 
74 
Treatment of Presumed Bacterial Corneal Ulceration. Brit. J. Opthalmol. 2004. 
88, (1), 25-28. 
(24) Langford, J. H.; Artemi 
, 
P.; Benrimoj, S. I. Topical Antimicrobial Prophylaxis 
in Minor Wounds. Ann Pharmacother. 1997,31, (5). 559-563. 
(25) Prescott, L. M.; Harley, J. P.; Klein, D. A. The Procaryotic Cell Wall. 
Microbiology; 4th ed.; The McGraw-Hill Companies, Inc., 1999; pp 51-58. 
(26) Rogers, H. J.; Perkins, H. R.; Ward, J. B. Microbial Cell Walls and , tlc, iib ones; 
1 st ed.; Chapman and Hall: London, 1980. 
(27) Salton, M. R. J. The Bacterial Cell Envelope -A Historical Perspective. 
Bacterial Cell Wall; Elsevier: London, 1994; pp 1-22. 
(28) van Heijenoort, J. Biosynthesis of the Bacterial Peptidoglycan Unit. Bacterial 
Cell Wall; Elsevier: London, 1994; pp 39-54. 
(29) Prescott, L. M.; Harley, J. P.; Klein, D. A. Differential Staining. ýtlicrobiolog ; 
4th ed.; The McGraw-Hill Companies, Inc., 1999; pp -15. 
(30) Diversity and Taxonomy of Living Kingdoms, 
http: //biology. unm. edu/ccouncil/Biology_124/Summaries/Kingdoms. html, 
accessed: March 2005 - July 2007. 
(31) Hubbard, B. K.; Walsh, C. T. Vancomycin Assembley: Nature's Way. , 4, rgew. 
Cheer., Int. Ed. 2003,42, (7), 730-765. 
(32) van Heijenoort, J. Recent Advances in the Formation of the Bacterial 
Peptidoglycan Monomer Unit. Nat. Prod. Rep. 2001,18, (5), 503-519. 
(33) Walsh, C. T. Enzymes in the D-Alanine Branch of Bacterial Cell Wall 
Peptidoglycan Assembley. J. Biol. Chen. 1989,264, (5), 2393-2396. 
(34) Bugg, T. D. H.; Walsh, C. T. Intracellular Steps of Bacterial Cell Wall 
Peptidoglycan Biosynthesis: Enzymology, Antibiotics and Antiiotic Resistance. 
Nat. Prod. Rep. 1992,9, (3), 199-215. 
(35) Mengin-Lecreulx, D.; van Heijenoort, J. Copurification of Glucosamine- l- 
Phosphate Acetyltransferase and N-Acetyl glucosamine-l-Phosphate 
Uridyltransferaýe of Escherichia coli: Characterisation of ginU Gene Product as 
a Bifunctional Enzyme Catalysing Two Subsequent Steps in the Pathway for 
UDP-N-Acetylglucosamine Synthesis. J. Bacteriol. 1994,176, (18). 5788-5795. 
(36) Brown, E. D.; Gehrig, A. M.; Lees, W. J.; Mindiola, D. J., Walsh, C. T. 
Acetyltransfer Preceeds Uridyltransfer in the Formation of UDP-N- 
Acetylglucosaminetn Seperable Active Sites of the Bifunctional GlmU Protein 
of Escherichia coli. Biochemistry 1996,35,579-585. 
75 
(37) Schleifer, K. H.; Kandler, 0. Peptidoglycan Types of Bacterial Cell Walls and 
their Taxonomic Implications. Bacteriol. Rev. 1972,36, (4). 407-477. 
(38) Ghuysen, J. -M.; Goffin, C. Multimodular Pencillin-Binding Proteins: An 
Enigmatic Family of Orthologs and Paralogs. Microbiol. Mot. Biol. Rev. 1998, 
62, (4), 1079-1093. 
(39) Ghuysen, J. -M. Biochemistry of the Penicilloyl Serine Transferases. Bacterial 
Cell Wall; Elsevier: London, 1994; pp 103-130. 
(40) Matsuhashi, M. Utilization of Lipid-linked Precursors and the Formation of 
Peptidoglycan in the Process of Cell Growth and Division: Membrane Enzyme,, 
Involved in the Final Steps of Peptidoglycan Synthesis and the Mechanism of 
their Regulation. Bacterial Cell Wall; Elsevier: London, 1994; pp 55-72. 
(41) Guilmi, A. M.: Dessen, A.; Dideberg, O.; Vernet, T. Bifunctional Penicillin- 
Binding Proteins: Focus on the Glycosyltransferase Domain and its specific 
Inhibitor Moenomycin. Curr. Pharm. Biotechno. 2002,3.63-75. 
(42) Bouhss. A.; Mengin-Lecreulx, D.: Le Beller, D.; van Heijenoort, J. Topological 
analysis of the MraY protein catalysing the first membrane step of 
peptidoglycan synthesis. Mol. Microbiol. 1999,34, (3), 576-585. 
(43) Ha, S.; Chang, E.; Lo, M.; Men, H.; Park, P.; Ge. M.: Walker. S. The Kinetic 
Characterization of Escherichia coli MurG Using Synthetic Substrate 
Analogues. J. , fin,. Chen. Soc. 1999,121, (37). 8415-8426. 
(44) McCormick, M. H.; Starck, W. M.; Pittenger, G. E.; Pittenger, R. C.. NIcGuire, 
G. M. Vancomycin: a new antibiotic.; Antibiotica: New York, 1956; pp 606- 
611. 
(45) Barna, J. C. J., Williams, D. H. The Structure and Mode of Action of 
Glycopeptide Antibiotics of the Vancomycin Group.. 4am. Rev. Microhiol. 1984, 
38,339-357. 
(46) Nagarajan, R. Antibacterial Activities and Mode of Action of Vancomvcin and 
Related Glycopeptides. 4ntrmicrob. Agents Cheinother. 1991,35. (4). 605-609. 
(47) Marshall, F. J. Structure Studies on Vancomycin. J. Aled. Cheri. 1965,8, (1), 
18-22. 
(48) Harris, T. M.; Harris, C. M.; Kopecka, H. Vancomycin: Structure and 
Transformation to CDP-I. J. Ain. Chem. Soc. 1983,105, (23), 69 15-6922. 
(49) Harris, T. M.; Harris, C. M. Structure of Glycopeptide Antibiotic Vancomycin, 
Evidence for an Asparagine Residue in the Peptide. J. Am. Chem. Soc. 1982. 
10-4, (15), 4'_93-42_95. 
76 
(50) Smith, G. A.; Smith, K. A.; Williams, D. H. Structural Studie,, on Antibiotic 
Vancomycin - Evidence for Presence of Modified Phenylglycine and Beta- 
Hydroxytyrosine. J. Chem. Soc., Perkin Trans. 1 1975,2108-2115. 
(51) Weringa, W. D.; Williams, D. H.; King, R. W.; Brown, J. P.: Feeney, J. 
Structure of an Amino-sugar from Antibiotic Vancomycin. J. Cliem. Soc., 
Perkin Trans. 1 1972,443-446. 
(52) Smith, G. A.; Williams, D. H.; Smith, K. A. Structural Studies on Antibiotic 
Vancomycin - Nature of Aromatic Rings. J. Chem. Soc., Perkin Trans. 1 1974. 
2369-2376. 
(53) Johnson, A. W.; Smith, R. M.; Guthrie, R. D. Vancosamine - Structure and 
Configuration of a Novel Amino-sugar from Vancomycin. J. Chemn. Soc., Perkin 
Trans. 1 1972,2153. 
(54) Williams, D. H.; Kalman, J. R. Structural and Mode of Action Studies on the 
Antibiotic Vancomycin. Evidence from 270 MHz Proton Magnetic Resonance. 
J. Am. Chem. Soc. 1977,99, (8), 2768-2774. 
(55) Sheldrick, G. M.; Jones, P. G.; Kennard, O.; Williams, D. H.; Smith, G. A. 
Structure of Vancomycin and it's Complex with Acevl-D-Alanyl-D-Alanine. 
Nature (London) 1978,271, (5642), 223-225. 
(56) Williamson, M. P., Williams, D. H. Structural Revision of the Antibiotic 
Vancomycin. The use of Nuclear Overhauser Effect Difference Spec tro copy. J. 
Am. Chem. Soc. 1981,103, (22), 6580-6585. 
(57) Williams, D. H. Structural Studies on Some Antibiotics of the Vancomyin 
Group, and on the Antibiotic-Receptor Complexes, by 1H NMR.. %rc. Chem. 
Res. 1984,17,364-369. 
(58) Harris, T. M.; Harris, C. M. Determination of the N-Terminal Residue of the 
Peptide in Ristocetin-A and Ristocetin-B by Reductive Isopropylation. 
Tetrahedron Lett. 1979,41,3905-3908. 
(59) Harris, T. M.; Harris, C. M. Structure of Ristocetin A: Configurational Studies 
of the Peptide. J. Am. Chefin. Soc. 1982,104, (1), 363-365. 
(60) Williams, D. H.; Rajananda, V.; Kalman, J. R. Structure and Mode of Action of 
the Antibiotic Ristocetin-A. J. Chem. Soc., Perkin Trans. 1 1979,3,787-79?. 
(61) Williams, D. H., Rajananda, V.; Bojesen, G.; Williamson, M. P. Structure of the 
Antibiotic Ristocetin-A. J. Chem. Soc., Chem. Commun. 1979.20.906-908. 
77 
(62) Williams, D. H.; Kalman, J. R. NMR-Study of the Structure of the Antibiotic 
Ristocetin-A - Negative Nuclear Overhauser Effect in Structural Elucidation. J. 
Am. Chem. Soc. 1980,102, (3), 897-905. 
(63) Williamson, M. P.; Williams, D. H. A 13 C NMR-Study of the Carbohydrate 
Portion of Ristocetin-A. Tetrahedron Lett. 1980,21, (43), 4187-4188. 
(64) Williams, D. H.; Butcher, D. W. Binding Site of the Antibiotic Vancomycin for 
a Cell-Wall Peptide Analogue. J. Am. Chem. Soc. 1981,103, (19). 5697-5700. 
(65) Williams, D. H.; Williamson, M. P.; Butcher, D. W.; Hammond, S. J. Detailed 
Binding Sites of the Antibiotics Vancomycin and Ristocetin A: Determination of 
Intermolecular Distances in Antibiotic / Subtrate Complexes by Use of the 
Time-Dependent NOE. J. Anl. Chem. Soc. 1983,105, (5), 1332-1339. 
(66) Williams, D. H.. Williamson, M. P., Hammond, S. J. Interactions of 
Vancomycin and Ristocetin with Peptides as a Model for Protein Binding. 
Tetrahedron 1982,40, (3), 569-577. 
(67) Harris, C. M.; Kopecka, H.; Kannan, R.; Harris, T. M. The Role of the Chlorine 
Substituents in the Antibiotic Vancomycin: Preparation and Characterization of 
Mono- and Didechlorovancomycin. J. Am. Chem. Soc. 1985,107, (23), 6652- 
6658. 
(68) Karman, R.; Harris, C. M.; Harris, T. M., Waltho, J. P.; Skelton, N. J.; Williams, 
D. H. Function of the Amino Sugar and N-Terminal Amino Acid of the 
Antibiotic Vancomycin in its Complexation with Cell Wall Peptides. J. Am. 
Cient. Soc. 1988,110, (9), 2946-2953. 
(69) Nakamura, K.; Shigeru, N.; Yamamura, S. Interaction Between Bacterial Cell 
Wall Model and Aglucovancomycin or its Synthetic Analogues. Tetrahedron 
Lett. 1995,36, (47), 8629-8632. 
(70) Cristofaro, M. F.; Beauregard, D. A.; Yan, H.: Osborn. N. J.; Williams, D. H. 
Cooperativity Between Non-polar and Ionic Forces in the Binding of Bacterial 
Cell Wall Analogues by Vancomycin in Aqueous Solution. J. , 4ntibiot. 1995,4S, 
(8), 805-810. 
(71) Ge, M.; Chen, Z.; Onishi, H. R.; Kohler, J.; Silver, L. L.; Kerns, R.; Fukuzawwa, 
S.; Thompson, C.; Kahne, D. Vancomycin deravatives that inhibit peptidoglycan 
biosynthesis without binding D-Ala-D-Ala. Science 1999,84.507-511. 
(72) Chen, Z., Eggert, U. S.: Dong, S. D.; Shaw, S. J., Sun, B., LaTour, J. V., Kahne, 
D. Structural requirements for VanA activity of vancomycin analogue,,. 
Tetrahedron 2002,58,6585-6594. 
78 
(73) Leimkuhler, C.; Chen, L.; Barret, D.: Panzone, G.; Sun, B.; Falcone, B.; 
Oberthur, M.; Donadio, S.; Walker, S.; Kahne, D. Differential Inhibition of 
Staphylococcus aurelus PBP2 by Glycopeptide Antibiotics. J. Am. Chem. Soc. 
2005,127, (10), 3250-3251. 
(74) Roy, R. S.; Yang, P.; Kodali, S.. Xiong, Y.; Kim, R. Lt.; Griffin. P. R.; Onishi, 
H. R.; Kohler, J., Silver, L. L.; Chapman, K. Direct Interaction of a Vancomycin 
Derivative with Bacterial Enzymes Involved in Cell Wall Biosynthe,, i:. Chem. 
Biol. 2001,8,1095-1106. 
(75) Try, A. C.; Sharman, G. J.: Dancer, R. J., Bradsley. B., Entre,,,,. R. iii. H.. 
Williams, D. H. Use of Model Cell Membranes to Demonstrate Templated 
Binding of the Vancomycin Group Antibiotics. J. Chem. Soc., Perkin Trans. 1 
1997,19,2911-2917. 
(76) Waltho, J. P.; Williams, D. H. Aspects of molecular recognition: solvent 
exclusion and dimerization of the antibiotic ristocetin when bound to a model 
bacterial cell-wall precursor. J. Am. Chem. Soc. 1989,111, (7), 247-248U. 
(77) Gerhard, U.; Mackay, J. P.; Maplestone, R. A.; Williams, D. H. The Role of the 
Sugar and Chlorine Substituents in the Dimerization of Vancomycin Antibiotics. 
J. Ant. Chem. Soc. 1993,115, (1), 232-237. 
(78) Beauregard, D. A.; Williams, D. H.; Gwynn, M. N.; Knowles, D. J. 
Dimerization and Membrane Anchors in Extracellular Targeting of Vancomycin 
Group Antibiotics. Antimicrob. Agents Chemother. 1995,39, (3), 781-785. 
(79) Schäfer, M.; Schneider, T. R.; Sheldrick, G. M. Crystal structure of vancomycin. 
Structure 1996,4, (12), 1509-1515. 
(80) Loll, P. J.. Bevivino, A. E.; Korty. B. D.; Axlesen, P. H. Simultaneous 
Recognition of a Carboxylate-Containing Ligand and an Intramolecular 
Surrogate Ligand in the Crystal Structure of an Asymmetric Vancomycin Dimer. 
J. Aire. Chem. Soc. 1997,119, (7), 1516-1522. 
(81) Kaplan, J.; Korty, B. D.; Axlesen, P. H.; Loll, P. J. The Role of Sugar Residue, 
in Molecular Recognition by Vancomycin. J.: %1ed. Chem. 2001.44. (]1). 1837- 
1840. 
(82) Lehmann, C.: Bunkoczi. G.: Vertesy, L.; Sheldrick. G. M. Structure,, of 
Glycopeptides with Peptides that Model Bacterial Cell-Wall Precursors. J. Vol. 
Biol. 2002,318, (3), 723-732. 
(83) Shiozaw a, H.; Zerella, R.; Bardsley, B.; Tuck, K. L.: Williams. D. H. 
Noncovalent Bond Lengths and Their Cooperative Shortening: Dimers of 
79 
Vancomycin Group Antibiotics in Crystals and in Solution. HeIt. Chim.. 4cta 
2003,86,1359-1370. 
(84) Rao, J.; Whitesides, G. M. Tight Binding of a Dimeric Deri \ ative of 
Vancomycin with Dimeric L-Lys-D-Ala-D-Als. J. Ani. Chem. Soc. 1997,119, 
(43), 102810290. 
(85) Staroske, T.; Williams, D. H. Synthesis of Covalent Head-to-Tail Dimers of 
Vancomycin. Tetrahedron Lett. 1998,39,4917-4920. 
(86) Nicolaou, K. C.. Hughes, R.; Cho, S. Y.; Wissinger, N.. Labischinski, H.: 
Endermann, R. Synthesis and Biological Evaluation of Dimers vv ith Potent 
Activity against Vancomycin -Resistant Bacteria: Target-Accelerated 
Combinatorial Synthesis. Chefin. Eur. J. 2001,7, (17), 38-14-3843 
(87) Nicolaou, K. C.; Hughes, R.; Cho, S. Y.. Wissinger, N.; Smethurst, C.; 
Labischinski, H.; Endermann, R. Target-Accelerated Combinatorial Synthesi' 
and Discovery of Highly Potent Antibiotics Effective Against Vancomvcin- 
Resistant Bacteria. An gew . Chem.. hit. Ed. 2000,39. (? 1). 3823-38-18. 
(88) Kirst, H. A.; Thompson, D. G.; Nicas, T. I. Historical Yearly Usage of 
Vancomycin. 4ntimicrob. Agents Chemother. 1998,42. (5). 1303-1304. 
(89) Leclercq, R.; Derlot, E., Duval, J.; Courvalin, P. Plasmid-Mediated Resistance 
to Vancomycin and Teicoplanin in Enterococrus faecium. Ne« Engl. J. ; tiled. 
1988,319, (3), 157-161. 
(90) Bugg, T. D. H.; Wright, G. D.; Dutka-Malen, S.; Arthur, M.; Courvalin, P.; 
Walsh, C. T. Molecular Basis for Vancomycin Resistance in Enterococcus 
faecium BM4147: Biosynthesis of a Depsipeptide Peptidoglycan Precursor by 
Vancomycin Resistance Proteins VanH and VanA. Biochemistry 1991,30, (43), 
10408-10415. 
(91) Walsh, C. T.; Fisher, S. L.; Park, I. -S.; Prahalad, M.; Wu, Z. Bacterial 
Resistance to Vancomycin: Five Genes and One Missing Hydrogen Bond Tell 
the Story. Chem. Biol. 1991,3, (1), 21-28. 
(92) Pootoolal, J.; Neu, J.; Wright, G. D. Glycopeptide Antibiotic Resistance. Annu. 
Rev. Pharmacol. Toxicol. 2002,42,381-408. 
(93) Dong, S. D.; Oberthur, M.; Losey, H. C.; Anderson, J. W.; Eggert, U. S.; 
Peczuh, M. W.; Walsh, C. T.; Kahne, D. The Structural Basis for Induction of 
VanB Resistance. J. , ern. Chem. Soc. 2002,124, (31). 
9064-9065. 
80 
(94) McCormick, M. H.; Crowley, B. M.; Boger, D. L. Partitioning the Lo,: in 
Vancomycin Binding Affinity for D-Ala-D-Lac into Lost H-Bond and Replusivve 
Lone Pair Contributions. J. Am. Chem. Soc. 2003,125. (31). 9314-9315. 
(95) Park, I. -S.: Lin, C. -H.; Walsh, C. T. Bacterial Resistance to Vancomycin: 
Overproduction, Purification and Characterisation of VanC2 from Entrococcus 
casseliflavus as a D-Ala-D-Ser ligase. Proc. Natl. Acad. Sci. U. S. A. 1997,9-1, 
10040-10044. 
(96) Glupczynski, Y.; Lagast, H.; Van Der Auwera, P.; Thy s. J. P., Crokaert, F.; 
Yourassowsky, E.; Meunier-Carpentier, F., Klastersky, J., Kains. J. P.: Serruyrs- 
Schoutens. E.; Legrand, J. C. Clinical Evaluation of Teicoplanin for Therap} of 
Severe Infections Caused by Gram-Positive Bacteria.. tntimicrob.. 1,, ý, c'nts 
Che, iiother. 1986,29, (1), 52-57. 
(97) Nicas, T. I.: Cole, C. T.; Preston, D. A.; Schabel, A. A.; Nagarajan, R. Acti\ ity 
of Glycopeptides against Vancomycin-resistant Gram-Positive Bacteria. 
Antimicroh. 1 'ciits Cltenwther. 1989,33, (9), 1477-1481. 
(98) Nagarajan, R.; Schabel, A. A.; Occolowitz, J. L.: Counter, F. T.: Ott, J. L.: 
Felty-Duckworth, A. M. Synthesis and Antibacterial evaluation of N-; \Ikyl 
Vancomycins. J. Antibiot. 1989,42,63-72. 
(99) Nagarajan, R.; Schabel, A. A.; Occolowitz, J. L.; Counter, F. T.; Ott, J. L. 
Synthesis and Antibacterial Activity of N-Acyl Vancomycins. J. , 4ntibiot. 1988, 
41,1430-1438. 
(100) Allen, N. E.; LeTourneau, D. L.; Hobbs, J. N.; Thompson, R. C. Hexapeptide 
Derivatives of Glycopeptide Antibiotics: Tools for Mechanism of Action 
Studies. Antimicrob. Agents Chemother. 2002,46. (8). -1344--1348. 
(101) Allen, N. E.; Le Tourneau, D. L.: Hobbs Jr, J. N. The Role of Hydrophobic Side 
Chains as Determinants of Antibacterial Activity of Semisynthetic Glycopeptide 
Antibiotics. J. Antibiot. 1997,50. (8). 677-684. 
(102) Allen, N. E.; Le Tourneau, D. L.; Hobbs Jr, J. N. Molecular Interactions of a 
Semisynthetic Glycopeptide Antibiotic with D-Alanyl-D-Alanine and D-Alin` l- 
D-Lactate Residues. Anti, nh rob. Agents Chemother. 1997,41. (1). 66-71. 
(103) Mackay, J. P.; Gerhard, U., Beauregard, D. A.. Maplestone, R. A.; Williams, D. 
H. Dissection of the Contribution,, toward Dimerization of Glycopeptide 
Antibiotics. J. Am. Chem. Soc. 1994,116, (11). 4573-4580. 
(104) Malabarba, A.. Nicas, T. I., Thompson, R. C. Structural Modificationw, of 
Glycopeptide Antibiotics. Med. Res. Rev. 1997,17. (1 ). 69-1 ý7. 
81 
(105) McAtee, J. J.; Castle, S. L.; Jin, Q.; Boger, D. L. Synthesis and Evaluation ot 
Vancomycin and Vancomycin Aglycon Analogues that Bear Modifications in 
the Residue 3 Asparagine. Bioorg. Med. Chem. Lett. 2002,12,1319-1322. 
(106) Crowley, B. M.; Boger, D. L. Total Synthesis and Evaluation of 
[Y[CH-, NH]Tpg4] Vancomycin Agylcon: Reengineering Vancomycin for Dual 
D-Ala-D-Ala and D-Ala-D-Lac Binding. J. Am. Chem. Soc. 2006,12S. 2885- 
2892. 
(107) Gale, T. F.; Gorlitzer, J.; O'Brien, S. W.; William, D. H. The S\nthesis and 
Binding of N-Terminal Derivatives of Vancomycin to a Bacterial Cell Wall 
Analogue. J. Chem. Soc., Perkin Trans. 1 1999,16,2267-2270. 
(108) Gorlitzer, J.; Gale, T. F.; William, D. H. Attempted Introduction of a Fourth 
Amide NH into the Carboxylate-binding Pocket of Glycopeptide Antibiotics. J. 
Cheer. Soc., Perkin Trans. 1 1999,3253-3257. 
(109) Nicolaou, K. C.; Cho, S. Y.; Hughes, R.; Winssinger, N., Smethurst, C.; 
Labischinski, H., Endermann, R. Solid- and Solution-Phase Synthesis of 
Vancomycin and Vancomycin Analogues with Activity against Vancomycin- 
Resistant Bacteria. CIwini., trv- ,4 European Journal 
2001,7, (17). 3798-38-3. 
(110) Booth, P. M.; Stone, D. J. M.; Williams, D. H. The Edman Degration of 
Vancomycin: Preparation of Vancomycin Hexapeptide. J. Chem. Soc., Chem. 
Coinniuni. 1987,22,1694-1695. 
82 
Chapter Two 
Design Phase 
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2.1 Introduction 
A significant part of this research was the design of the fragments intended to extend the 
hexapeptide core of vancomycin. This aspect of the work was novel as computer aided 
design had not been used in the design of complex semi-synthetic drugs. It was also an 
unusual application of the design software, SPROUT, as this program was developed by 
the ICAMS group at the University of Leeds to use the constraints of a cavity (active or 
allosteric site) within the structure of a target protein in order to help design strong 
binding inhibitors for that protein. Here, the problem is effectively reversed as 
vancomycin acts as a receptor for the peptides of the cell wall or the mimic: of these 
peptides. This means that there were not the constraints normally a\ ailable. 
This section will explain SPROUT, the results achieved and how they were processed 
with MOLOC, a molecular modelling program. 
2.2 SPROUT 
SPROUT was created in the Institute for Computer Applications in Molecular Sciences 
(ICAMS), University of Leeds. The basic concept of the program is to design ligands by 
combining templates that represent small molecular fragments. These are usually 
constrained within a protein cavity, which provides electrostatic and 1teric control, 
preventing a combinatorial explosion. The program is composed of sir modules that 
deal with different aspects of the structure generation process. 
Five of the modules are regularly used and are discussed in detail below, most u"er, do 
not often use the sixth module, which is the Template Library Manager (TLM) module. 
The TLM helps the user import new templates or edit existing templates and is not 
discussed here in detail. 
SPROUT mainly uses PDB files, but MOL files can be used to import templates in the 
TLM module, and ligands or partial structures in the ELEFANT module. Neither 
hydrogens nor lone pairs of electrons are implicit in PDB files, so the program adds 
these. SPROUT represents both hydrogens and lone pairs as dummies. Dummy 
positions are calculated based on the existing atoms surrounding the atom to which the 
dummies are attached. Dummies are essentially vectors of a defined length, which have 
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assignable properties and represent the unsatisfied valancies of atoms in the existing 
structure. Dummies can have a combination of any of the following characteristics: they 
can be H-bond acceptors, donors, hydrophobic and/or joinable. Acceptor, donor or 
hydrophobic means the dummy would satisfy that type of site. joinable means that it can 
be used in forming new bonds during structure growth. 
2.2.1 CANGAROO 
CANGAROO stands for Cleft ANalysis by Geometry based Algorithm Regardless Of 
the Orientation. This is the first of the five modules and is used to analyse a PDB file of 
the target structure. The target would normally be an enzyme complex and the tool, 
within this module are used to identify an appropriate cavity for an inhibitor. Existing 
ligands and solvent molecules can be separated from the chains of a protein. Two files 
are created within this module: the cavity file, a PDB file that roughly defines the area 
of interest in the protein, and the receptor file, a PDB file that contains the re"idues that 
surround the cavity. 
2.2.2 HIPPO 
HIPPO stands for Hydrogen bonding Interaction site Prediction as Positions wk ith 
Orientation. This module uses the two files created in CANGAROO to create target 
sites within the area of interest in a protein. The first stage is grid box generation, which 
takes the cavity file as a starting point and adds a user-defined margin (the grid box 
tolerance) to generate a box centred on the cavity and this defines the area of interest. 
The program ignores any part of the protein structure outside this grid box. 
The program then uses the residue set defined within the receptor file to generate target 
sites. The residues are interpreted using a set of knowledge-based rules which firstly 
assigns dummies to satisfy the valency of all the atoms, and then examines the hetero- 
atoms that have dummies and generates target sites for each of these. The program 
attempts to match the sites into donor and acceptor pairs that satisfy the internal 
hydrogen bond interactions of the receptor and then it displays all the remaining 
unsatisfied sites for the user. 
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SPROUT can generate target sites for hydrogen-bond donor or acceptor sites, 
hydrophobic, covalent and metal ion sites. However, only acceptor and donor sites were 
used in this project and thus are discussed in detail below. 
Acceptor sites are defined by locating electronegative hetero-atoms in the residue set the 
have unsatisfied donor dummies, then applying the set of knowledge-based rules that 
generate the site based on a series of tolerances around the perfect geometry for a 
hydrogen bond. The perfect geometry for a hydrogen bond would have the donor 
hetero-atom, the hydrogen, the lone pair and the acceptor hetero-atom all aligned. This 
means the angle between the donor, the hydrogen and the acceptor would be 180. The 
hydrogen would be IA from the donor and 1.85 A from the acceptor. The perfect 
arrangement for a hydrogen bond very rarely occurs, so tolerances are added that 
favours the optimal placement of the acceptor atom to create the hydrogen bond. 
Adding a minimum and a maximum distance from the hydrogen, and allowing an angle 
tolerance frone the line of the dummy creates the site. If an acceptor atom can be placed 
inside the red region it satisfies the site and can form a hydrogen bond to the donor, as 
show in Figure 2.1. 
111111. dIltJIIL'C Default ýalurý: min dktanrc =I 6A 
max. diltance = 2.2A 
D H----------- AIä t> 
A= acceptor 
D= donor 
may. Int; inr 
Figure 2.1. An acceptor site. 
The user can alter the angle, 6, and the minimum and maximum distance,,. but the 
default values are defined based upon analysis of the Cambridge Crystallographic 
Database. 
Donor sites are created in a similar fashion, again hetero-atoms that have an unsatisfied 
dummy are found, but this time the dummy must be an acceptor. The site is slightly 
more complex and has two regions, the first (white in Figure 2.2) is generated by taking 
the minimum and maximum distances and the angle tolerance, and the second (blue in 
Figure 2.2) is generated by adding IA to the minimum and maximum distances, but 
uses the same angle tolerance. This `generates two region,, that are both part spheres a 
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smaller white, hydrogen atom region and a larger blue, donor atom region. If a donor 
atom can be placed in the blue region so that a dummy is in the white region, the site is 
satisfied and a hydrogen bond can be formed to the acceptor, as show in Figure 2.2. 
fu r). ý! i ýLalll/ \6 
A------H 
IA 
max. di. t. incr 
I)etault \ulueý: rain. di, tan c=I. bA 
max. distance ='_. 2A 
(S=45° 
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I)=doll 
Figure 2.2. A donor site. 
The user can also alter the angle, 6, and the minimum and maximum distances for donor 
sites, but again the default values were set based on analysis of the Cambridge 
Crystallographic Database. 
There are also sites called spheric sites that can be placed by the user. These are spheres 
that can be varied in size and can have defined types. The default spheric sites are 
generic and are satisfied by any atom. Donor, acceptor or hydrophobic spheric sites can 
only be satisfied if the corresponding atom type is docked to it. 
The user selects a subset of targets in the HIPPO module that are taken on to the next 
module. 
2.2.3 ELEFANT 
ELEFANT stands for ELEction of Functional groups and ANchoring them to Target 
sites. In this module the user selects a site or a group of sites from the target set created 
in HIPPO and then templates, from the template list, are selected to dock to them. More 
than one template can be docked to each site or set of sites. When any template is 
selected the program docks it to the site in all the possible poses that satisfy the site type 
and the electrostatic and steric constraints around the site. Any undesirable poses can be 
deleted in this module. An example of an undesirable pose would be one that orientates 
all the joinable dummies away from the next docked template and would prevent that 
template being efficiently joined in the next module. 
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A set of templates that satisfies one site or one group of sites is called a tree, the whole 
set of trees is described as the forest. The poses of each template within the tree are 
described as nodes. 
Once all the required sites have templates docked and the undesirable template pose; 
removed, the forest is saved for use in the next module. 
2.2.4 SPIDER 
SPIDER stands for Structure Production with Interactive DEsign of Results. This 
module generates whole structures that satisfy all the sites by joining the trees together. 
This is done with a repeated tree pair joining technique, where pairs of trees are selected 
and joined, then another pair is selected and joined, until all the trees are joined and 
there is only one tree that satisfies all the sites. The joining process begins by assigning 
a seed vertex, this is the atom within the node (docked template) of one tree which is 
closest to the node of the other tree in the pair. Each node in each tree is given a seed 
vertex and then the nodes are extended towards each other from the seed vertex with 
spacer templates that are selected by the user. The spacer templates can be added by a 
Spiro, a fuse or a new bond join (Figure 2.3). 
a 
Docked template Spacer template 
1 
zýz: ý7ý New bond join = seed vertex 
Spiro join 
ZýýD 
Fuse join 
Figure 2.3. Spacer template addition. 
During the extension process every spacer template is used to extend every node, so that 
all possible combinations are explored up to the point where the combinations are 
exhausted, the part-structures created span over half the distance between the two sites 
or the system runs out of memory. 
When every node of both trees has been extended so that the halfway point between the 
two trees is reached, the program attempts to join the trees by overlapping fragments of 
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both part-structures (Figure 2.4). If they can be overlapped then the solutions are tested 
to ensure that they do not violate the boundary of the cavity or any of the user defined 
parameters. If they do not they are placed in the results tree, if they do they are 
discarded and then the search moves on to the next pair of extended node. 
ck::: ý Cb Site 1 Site 2 
Addition of 
spacer templates 
Site 1 Site 2 
Overlap and 
connection 
Site 1 Site 2 
Figure 2.4. Extension and overlap during connection. 
It is possible for the user to intervene after each tree pair is coupled and prune 
unfavourable nodes from the solution tree. This can be done manually, by deleting 
single nodes or it can be done using the automated tools of the next module. 
Alternatively, the program can be run continuously to automatically connect all 
available trees. It should be noted that although in most cases the user will connect all 
trees in SPIDER, this is not a requirement of the software and the user can stop after 
any number of tree pair connections and evaluate the results as complete structures. 
2.2.5 ALLIGATOR 
ALLIGATOR stands for ALgorithm for LIGAnd Testing and Ordering of Result". 
This module is used to sort the structures produced and there are a number of tools 
available for this. Structure can be sorted on their physical properties, like ?D similarity, 
number of rotatable bonds, numbers of stereo-centres etc. There are also two scoring 
functions, one that estimates the affinity and the other that estimates the complexity. 
The affinity scoring function assesses the interaction between the structure and the 
target. This function takes into account hydrogen bonding, van der ýý'aal,. metal ion. 
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electrostatic and hydrophobic interactions, each factor is given a value that reflects its 
magnitude and is multiplied by a weighting factor. The values for each property are then 
added together and give an overall score, expressed as a pK; value, which can be used to 
rank the structures created. The larger the negative number the higher the structure 
scores. The complexity function analyses just the structure and looks at the number of 
rotatable bonds, the number of stereo-centres, gauche interactions and the number of 
atom. Again each factor is given a value that reflects its magnitude and is multiplied by 
a weighting factor. The values for each property are then added together and give an ltý 
overall score that can be used to rank the structures created. The larger the positive 
number, the worse the structure is. Complexity is an undesirable propert\ as it makes 
the structures less synthetically accessible. 
There is a substructure search tool that can be used to find certain structural motifs, and 
this is often a useful way to prune partial-structures that are brought into ALLIGATOR 
part way through the joining phase in SPIDER. There are also a number of selection 
tools allowing the user to sort on a property then select structures that score either high 
or low in the given property. 
There is a further tool in this module - hetero-substitution. This replaces generic atoms 
of the templates with specific hetero-atoms that satisfy the electrostatic constraints of 
the environment. 
All these tools combine to help the user select structures with a high-predicted affinity 
and high synthetic tractability. 
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2.3 Results 
SPROUT and MOLOC have been successfully used to create a number of analogue, of 
vancomycin with predicted increased affinity for the tripeptide cell wall mimic. 
2.3.1 SPROUT 
Extensions of vancomycin hexapeptide have been designed using the crystal structure 
(PDB code 1 FVM') of the complex between vancomycin and a tripeptide cell wall 
mimic. This tripeptide is diacetyl-L-lys-D-ala-D-ala. The mimic approximates the 
intermediate that is bound by vancomycin in order to inhibit bacterial cell wall growth. 
The crystal structure with resolution 1.8 A was imported into SPROUT frone the RCSB 
Protein Data Bank. 2 The tripeptide ligand was defined in CANGAROO as both the 
cavity and the receptor. This gave sites shown in Figure 2.5, when the sites were 
explored in HIPPO with the grid box tolerance set to 4.0. 
The sites generated from the two N-acyl residues were omitted for clarity and were not 
used in any of the SPROUT runs. 
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Figure 2.5. The tripeptide and its generated sites. 
O-Lys, N-Alai and O1-Alai are all fully satisfied by vancomycin or its hexapeptide. 
02-Alai is only partially satisfied, as only one of the two available hydrogen bonding 
lone pairs is used. 
In all cases the extending fragments were joined to the vancomycin core by means of an 
amide bond. This amide was formed on the N-terminal amine of the last amino acid in 
the hexapeptide. Therefore three spheric sites were placed and an amide docked into 
them in order to represent this connection. 
In the initial attempts to generate extending structures the three spheric site, for the 
amide and three unsatisfied sites along the top face of the tripeptide were selected, the 
sites were N-A1a2, O-Ala2, and 02-Ala I (Figure 2.6). 
connecting amide. 
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Figure 2.6. The tripeptide ligand, the generated H-bonding sites and three spheric sites for the 
The following templates were docked to each site (Table 2.1). 
Site(s) Template(s) 
Spheric 1,2 and 3 Amide 
02-Ala I Amide, piperazine, 6-membered aliphatic ring, 6-membered 
aromatic and 5-membered aromatic 
O-Ala2 Amide, spa amine, 6-membered aromatic and 5-membered 
aromatic 
N-Ala2 Amide, carboxylic acid, sulphonamide and carbonyl 
Table 2.1. Template selection in run 1. 
Single gip` carbon, amide, 6-membered aromatic ring and 5-membered aromatic ring 
spacer templates were used during the connection phase in SPIDER. The lack of a steric 
constraint to minimise the combinatorial explosion, resulted in a large number of 
structures being generated. In fact, the number of results was large enough to cause 
SPROUT to crash. The structures created before the program crashed highlighted a 
further problem. The extending structures created were very close to the edge of sites 
02-Ala 1 and O-Ala2 and as a result would clash with the hexapeptide. Thus in order to 
add a steric constraint and provide a barrier to prevent the structures being created that 
would clash with the hexapeptide, a number of runs were performed where the 
tripeptide and parts of the hexapeptide were saved as a single PDB file and this was 
defined as both the cavity and the receptor. This did decrease the number of structures 
and prevented some of the clashes being present, but these combined structures ww ere 
time consuming to create and did not remove all the undesirable results. 
An alternate and more successful approach was to place a further spheric site 
(I A in 
diameter) within each of the donor sites (Figure 2.7) and dock the templates to 
both the 
donor and the spheric site at the same time as shown in Table ,. _' and 
2.3. 
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connecting amide and the two additional spheric sites. 
One run was performed using spheric site 4 and the 6 original sites. with the templates 
in Table 2 
. 
2. The addition of . spheric site 
4 introduced a further steric constraint. 
Site(s) Template(s) 
Spheric 1,2 and 3 Amide 
02-Ala I and spheric 
4 
Piperazine, 6-membered aromatic and 5-membered aromatic 
O-Ala? Amide, sp amine, 6-membered aromatic and 5-membered 
aromatic 
N-Ala2 Amide, carboxylic acid, sulphonamide and carbonyl 
Table 2.2. Template selection in the run with the addition of spheric site 4. 
Single spa carbon, 6-membered aromatic and 5-membered aromatic ring spacer 
templates were used during the connection phase in SPIDER. This produced twenty 
extending structures after removal of chemically unstable or undesirable results. Of 
these, the eight highest scoring were taken on to combine in MOLOC. 
A further run was performed using spheric site 4 and 5 with the 6 original sites and the 
templates shown in Table 2.3. This run has even greater steric constraint, as the addition 
of spheric site 5 provides further constraints to the growth of the structure. 
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Figure 2.7. The tripeptide ligand, the generated H-bonding sites, the three spheric sites for the 
Site(s) Template(s) 
Spheric 1,2 and 3 Amide 
02-Ala 1 and spheric 
4 
Piperazine, 6-membered aromatic and 5-membered aromatic 
O-Ala2 and spheric 5 Amide, sp amine, 6-membered aromatic and 5-membered 
aromatic 
N-Ala2 Amide, carboxylic acid, sulphonamide and carbonyl 
Table 2.3. Template selection in the run with both spheric site 4 and 5. 
Single sp 3 carbon, 6-membered aromatic and 5-membered aromatic rings spacer 
templates were used during the connection phase in SPIDER. This produced eleven 
extending structures after removal of chemically unstable or undesirable results. Of 
these, the four highest scoring were taken on to combine in MOLOC. 
95 
2.3.2 MOLOC 
The SPROUT runs had produced twelve structures that were to be combined with the 
hexapeptide to produce vancomycin analogues. During the editing process in MMOLOC a 
number of additional structures were created by adding or removing spacer carbons 
from the original SPROUT structure and by variation of the placement of hetero-atom". 
The extending fragments and the hexapeptide were combined by removing the amino 
group from the N-terminus of the hexapeptide. The hexapeptide and each extending 
fragment were then made single entries and then the bond that connects the extending 
fragment to the hexapeptide was added. When each analogue was complete they were 
minimised in MOLOC using the MAB force field, in the presence of the tripeptide in 
the conformation it adopted in the PDB I FVM. 1 
This process created 18 analogues that were evaluated in MOLOC. For each of these 
five intermolecular energy interactions were recorded. These interactions were between 
the vancomycin analogue and the tripeptide chain after energy minimisation. They were 
hydrogen bond energy, repulsive and attractive van der Waals energies and repulsive 
and attractive columbic energies. From these five energies. the total energy of the 
intermolecular interactions was calculated, i. e. the sum of three attractive forces minus 
the sum of the two repulsive forces. A higher value for this total energy predicts a more 
stable complex between the analogue and the tripeptide. The five highest scoring 
complexes were taken back into SPROUT and scored and are shown on the following 
pages with their SPROUT scores, abbreviated structures are included for clarity. The 
complex of vancomycin and the tripeptide is included for comparison. The hydrogen 
bond network is shown in yellow for each complex. 
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Figure 2.8. Compound 1, SPROUT score -9.25. 
Figure 2.9. Compound 2, SPROUT score -9.10. 
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Figure 2.10. Compound 3, SPROUT score -8.93. 
Figure 2.11. Compound 4, SPROUT score -831. 
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Figure 2.12. Compound 5, SPROUT score -8.20. 
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Figure 2.13. Vancomycin, SPROU1' score -7.63. 
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2.3.3 Target selection 
Examining the results showed that structures where a piperazine i, docked to O? -. \Ial 
were high scoring. In ALLIGATOR there is a function called the vertex , core table that 
breaks down the score and shows the contribution each atom of a structure male, to the 
total score. Analysis of this table for the piperazine methylene group', shoýý s that they 
score well as hydrophobic atoms. This is because of a hydrophobic interaction's ith the 
methyl substitutent of alaninel. This interaction was highly desirable as it mimics the 
strong interaction between the N-methyl leucine side chain that is present in the 
tripeptide vancomycin complex. This resulted in the rejection of compound 1, as it did 
not contain a piperazine ring and the phenyl ring present formed only a ww eak interaction 
with the methyl of alaninel. Compound 2 was the next highest scoring compound and 
appeared to be synthetically amenable, it was predicted by SPROUT to have o\ er an 
order of magnitude increase in affinity as compared to vancomycin and "o wwa. selected 
as the target compound. 
2.4 Further designs 
2.4.1 Amino acid variation 
During the synthetic process that was underway to produce the initial target it became 
obvious that it should be relatively simple to produce further analogues of compound 2 
by varying the terminal amino acid of the extending fragment. It was thought that 
inclusion of an amino acid with a lipophilic side chain would allow an extra 
hydrophobic interaction with the methyl substitutent of the second alanine in the 
tripeptide. The structure of compound 2 was therefore edited in MOLOC by adding a 
phenyl ring or a benzyl group. This created two new structures that were 
both 
minimised with the MAB force field in the presence of the tripeptide, with the 
conformation of the tripeptide fixed as it was in the PDB I 
FVM. 1 The resulting 
structures were then imported into SPROUT to be scored. 
These are shown on the next 
page with their SPROUT scores. the abbreviated structure, and the 
hydrogen bond 
network displayed in yellow (Figures 2.14 and 2.15). 
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Figure 2.14. Compound 6, SPROUT score -9.38. 
Figure 2.15. Compound 7, SPROUT score -814. 
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Both compound complexes have good predicted affinities, the compound 7 complex has 
over a 5-fold predicted increase in affinity and compound 6 complex has a predicted 
affinity nearly two orders of magnitude above that predicted for the vancomycin 
complex. Analysis of the vertex score table confirmed that the phenyl rings in both 
compounds had predicted hydrophobic interactions with the methyl group of the second 
alanine of the tripeptide. It was therefore decided to synthesise both of these 
compounds. Examining the structures shows that the amino acid must be the unnatural 
D-configuration. 
2.4.2 A rigid analogue 
The extending fragment for compound 2 has a large degree of conformational freedom 
and this is undesirable because of the large entropic penalty that results when the 
structure is fixed into its bioactive conformation as it binds the tripeptide. A rigidified 
structure was therefore designed based on the commercially available bicyclic 
compound theophylline, shown in Figure 2.16 this is discussed in greater detail in 
Chapter 3, Section 1.10). This structure was designed by importing the structure of 
compound 2 into MOLOC and editing it to include theophylline in a pose which 
satisfied the same hydrogen bonding interactions as the original structure and then 
minimising the structure in the presence of the tripeptide. It was necessary to allow the 
side chain of the lysine group to be minimised as well, because of an unfavourable 
interaction between it and the theophylline ring. The resulting structure was imported 
into SPROUT and scored. The structure is shown in Figure 2.17 with its SPROUT score 
and an abbreviated structure, the hydrogen bonding network is shown in yellow. 
0 
N N/ 
Ný 
HN 
Figure 2.16. Theophylline. 
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Hex 
Figure 2.17. The rigid analogue, SPROUT score -8.14. 
2.5 Conclusions on the design phase 
The initial design phase was very successful producing five potential compounds with 
predicted affinity for the tripeptide higher than predicted for vancomycin. The selection 
of a target compound with synthetic accessibility was possible and the chosen structure 
stimulated a further design phase, which produced three further variations all with 
predicted increased affinity to the tripeptide. 
This is the first instance of rational design of semi-synthetic natural product drugs of the 
vancomycin family. 
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Chapter Three 
Results and Discussion 
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3.1 Synthesis of piperazine extenders 
3.1.1 Retrosynthesis of the piperazine extenders 
Following the design phase and the adoption of the piperazine-based compounds as 
extensions of the vancomycin hexapeptide, it was necessary to analyse the compounds 
and produce a synthetic strategy. The first stage of this process was a retrosynthetic 
analysis, shown below in Figure 3.1. 
dis 2 
acid 2 
acid ]H 
711/ý 
IN 
ti- 
t dis3 
iss I 
Figure 3.1. A retrosy nthesis of the piperazine target. 
It was necessary to be able to distinguish the two acid groups. as acid I will be coupled 
to vancomycin hexapeptide and the other will be left as the free acid. This requires the 
use of protecting group chemistry. Esters were the obvious choice as acid protecting 
agents and a number of strategies for the orthogonal protection of these acids are 
available. 
3.1.2 The designed fragment - first attempted synthesis 
The designed fragment (I) was required as the mono-ester of acid 2. 
HO 
1 
OýN O-R 
0 
HO 
(1)-R=H 
(2) -R= Bu 
The use of a commercially available mono-alkylated piperazine (3) as the starting 
material in this synthesis avoided the need for the disconnection at dis I (Figure 3.1). 
The necessity of cleaving the ethyl ester introduced by compound (3) under basic 
conditions led to the selection of an acid labile ester for acid 2. It was therefore decided 
to utilise a tent-butyl ester to protect acid 2. tent-Butyl esters should be cleavable with 
trifluoroacetic acid (TFA) after coupling to vancomycin: thus piperazine (2) became the 
initial target. 
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A possible retrosynthesis of (2) (Figure 3.1) is i'ia disconnection at dis 3 to give tert- 
butyl glycine and the free acid, followed by disconnection at dis 2 to give a- 
chloroacetic acid and the commercially available mono-alkyl piperazine (3). A proposed 
forward synthesis is shown in Scheme 3.1. 
CI(-OH 
ýN'H 
0p N'rOH 
0 
EtO "-N EtOH, KZCO3 Nr 
EtO 
0 
(3) 
(4) 
DCC, HOBt, 
Et3N, CH3CN 
0 
H2N-'ý'O'Bu 
HOO 
0 NN O'Bu LiOH, H2O 
0 NN-ýAO'Bu 
0 
HO vv 
CH3CN R, 
/Nr 
O 
EtO v 
(2) (5) 
Scheme 3.1. 
Alkylation of piperazine (3) with chloroacetic acid using the conditions of Witiak et al. 2 
appeared to be efficient, judged using TLC analysis as the reaction progressed. TLC 
showed that the reaction had gone almost to completion, and starting material (3) had 
been consumed. However, the product was very difficult to isolate due to its high water 
solubility. Attempts to extract into different organic solvents from the aqueous reaction 
media were unsuccessful and the solvent system used for TLC analysis, although 
sufficient to monitor the reaction, was not suitable for use in column chromatography, 
due to the high methanol content. Further attempts were made to purify this compound 
by trituration using a number of solvents and an attempt was made at finding suitable 
conditions for the purification of this compound using HPLC, without success. 
The difficulty in the isolation of this product appears to stem from its highly polar 
nature, as presumably it exists as a zwitter ion (6) in solution. 
EtOýN^ 
O 
(6) 
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It was reasoned that an alternative method which would avoid the formation of product 
(6) by alkylation of piperazine (3) using an a-halo ester could be used to yield the fully 
protected piperazine di-ester (7). It was decided to use a tertiary butyl protecting group 
on the a-halo ester, as this would allow differentiation between the two ester groups. 
allowing them to be used selectively in different coupling steps (Scheme 3.2). It was 
reasoned that the tert-butyl moiety would be cleaved first and then taken without further 
purification to react with tert-butyl protected glycine. Then the ethyl ester could be 
cleaved and used to couple to vancomycin hexapeptide. After the coupling, the 
remaining tent-butyl ester could then be removed with TFA (Scheme 3.2). 
O 
O NýH 
Br v O'Bu O'Bu 
/N Et0"ýv EtOH, K2CO3 0 Et0 
(3) 86% (7) 
1) TFA 
74% 
O H 
0N O'Bu 
HO 
Ný O 
LiOH, H2O 
CH3CN 
2) DCC, HOBt, 
Et3N, CH3CN 
O 
H2 N--_, -U, -, OtBu 
O H 
ýN(N OtBu 
ýNJ 
0 
Et0 
(2) (5) 
Scheme 3.2. 
For the initial attempt to prepare (7), the reaction conditions described by Witiak2 for 
the di-alkylation of piperazine-2,5-dicarboxylic acid with bromoacetic acid in aqueous 
potassium carbonate were used. However, it was found that tert-butyl bromoacetate was 
insoluble in the aqueous solution and addition of methanol was required in order to 
allow the bromoacetic ester to dissolve and the reaction to proceed. 
Whilst facilitating the reaction, the addition of the methanol unfortunately also induced 
a trans-esterification of the desired ethyl ester into a methyl ester. This transformation 
was not complete and resulted in a mixture of ethyl and methyl esters. Therefore, in 
order to facilitate characterisation, this mixture was converted entirely into the methyl 
ester via treatment with an excess of basic methanol. This however, was a rather 
cumbersome process and the repeated handling steps greatly reduced the yield. Bearing 
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this in mind, a second attempt used ethanol as the reaction medium and yielded the 
ethyl ester (7) in 86 9c yield. 
Conversion of the di-ester (7) to intermediate (5) was performed by selective hydrolysis 
of the tert-butyl ester with TFA, followed by the direct coupling of the crude product to 
the tert-butyl ester of glycine using DCC and the conditions of Rees et al. 3 Purification 
using prep LCMS gave the desired compound in 74 % yield. 
The key step in this synthesis was the cleavage of the ethyl ester of compound (5) to 
yield the acid required for coupling to vancomycin. In order to achieve this it was 
necessary to perform a basic hydrolysis' of the ethyl ester and it was hoped that the tert- 
butyl ester would be stable under these conditions. ' 
O 
O NýNO Bu 
3eq LiOH 
ýNJ 
O 
EtO H2O, CH,, CN 
(5) 
Scheme 3.3. 
O 
H 
0 NýN OBu 
N, 
vJ 
O 
HO 
ý 
(2) 
However, despite three attempts to prepare compound (2) via this method, only the di- 
acid, resulting from the cleavage of both esters, was produced in any significant 
quantities. 
Cleavage to the di-acid was almost complete and essentially no desired mono-ester was 
observed. This seems to imply that hydrolysis of the tert-butyl ester was quite fast. This 
problem arose again in later experiments (Sections 3.1.3,3.1.8 and 3.1.9), where di- 
ester (7) is cleaved using these conditions. Again tert-butyl ester cleavage competes 
with ethyl ester cleavage, but the predominant product is cleavage of the ethyl ester. The 
significant difference between the two experiments is that the reaction time is shorter 
(35 minutes as opposed to overnight). A further difference in the synthesis of the D- 
phenylglycine analogue was that the amount of LiOH used was reduced to 1.1 
equivalents, further reducing this undesired cleavage. Had these alternative conditions 
been employed here more of product (2) may have been obtained. 
However, it does appear that the tert-butyl ester in this compound is less stable to base 
than would be expected and less stable than di-ester (7). A possible explanation of this 
109 
is that the hydrolysis occurs in two steps; the first involves de-protonation of the amide 
NH by the basic nitrogen of the piperazine ring pushes electron density onto the oxygen 
of the amide. Then attack from the oxygen of the amide on the carbonyl of the tert-butyl 
ester displaces tert-butoxide forming a five membered ring. This ring is then hydrolysed 
by a hydroxide ion and produces the di-acid (Figure 3.2). This avoid', direct attack on 
the sterically hindered tert-butyl ester, which would be a .. "low process. and thus could 
explain the higher rate of cleavage for the tert-butyl ester. 
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Figure 3.2. A proposed mechanism for the rapid hydrolysis of compound (2). 
3.1.3 Piperazine fragments with alternative protecting groups 
Following the failure to selectively cleave the ethyl group from ester (5) to yield the free 
acid (2) (Scheme 3.3), a new approach to the synthesis of acid (2) was necessary. The 
tert-butyl protecting group was still desired, as this is easily cleavable once coupled to 
vancomycin hexapeptide. Therefore, it was decided to replace the ethyl ester with an 
alternate ester. It was reasoned that the most acceptable replacements would be either a 
benzyl ester or a trimethylsilylethyl (TMSE) ester. These two alternatives offer 
synthetic benefits as they are both cleaved in neutral solution, therefore avoiding the 
basic conditions that were responsible for the cleavage of the tert-butyl group and the 
failure of the previous synthetic attempts. 
The fact that the available starting material already contained an ethyl ester moiety 
necessitated a transesterification. With benzyl alcohol, this could be done directly, as 
using a large excess of this inexpensive material was acceptable. However, the TMSE 
protected alcohol was more expensive and the preferred route was i'ia the free acid, as 
this allowed the formation of the desired ester using only a small excess of the alcohol. 
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The synthesis of both compounds could be achieved from a common intermediate (7). 
derived by the alkylation of the commercially available mono substituted piperazine (3), 
therefore the re-synthesis of intermediate (7) was necessary. This combined to give the 
synthetic plan shown in Scheme 3.4. 
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Scheme 3.4. 
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The re-synthesis of intermediate (7) was performed utilising the conditions developed 
previously. It was carried out on a large scale and resulted in 10 g of compound (7) 
(90 C/c yield) with good purity, providing a sufficient pool to allow for the examination 
of the subsequent reactions. 
Due to the increasing reliance on tert-butyl glycine (14) in the synthesis of the 
piperazine extenders it was decided to synthesise a significant quantity from the 
inexpensive a-bromo intermediate (13), Scheme 3.5. 
O NH3 (1) 0 
Br-_,, 
It, 
OtBu Dry THE H2N--- \O'Bu 
(13) 32% (14) 
Scheme 3.5. 
This was carried out on a large scale, but unfortunately amine (14) was obtained in only 
32 c/c yield. The most likely explanation for this poor conversion is that the reaction was 
not cooled for long enough and the liquid ammonia evaporated prior to completion of 
the reaction. 
The transesterification of ethyl ester (7) to benzyl ester (11) was accomplished via 
treatment of the ethyl ester with a four-fold excess of benzyl alcohol, which had been 
treated with a small quantity of sodium hydride. It was necessary to treat the mixture 
twice with the benzyl alcohol mixture. After reaction with the first quantity of benzyl 
alcohol the reaction mixture was evaporated, removing the ethanol produced in the 
reaction, before re-treating the solution with the second portion of benzyl alcohol, thus 
the reaction was forced forward (le Chatelier's principle, ). This yielded the product (11) 
in 71 % yield, after purification using prep LCMS. 
Two attempts were made to convert the ethyl ester (7) to the TMSE ester (9). detailed in 
Scheme 3.6. The first step of each of these was the conversion of the ethyl ester to the 
free acid (8), using a three-fold excess of LiOH in a base-catalysed hydrolysis. The free 
acid (8) was not isolated or characterised but its presence was indicated by the 
observation of a peak in the MS at 259 m/z, there was also a peak at 203 m/z this could 
be either the di-acid produced by cleavage of both esters or from fragmentation of the 
desired product (8). The initial attempt then utilised a coupling mediated with 
Mukaiyama's reagent, N-methyl, 2-chloropyridine. 6 This method proved inefficient, 
producing the product in only 17 (/c yield over two steps. A further problem with this 
reaction was the presence of excess LOH (-2eq) carried through from the first step. 
This necessitated the use of 3.2 equivalents of the coupling agent, instead of the 1.2 eq. 
normally used for this type of esterification (Scheme 3.6). An interesting observation 
during this reaction was the TMSE di-ester was not seen, this suggests that the peak 
observed at 203 m/z in the MS is a fragment ion and the tert-butyl ester of di-ester (7, 
Scheme 3.6) is more stable than that of di-ester (5, Scheme 3.3). 
The second attempt to convert ethyl ester (7) to the TMSE ester (9) overcame the 
problem of the excess LiOH by neutralising the solution with a small quantity of 3M 
HCl before concentrating under reduced pressure. Oxalyl chloride was then used to 
convert the free acid (8) to the corresponding acid chloride (1.5 ). The acid chloride was 
then reacted with TMSE alcohol in an attempt to yield the TMSE ester (9). This was not 
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successful however and it is likely that the acid chloride did not form. This could easily 
result if compound (8) was not sufficiently dry when it went into the reaction to form 
the acid chloride (15), (Scheme 3.6). 
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Scheme 3.6. 
Other routes to this product were considered, but progress in other areas has made this 
route redundant and no further work was attempted. 
3.1.4 Linear synthesis via the benzyl ester 
Although both a benzyl ester and a trimethylsilylethyl (TMSE) ester were considered as 
alternative protecting groups for the acid unit that was eventually to be coupled to 
vancomycin, only the benzyl ester has been successfully formed. The TMSE ester 
proved difficult to synthesise, as discussed in Section 3.1.3, and it was therefore decided 
to concentrate on the benzyl ester. The benzyl group gives significant advantages; 
namely it introduces a good chromophore, imparts reasonable physical properties and is 
made with cheap starting materials. The water soluble coupling agent, 1-ethyl-3-(3- 
dimethylaminopropyl)-carbodiimide hydrochloride (EDC), was also used, as it was 
hoped that this would aid purification. These changes produced the new synthetic plan 
shown in Scheme 3.7. 
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Scheme 3.7. 
As discussed above in Section 3.1.3, the linear synthesis had progressed as far as the 
synthesis of the dialkyl piperazine (I 1). However, a further attempt at its synthesis was 
unsuccessful and mainly yielded the free acid (16). due to the premature hydrolysis of 
the tert-butyl ester of intermediate (11). The crude reaction mixture contained both the 
tert-butyl ester and the free acid, as indicated by LCMS, as well as significant amount', 
of other impurities. Due to the presence of the chromophore introduced by the benzyl 
ester, it was believed that separation using silica column chromatography would be 
feasible. This was attempted using a gradient elution of petrol and ethyl acetate. This 
was unsuccessful and resulted only in the isolation of benzyl alcohol and the dibenzyl 
ester, which resulted from the transesterification of both the ethyl and the tert-butyl 
esters of (7). The material remaining on the column was therefore removed using neat 
MeOH and the resultant solution was shown to contain the free acid (16) following 
LCMS analysis. The free acid was isolated in a 20 9c yield using prep LCMS. It is 
unclear at which point the tert-butyl ester was cleaved as the acid is always present in 
the mass spectrum of these esters as a fragment ion, but due to the failure to isolate any 
tert-butyl ester (I I) from the column it is evident that the silica induced at least partial 
hydrolysis. This partial hydrolysis may result from the acidic nature of silica gel, but is 
unusual as other tert-butyl esters have been purified on silica gel without cleavage. 
The free acid (16) was then taken onto the peptide coupling with tert-butyl glycine to 
yield the extended precursor (12), (Scheme 3.7). The use of an alternative coupling 
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agent, 1-ethyl -3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) was 
examined in this reaction. This was preferred to the normal coupling agent, 
dicyclohexyl carbodiimide, which produces a by-product, dicyclohexyl urea, which is 
very difficult to separate from the product. It was hoped that this would make the 
purification easier. A trial of this reaction using a small amount (50 mg) of the free acid 
(16), was attempted using the bi-phasic solution of dichloroethane (DCE) and H2O, with 
HOBt, following the procedure of Nozaki and Muramatsu. 7'8 This produced 41.4 mg (60 
c/c) of the desired compound (12), which was afforded in reasonable purity followw ing a 
simple aqueous work-up. Repeating this experiment replacing the bi-phasic solvent with 
dry DMF, seemed to improve the yield, but this could not be confirmed as the product 
was impure (> 100 ck yield). The samples from the reaction in the bi-phasic solution 
and the DMF reaction were combined for the next step and used without further 
purification. 
The critical step in this sequence was again the selective de-protection of final 
piperazine di-ester to yield the target piperazine (2). 
O0 
0Nv OtBu H0 
/-N N--, 'JýO'Bu 
ý/Po0 
BnO v HO v ýý 
(12) 
Scheme 3.8. 
(2) 
The cleavage of the benzyl ester was attempted using palladium on charcoal suspended 
in a stirred ethyl acetate solution of precursor (12), under an atmosphere of hydrogen 
(Scheme 3.8). 9 This was partially successful as it did result in the cleavage of some of 
the precursor, although this was not complete as shown by LCMS. It proved impossible 
to purify the sample by partitioning between a range of aqueous and organic solvents, 
again this stems from the highly polar nature of the compound, which presumably exists 
as the zwitter ion. There was insufficient material for purification using column 
chromatography, and there was no desire to use material this impure in a coupling with 
the valuable hexapeptide, so this reaction was terminated. 
No further attempts at the linear synthesis were undertaken, as the alternative 
approaches have proved more successful. 
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3.1.5 Direct synthesis of piperazine (2) from the common intermediate 
A report by Santilli et al, 10 describing the conversion of ethyl esters directly to amide" 
offered an alternative approach to the synthesis of piperazine (2). This synthe,, i, began 
with the common intermediate (7) and the cleavage of the tert-butyl protecting group 
using TFA, followed by the displacement of the ethyl ester with tert-butyl protected 
glycine in order to prepare compound (2) directly. The free acid intermediate (4) was 
not isolated or characterised, but was observed using MS analysis (Scheme 3.9). 
O r'-"N-yO1Bu TFA 0 
- Tr 
OH 
JO 
EtO "NO EtO 
Ä, 
_N 
(7) (4) 
0 
H2N--, -U-ýOtBu 
OH 
Q 
tBuO NiýNO 
H 
0 
(2) 
Scheme 3.9. 
The tert-butyl group of piperazine (7) was removed because it would have been 
impossible to differentiate between the two tert-butyl groups of the potential product 
(17) if tert-butyl glycine had displaced the ethyl ester of compound (7). 
O ýN-,,,, 
OtBu 
tBuO NNý% 
O 
H 
0 
(17) 
It was also believed that the tert-butyl ester of product (2) would be stable under these 
conditions as it would be too bulky to be displaced by an incoming amine. This was 
supported by the use of 4-amino-benzoic acid ethyl ester (18) in Santilli's paper. 
'° 
where it appeared that the phenyl ring offered sufficient steric bulk to prevent the 
reaction of the adjacent ethyl ester. 
H2N 
OEt 
0 
(18) 
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Although the paper reported good or reasonable yields in this type of reaction, using a 
diverse range of amines and examples that contained tertiary amine centres and amino 
acids, in our hands this reaction failed to produce any of compound (2). despite using a 
range of solvents, including ethanol, butanol and pyridine. '° 
It is believed that the failure of this reaction stems from the nature of the ethyl ester 
being converted, in all the examples in this paper the amines were reacted with ethyl 
cyanoacetate (19) and it is likely that this sort of activated ester is necessary for this 
reaction. It may even be the case that the reaction proceeds via an enone intermediate 
where one of the acidic a-hydrogens has been lost and the resultant anion displaces the 
alcohol from the ester to give the enone (20). This enone is then attacked by the amine 
to give the product (21), as shown in Figure 3.3. 
o/N 
EtO N 
H Eta EtO ) 
B (19) 
j E-- 
R 
(20) 
%'A N 
RHN 
RHN HZN, 
(21) gJ Hsi 
Figure 3.3. The suggested mechanism of direct conversion from Santilli et al. 
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3.1.6 Convergent synthesis of piperazine (2) 
Following the continued difficulty obtaining the desired compound (2). an alternative 
approach utilising a convergent synthesis was considered (Scheme 3.10). 
O^ NAH 
Nr 
EtO 
(3) 
BnOH, NaH, 
Dry DCM 
H N 0 
I I-,, 
iN Bn0 
(22) 
O 
H2N--"ý'OtBu 
(14) 
K2CO3, EtOH 
BrBr 
(23) 
N a2CO3, 
Dry DCM 
0 
H 
BrýN- OtBu 
O 
(24) 
O0 
0 NN----U--'OtBu H21 Pd on C0N, -yN---'JýlOtBu 
BnO 
Nv0 
HON 
J0 
(12) 
Scheme 3.10. 
(2) 
This synthesis has twin benefits. Firstly, convergent synthetic pathways are usually 
higher yielding than the corresponding linear routes and secondly, this route reduces the 
number of steps where it is necessary to handle compounds containing a piperazine 
ring. The high water solubility of these piperazine compounds means that their isolation 
is difficult and often necessitates the use of prep HPLC or prep LCMS purification. This 
tends to reduce the yields; therefore limiting the number of steps where this is necessary 
offers significant advantages. 
It was reasoned that piperazine ethyl ester (3) could be converted into the desired benzyl 
ester (22) in a transesterification analogous to that used for the conversion of dialkylated 
piperazine (7) to piperazine (1 1), (Scheme 3.7). However this was unsuccessful and 
although some desired compound was obtained, it was insufficient for full 
characterisation. 
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An alternative approach to benzyl ester (22) was the direct synthesis from piperazine 
(25) and benzyl-a-bromoacetate, both of which are commercially available (Scheme 
3.11). 
N ,H 
HN 
(25) 0 
Br, -k OBn 
K2CO3, CH3CN 
80% 
O NH 
BnO 
(22) 
O 
0 NNO'Bu 
O 
Bn0 _, 
J 
0 
Br"'ý'Br 
(23) 
O 
HZN--"ý'O'Bu 
(14) 
K2C031 CH3CN 
Na2CO3, 
Dry DCM 
10% 
0 
H 
N UBu Br 
0 
X24) 
O H 
H21 Pd on C_O (N OBu 
HOIL, _,, 
N 0 
(12) (2) 
Scheme 3.11. 
Three attempts have been made to produce the benzyl piperazine (22) using this direct 
method. The first used the conditions adapted from Witiak's paper to synthesis 
piperazine (7), using ethanol as the solvent and potassium carbonate as base. This 
proved unsuccessful, as the ethanol transesterified the benzyl ester, giving ethyl ester (3) 
as the major product. However, Parker et al. 11 reported that nitrogen-containing 
macrocycles were alkylated using potassium carbonate in acetonitrile. Parker et al. also 
added sodium iodide to the reaction mixture, as this increases the reaction rate by 
halogen exchange to give the more reactive iodide as the alkylating agent. instead of the 
bromide. It was decided to omit the addition of the sodium iodide as only mono- 
alkylation was desired and a slower reaction rate would increase the chance of isolating 
this product. The reaction was therefore repeated using acetonitrile as the solvent. This 
produced the desired benzyl ester (22) with an impurity resulting from alkylation on 
both amines. Purification was attempted via silica column, but this proved inefficient 
with only a 37 C/c yield. The material isolated still had minor impurities, but was used as 
is in later synthesises. The major impurity in this reaction was the di-benzyl ester and it 
was believed that this was produced as the reaction mixture was too concentrated and 
possibly the addition of the benzyl-a-bromoacetate was also too rapid. Therefore in the 
third attempt to produce benzyl ester (22) both the solution of the piperazine (25) and 
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the solution of benzyl-a-bromoacetate were very dilute and the addition of the 
bromoacetate was very slow, drop-wise, over one hour. The product was again purified 
by column chromatography, but again failed to yield entirely pure material. This 
material had the free acid of (22), produced ''ia loss of the benzyl group as a minor 
impurity. The material recovered represented an 80 cIc yield, though it was impure. No 
further attempts were made at purification of this product as the project finished before 
it was required for further syntheses. 
Several attempts have been made towards the synthesis of compound (24). by reaction 
of a-bromoacetyl bromide (23) and tert-butyl glycine (14). Variations of the nature and 
the quantity of the base used in the reaction have produced a startling array of results. 
The initial conditions were from papers by Parker et al. " and White et al. '' using 
sodium carbonate in DCM, Parker used these conditions to form the ethyl ester and 
White used them to form the methyl ester. The use of these conditions produced the 
desired compound, but this could not be purified despite the use of silica gel column 
chromatography. The column chromatography was ineffective due to the lack of a 
significant chromophore, which prevented monitoring by TLC. 
This first attempt had used tert-butyl glycine ester that had been prepared previously 
and it was considered that some of the impurities present after the reaction might have 
come from this reactant. The reaction was repeated with commercially available tert- 
butyl glycine ester. This also yielded the desired product, but again in the presence of 
impurities. LCMS conditions were examined to purify this product, but none of the 
available methods offered sufficient separation. 
In these reactions the carbonate does not dissolve in the organic solvent and it was 
therefore reasoned that the use of an organic base would create a homogeneous solution 
and might prevent the formation of these by-products. Triethylamine was selected as the 
organic base, because it had been used in the synthesise of methyl ester by O'Neil et 
al. 13 using THE as the solvent and by Marzilli et al. 14 to synthesise the ethyl ester using 
DCM as the solvent. It was decided to use DCM as the solvent and a four-fold excess of 
triethylamine (relative to the glycine), this produced compound (26), where 
triethylamine had displaced the a-bromine. 
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0 H 
Ný, -,, rNO 
0 
(26) 
As the glycine is added as the HCl salt and the reaction should produce one equivalent 
of HBr, it was thought that the use of two equivalents of triethylamine would be 
sufficient, thus removing the excess triethylamine and reducing the displacement of the 
a-bromine. However, these conditions did not appear to produce any desired product as 
indicated by LCMS analysis. Further analysis using NMR ('H and C) shoýNed that the 
desired compound may be present, but as a very minor component of the reaction 
mixture. 
It was therefore decided that an alternative base was necessary and the next attempt at 
this reaction utilized diisopropylethylamine (Hunigs base). This is also an organic base 
and miscible with DCM, but is far less nucleophilic than triethylamine due to the steric 
hindrance of the two-isopropyl groups. Reaction with two equivalents of Hunigs base 
resulted in the formation of compounds (27) and (28). Acid (27) is the desired product 
that has lost the tert-butyl group and (28) is the result of tert-butyl glycine displacing 
both the acid bromide and the a-bromine (Figure 3.4). 
O0 
Br 
NýOH 
tBuO 
NOtBu 
01 O 0 
(27) (28) 
Figure 3.4. By-products (27) and (28). 
Using three equivalents of Hunigs base the desired product was obtained, and a simple 
aqueous work up in diethyl ether removed all the impurities with the exception of a 
single compound. Analysis by MS showed that this compound has an m/z of 474. and 
fragment ions that indicate the sequential loss of three tert-butyl groups. This 
that this compound has resulted from the addition of two molecules of the desired 
product with a third molecule of tert-butyl glycine ester to give (29). 
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(29) 
The sample containing compound (24) was purified using prep LCMS. to remove this 
final impurity (29). This was successful, but gave (24) in low yield (10 c/c). Due to the 
failure to produce the acylated amino acid derivative (24) in sufficient yield and purity. 
despite extensive alterations to the conditions, it was considered necessary to alter the 
reactants used. It was believed that changing from bromoacetyl bromide (23) to 
chloroacetyl chloride (30) would be advantageous, as the a-chlorine would be less 
reactive than the corresponding bromide and therefore less likely to participate in the 
detrimental side reactions. 
3.1.7 Convergent approach with altered reagents 
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ýNJ 
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H2N-I'U-ýO'Bu 73 % 
(14) 0 
H 
CI--Y 
Ný0 Bu 
0 
(31) 
K2CO3, CH3CN 
O 
H21 Pd on C_0 NN-----'ýO'BU 
HOýN 
0 
(2) 
Scheme 3.12. 
Switching to the less reactive chloroacetyl chloride (30) in this synthesis allowed the 
conversion of Ia of tert-butyl glycine (14) to product (31) in a 73 yield, after 
purification via silica gel column. 
122 
The addition of the a-chloro-compound (31) to the benzyl piperazine ester (22) aý 
attempted using the conditions adapted from Witiak. 2 The reaction was followed by 
LCMS and appeared to yield product, but problems during the silica column 
chromatography of this compound resulted in failure to isolate the product. It ww as 
intended to repeat this synthesis and isolate the product correctly, but as other ,ý nthetic 
routes yielded product this has not been achieved. 
3.1.8 Alternatively protected piperazine target - methyl esters 
Due to the problematic nature of synthesising and selectively de-protecting piperazine 
(5) orpiperazine (12) to yield piperazine (2). an alternative target was proposed. This 
target was the piperazine (32): it differs from (2) by utilising a methyl ester, %vhereas (2) 
had a tert-butyl ester. This removed the inherent instability of the tert-butýrl ester, 
allowing a more facile selective deprotection. A large amount of compound (7) had 
already been prepared for the linear synthesis and was therefore available for this 
reaction. 
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, BuO0 
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H2 OH 
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_ý, 
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Scheme 3.13. 
Scheme 3.13 shows the synthetic path to piperazine (3-1), however intermediate (8) ýýas 
not isolated and was formed and used in sitze. The synthesis «as stopped at (35). as 
(3-) 
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would be very difficult to purify and therefore would only be formed and used in situ 
when required. 
Glycine (33) was converted to product (34) using conditions described by Hulme et al. 15 
Hulme used these conditions to prepare N, N, O-tribenzyl serine meths l ester. These 
conditions gave product (35) as the hydrochloride salt wt ithout the need for purification 
in 99 % yield. 
In each synthesis di-ester (7) was hydrolysed to piperazine (8) utilising aqueous lithium 
hydroxide to cleave the ethyl ester. The first attempt to convert (8) to (35) fol lowed the 
reaction conditions of Nozaki and Muramatsu7'8 for the peptide coupling, \w here they 
had used EDC in a bi-phasic solution of H2O and diehloroethane (DCE) for coupling 
reactions. Although used earlier in Section 3.1.4 ww here it gave a good yield, in this 
example it was unsuccessful; yielding only 4.6 mg of product from 200 ma of starting 
material, a2 11c yield. It was believed that the use of a polar organic solvent that was 
miscible with water, instead of the DCE, would produce better results in the coupling 
step; therefore acetonitrile was used in this reaction. Upon attempting the reaction using 
acetonitrile the product was successfully formed. However. IM Na2CO, was used in the 
work-up and this cleaved the methyl ester. A further paper by Nozaki16 using neat DMMF 
as the solvent for EDC/HOBt coupling showed quantitive yields for the production of 
simple fully protected dipeptides. It was thus decided to use these conditions in a repeat 
of the coupling and the pH of the aqueous solvents used in the work-up was kept below 
pH 8. This produced the piperazine (35) in 53 % yield. 
3.1.9 Variation of the amino acid 
The nature of the synthetic route to the target piperazine methyl esters makes it easy to 
vary the amino acid used, it is simply a case of replacing the glycine with an alternative 
amino acid and repeating the synthesis laid out in Scheme 3.13. Examination of the 
SPROUT designed structure that results from the coupling of piperazine (3-1) to 
vancomycin hexapeptide, bound to the L-lys-D-ala-D-ala tripeptide, suggested that the 
use of D-amino acids with hydrophobic side chains vtiould yield the best results. This is 
because the hydrophobic group would be positioned over the methyl group of the 
second D-alanine creating a strong lipophilic interaction (discussed 
in Chapter 2. 
Section 2.4.1). Two amino acids have been selected to produce these initial variations. 
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D-phenylalanine and D-phenylglycine. Both are commercially available and relativer 
inexpensive. 
D-phenylalanine was not available as the methyl ester and was therefore purchased a, 
the free acid, this necessitated the synthesis of D-phenylalanine methyl ester (37) and 
this was achieved using the method described by Hulme et al. ' 
O0 
AcCI, MeOH 
H2N 
OH A 
H2N 
OMe 
Ph 99% 
LPh 
(36) (37) 
Scheme 3.14. 
This reaction involved using three equivalents of acetyl chloride in an excess of 
methanol and heating at reflux for three hours. A reaction starting from 1.00 g of 
phenylalanine afforded 1.29 g of desired product (37). a 99 r/c yield (Scheme 3.14. 
Piperazine (38) was formed using the approach established in the synthesis of (3? ), as 
shown in Scheme 3.13, which followed the work of Nozaki et (11.7,8 , 16 utilising EDC in a 
peptide coupling reaction. 
0 rN -,, jrOEt 
tBuOýN,, _) 
0 
(7) 
1) LiOH, H2O 
CH3CN 
2) 0 
H2N OMe 
Ph 
(37) 
EDC, HOBt, 
Et3N, DMF 
15% 
0 
H 
0 NNOMe 
BuO0 Ph 
(38) 
Scheme 3.15. 
The product needed both a silica column and an alumina column to yield a sample that 
was pure as determined by NMR analysis. The reaction was attempted on 1.33 L, of 
intermediate (7) and yielded 0.28 a (15 '/- yield) of piperazine (38) (Scheme 3.15 ). 
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Piperazine (40) was synthesised using the same approach, starting from the 
commercially available D-phenylglycine methyl ester (39). utilising EDC coupling of 
Nozaki et al. 7,8,16 (Scheme 3.16). 
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tBuOýý/Nýý 0 
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(40) 
Scheme 3.16. 
The product was obtained in good purity, as determined by NMR analysis, following 
purification by silica column chromatography. The reaction was attempted on 500 mg 
of intermediate (7) and yielded 224 mg of compound (40), as a glassy solid (3? ý, 'C 
yield). 
3.1.10 The rigid analogue 
The principle of rigidifying a drug is not a new one and works on the . imple premise 
that the more rotatable bonds a drug possesses the greater the entropic cost of binding. 
This entropic cost is incurred because binding can only happen in one conformation of 
the many possibilities available to the freely rotating molecule. Rigidifying the 
molecule removes some of the rotatable bonds; this reduces the number of possible 
conformations and lowers the entropic penalty of binding. This principle was therefore 
applied to the extended piperazine fragments and the obvious choice was to rigidify the 
terminal amino acid portion of structure (see A in Figure 3.5). This linear chain could be 
rigidified into two fused rings (B in Figure 3.5). 
L-lysDalaDala 
O 
H 
0 N-yN---ýOMe 
Hex'-'-- /NJ 
0 
(A) 
lys D aI D ala 
H 
N 1)Y 
He 
(B) 
Figure 3.5. A representation of binding in A) the initial methyl ester design and 
B) the rigidified analogue. 
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It is necessary to retain the double bond in ring 1 of (B) so that the amine of that ring 
remains amide like, thus the X atom in ring 1 would ideally be a nitrogen atom, but 
could be carbon. In ring 2, the Y atom could be 0, NH or even S. but Y being NH 
would make the carbonyl oxygen a better acceptor. Also in ring 2 the remainder of the 
ring could be saturated or aromatic. However, if ring 2 was aromatic it would ensure the 
entire structure was planar and this is preferable. In addition, structures that leave 
hydrophilic groups exposed to solvent would be more advantageous. 
After a search of commercially available compounds had been undertaken, the best 
candidate for the rigid terminus was theophylline (-11). a structure closely related to 
caffeine. It satisfied the needs for both rings and although ring ? is not aromatic, it is 
planar and there are hydrophilic groups exposed to solvent. 
O 
H 
N N/ 
NNO 
(41) 
The synthetic pathway to convert theophylline (41) to a derivative containing a 
carboxylic acid (42) for coupling to vancomycin hexapeptide is set out below in Scheme 
3.17. 
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Scheme 3.17. 
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The first steps in this sequence are the protection of free NH using 
(3-trimethylsilylethoxymethyl chloride (SEM-Cl) to `rive compound (43), followed by 
the introduction of a formyl group to give (44) by metalation and quenching «ith 
dimethyl formamide. Analoguous reactions have been performed on 4-isobut\ l- 
imidazole as detailed by Lipshutz et al. 17 Compound (44) could then be reductively 
aminated with the commercially available piperazine ethyl ester to yield (45). Cleavage 
of the ethyl ester should furnish the free acid (42), which would allow coupling to 
vancomycin hexapeptide and then after the coupling treatment with tetrabutylaminium 
fluorate would remove the SEM protecting group. 
SEM protection of theophylline was undertaken following the work of Lovely et al. 18 
using sodium hydride to deprotonate theophylline (41) and then quenching with SENI- 
Cl to yield the protected theophylline (43). Purification by silica chromatography gave 
(46) as a yellow solid, 102 mg, 59 %. 
The attempted formylation of the protected theophylline (43) via metalation and 
addition of DMF using the conditions of Brown19 failed to yield the product. The most 
likely explanation of the failure of this reaction is that the reaction conditions were 
insufficiently anhydrous for the product to form and the metal species, if formed, was 
quenched back to the starting material. 
There was insufficient starting material to repeat this reaction and an alternative route 
emerged before the re-synthesis of compound (43) could be completed. 
3.1.11 An alternate approach to the rigid analogue. 
Following failure of the formylation step, discussed above, renewed literature searching 
yielded a patent abstract, Danila et al.. 
20 that indicted the direct alkylation of a 
piperazine with theophylline was possible using formaldehyde to 
form a iminium ion 
(Figure 3.6) that would undergo nucleophilic addition of the theophylline. Danila used 
this method to synthesise 8-[-1-(phenyl- I -piperazinyl)methyl ltheophy'Iline. 
DO'rN 
0L 
Figure 3.6. The iminium ion. 
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This method significantly shortened the synthetic route and led to the path set out in 
Scheme 3.18. 
O0 NH 0 
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DO v 
Nýý 0 
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Et0 
/0 
p-toluene sulphonic acid (46) 
(41) 
12% 
Scheme 3.18. 
Three attempts were made at this synthesis using conditions adapted from the patent'9 
and work by Joshi et al. 2' The first replicated the conditions of the patent abstract, 
utilising formaldehyde in an aqueous solution (37 9c by volume) and had no acid for 
catalysis, this failed to yield product. The second attempt again used aqueous 
formaldehyde, but this time utilising acetic acid as a catalyst, this yielded product. 
However, after column chromatography and aqueous wish only 57 mg, of product \ý as 
recovered (6 %). The reaction was therefore repeated increasing the number of 
equivalents of formaldehyde and acid. This still did not result in full con\ersion 
therefore more acetic acid, para-toluene sulphonic acid and solid para-formaldehyde 
were added to the reaction mixture. This afforded the product as a solid in 12 c70 yield, 
after column chromatography and re-crystallisation from ethanol and hexane. 
3.1.12 Conclusions and further work on piperazine synthesis 
These piperazine based extending fragments have been difficult and time consuming to 
synthesise, but significant progress has been made reducing and in most cases removing 
the need for purification by HPLC or LCNIS. Routes have been established to the 
methyl ester of the original target and two analogues of this compound.. novel 
rigidified extending structure was also successfully synthesised. The opportunity also 
exists to revisit the convergent synthesis of the free acid series and furnish at least one 
analogue there. 
In both the convergent route to the free acid series and the route to the meth\ I e,, ter, the 
scope remains for the introduction of further analogues and the ,v nthe,, k of either type 
of compound is limited only by the commercial availability of appropriately protected 
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amino acid esters, tert-butyl esters for the free acid series and methyl esters or 
unprotected amino acids for the methyl ester series 
The piperazines posed a difficult synthetic problem due to the considerable 
complications purifying and isolating these highly water soluble intermediates. It should 
also be noted that purification of piperazines with free carboxyl groups proved very 
difficult and should be avoided where possible. Despite these difficulties, large steps 
have been taken in developing methods and protection schemes and four variations of 
the original designed target have been achieved. This has fulfilled the second step in 
satisfying the aims of the project, as synthesising these extending fragments is the first 
step in synthesising the vancomycin analogues. Further more this work has developed 
the synthetic methods necessary and gained insights into the synthesis of these 
potentially problematic compounds, which now could be exploited if further work was 
continued in this area. 
3.2 The synthesis of the hexapeptide skeletons 
The main focus of this project was the synthesis of analogue', of vancomycin, produced 
by acylating the vancomycin hexapeptide with fragments that had been designed in 
silico. As a result it is necessary for sufficient quantities of the hexapeptide to be 
available and this in turn necessitates the availability of a quick and high yielding 
method to produce this material. Such a method was not available at the beginning of 
this work, so it was necessary to develop suitable methodology as part of the project. 
3.2.1 Edman degradation on vancomycin 
The terminal amino acid residue of vancomycin is N-methyl leucine, which has been 
shown to adopt a conformation in which the terminal amine points away from the 
binding pocket. There is evidence for this in both the crystal structures reported by 
Williams''' and Loll'`3 and the PDB file (1FVM) used in the design phase. Williams et 
al. 24 also report this conformation in the solution phase and later confirmed it in a paper 
co-written with Harris. The argument made for the adoption of this conformation is 
that this allows the leucine side chain to complete the carboxvlate binding pocket, by 
providing a hydrophobic wall. whilst maintaining the salt bridge (a columbic or 
electrostatic interaction) between the N-Me and the carboxylate. A further consideration 
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is that if this residue was acylated it would become an amide and because the residue i" 
N-methyl leucine, the nitrogen would be methylated and thus unable to form a hvdrogen 
bond. It would also not be protonated under physiological conditions, and therefore 
could not form a salt bridge or a hydrogen bond, thus preventing it from satisfying the 
potential interactions with the carboxylate. 
Therefore any functionality coupled to this amine would be missing crucial interactions 
with the peptide ligand and also would probably be oriented into solution and thus 
would have no effect on the binding to the tripeptide. It was therefore concluded that 
this terminal residue must be removed in order to produce stronger binding and 
hopefully more potent compounds. 
The removal of the terminal amino acid can be achieved with an Edman degradation. 
This is a two-step reaction that initially involves alkylation of the terminal amine with 
an isothiocyanate to give a thiourea, followed by an acid catalysed cyclikation to cleave 
this alkylated residue from the remaining peptide chain and form a thiohydantoin 
derived from the terminal amino acid and the isothiocyanate used. This technique was 
developed by Pehr Edman26'27 as a method for identifying amino acid sequences in 
protein and peptide chains. 
When this technique is applied to vancomycin (47), using phenyl isothiocvanate (48 
the thiourea (49) is produced. Treatment of this thiourea with TFA gives the 
hexapeptide (50) (33 c1c yield) and thiohydantoin (51). as described by Williamsand 
shown in Scheme 3.19. 
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Initial examinations of the Edman degradation followed the procedure reported by 
William's. 28 Two attempts were made, each on 200 mg of vvancomycin. The first exactly 
replicated the conditions used in the paper and gave only 13 mg of hexapeptide product, 
(7 I/c yield). However, unreacted vancomycin was detected in the HPLC trace during the 
purification of this product. 
Therefore in the second attempt, the procedure was modified and the progress of the 
initial reaction with the isothiocyanate was followed by mass spectroscopy. Monitoring 
by MS indicated that the reaction required approximately 45 hrs until there «a', no trace 
of vancomycin. Also in the first attempt the recovery of the product after HPLC wk a, " 
accomplished using the Gene-vac, a heated vacuum centrifuge, which left a hard solid 
that was washed out of the vials, then re-dissolved in water and freeze-dried. In order to 
minimise the loss of material due to these various manipulations, which followed 
purification by HPLC, in the second attempt the fractions containing hexapeptide (51) 
were combined and concentrated on a rotary evaporator to afford a paste. Water \\ as 
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then added and the solution was freeze-dried in the same flask. As a result of the 
reduction in the number of handling steps and ensuring that the reaction had gone to 
completion in the first step, the yield was significantly improved, resulting in 72 mR of 
product, (39 c/c yield) which is an improvement on the 33 % yield reported in the 
literature. 
The literature was searched for alternative methods for the Edman degradation and a 
paper by Törngvist et al. 29 was found that used IM sodium carbonate to perform the 
cyclisation and cleavage stage of the degradation. Therefore an experiment was carried 
out to see if vancomycin could be converted to the hexapeptide (50), using the 
conditions of Williams to form the thiourea and aqueous base to induce the cyclisation. 
For this reaction 100 mg of vancomycin was converted to the thiourea and then I NI 
sodium carbonate was used to effect the cyclisation and cleavage. The yield for this 
reaction was disappointing however, furnishing only 27 mg, a 30 1/(- yield. Attempts to 
improve this reaction by using two organic bases, DMAP and DBU, were unsuccessful. 
However, these reactions were also attempts to perform the transformation in a single 
step, in which the organic base was added to the reaction mixture after the first step and 
perhaps may have been more successful if the base had been added separately. 
Further experimentation on the conditions of the first step were undertaken; t' o 100 mg 
reactions were compared, one with the standard conditions, using DMF, water and 
pyridine, and one in anhydrous DMF with pyridine. These `gave interesting results as the 
anhydrous DMF reaction stopped at the thiourea, but the reaction using standard 
conditions resulted in all the thiourea formed being converted to hexapeptide, although 
this did require stirring for 7 days. Neither of the products was taken on further. 
A similar reaction on 200 mg of vancomycin, using DMF, water and pyridine, gave 1-t8 
mg (83 c/c yield) of vancomycin hexapeptide, after HPLC purification, although this did 
require a total of 5 days for all the thiourea to be converted to hexapeptide. 
Three further attempts have been made at producing vancomycin hexapeptide through 
this base catalysed process. Two of these were at 50 "C using aqueous base with 
conventional heating and one was at 65 °C using aqueous base again, but this time vv 
ith 
microwave heating. 
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Both the reactions utilising aqueous base and conventional heating were unsuccessful. 
The first was purified by prep LCMS to yield the product in 28 9c yield and the , econd 
was purified using prep HPLC and yielded the hexapeptide in 14 9c yield. 
The reaction attempted in the microwave was even less promising, and purification was 
abandoned because MS of the HPLC fractions indicated an unknown impurity that was 
inseparable by HPLC. 
Following the failure of the degradations at elevated temperature to match the yield of 
hexapeptide achieved in the reaction at room temperature; other avenues for an 
improvement in this reaction were sought, because despite the significant improvement 
in yield, the room temperature aqueous base reaction was too slow to be synthetically 
useful. A paper written by researchers from Lilly, 30 utilised a similar degradation. 
However, the initial formation of the thiourea was done in the absence of DMF and the 
cyclisation and cleavage were carried out at reduced temperature 
The Lilly procedure also required two-stages. In the first stage vancomycin 
hydrochloride was treated with phenyl isothiocyanate in the presence of pyridine and 
water, and the crude thiourea (49) was recovered by evaporation. TFA in DCM 
then used to induce the cleavage of the thiourea to yield the desired hexapeptide in 13 
yield, after HPLC purification and freeze-drying. 
Although this did not improve the yield, a noteworthy observation from this experiment 
was that in the absence of DMF the initial reaction ý ith phenyl isothiocyanate stopped 
at the thiourea without any further degradation to the hexapeptide as is observed in 
reactions where DMF is present. Perhaps for this reason it appears to produce fewer by- 
products from this initial stage of the reaction. Following this observation it was 
decided to produce a quantity of thiourea via this route and attempt to degrade it in a 
variety of different ways to optimise this part of the reaction. 
3.2.2 Variation in the cyclisation and cleavage of the thiourea 
Using the Lilly procedure, 3° 200 mg of vancomycin hydrochloride was treated with Z-- 
phenyl isothiocyanate: this yielded 203 mg (95 %) of the crude thiourea after isolation 
under reduced pressure. Following this. 10 mg portions of this were then taken and 
degraded in a variety of ways, as detailed in the tables below. 
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Degradation 
4impurity 
over 10 I-c 
253 31: 69 intensity - unreacted 
vancomycin from thiourea 3 10 3 35: 65 formation 
a- Ati judged h% relutice peak heilt*htN in MS of crude an ple. h- : \. jiid ed h\ \IS )t crude oIid. 
Table 3.1. Variations of amount of TFA in the Edman degradation of vancomycin. 
Comparison of 5 or 10 equivalents of TFA or formic acid in DCM at 0"C. 
Degradation Acid 
Eq.. of Time Ratio Purity b Ac id (hrs) Hex : Thiourea 
4 11fi\ 5 
-14 unknown 
5 TFA 10 24 78: 22 impurity at 623.0 
m/Z. 
6 Formic 5 24 34: 66 
Poor many 
im critic', 
OK - unknowns 
7 Formic 10 24 23: 77` at 435.4 and 
519.0 m/Z. 
t-As judged by relative peak heights in h1S of crude , ample. h- . As j udi-, ed hM NIS of reaction nurture. c- I)( \1 cý: ipor. acd Imni 
reaction, theretore reaction did not ýet hill '4 hr period. Bence vn, r, e ratio then seq. 
Table 3.2. Comparisons of TFA and formic acid in the Edman degradation of sancomycin. 
Above reaction mixtures allowed to warm to 10 T and , tirrin« continued. 
Ratio a 
Degradation Acid 
Eq. f Time Hex : Purity b 
cid A (hrs) Thiourea 
4 TFA 5 14 70: 30 
Good minor- 
impurities at 
5 TFA 10 14 92: 8 
988.2 and 494.3 
m/z 
6 Formic 5 14 17: 83 High - minor 
impurity at 394.4 
7 Formic 10 14 16: 84 m/z. 
a- Al, judged h\ relil[1\e peaK nel°r1L HI I%I) 01 LIuuc ýw IIFrc. v- : ý. ýuu c.. u .., ,.....,......., .,.. --. 
Table 3.3. Comparisons of TFA and formic acid in the Edman degradation of vancomy-cin. 
These results show that the initial conditions for the degradation using excess acid were 
unnecessary and that the excess acid results in elevated levels of 
impurity. The use of 
formic acid and low temperatures does not improve the synthesis, 
in fact, they are 
detrimental as they necessitate longer reaction times. 
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Variations of amount of TFA, all reactions are in DCM at room temperature. 
3.2.3 Edman degradation without HPLC purification 
In an attempt to compare the effectiveness of TFA versus formic acid in the cleavage 
step, a further experiment was performed using 20 equivalents of each acid in separate 
200 mg reactions. This reaction confirmed that TFA gives superior results in the 
cleavage step, but also introduced an interesting observation: whilst attempting to 
examine the TFA reaction by MS the sample prepared separated into two layers. The 
top layer was acetonitrile and the bottom layer water. These were decanted and the 
separate solutions analysed by MS; this indicated that the major product in the top laver 
was the thiohydantoin by-product and the bottom layer contained a reasonably clean 
sample of the hexapeptide. The reaction mixture was diluted with water and purified hv 
washing it with acetonitrile to give a solid, which was predominantly the hexapeptide. 
However, MS of the crude solid showed that some thiohydantoin was still present, so 
this solid was suspended in acetonitrile with vigorous shaking, then collected by 
centrifugation. This yielded 182 mg of product, which suggests a yield of over WO % 
However, both HPLC and MS showed that the solid was largely hexapeptide (91 
based on HPLC peak areas) and it was felt that this would be sufficiently pure for use in 
the coupling reactions without the need to resort to HPLC purification. 
Further examination of the literature led to a paper by Nicolau, 
3' which contained a 
purification of vancomycin analogues using methanol to dissolve the crude solid and 
Et-O to precipitate it from solution and also indicates the use of acetone to precipitate 
vancomycin analogues from reaction mixtures. By combining this with the knowledge 
gained from the earlier attempts, a very successful preparation of the hexapeptide was 
possible. This entailed forming the thiourea by addition of phenyl isothiocyanate (51) 
in 
water and pyridine, without DMF. The reaction mixture was then evaporated to 
dryness 
and the cleavage performed using 20 equivalents of TFA in dry DCM. 
The DC M was 
evaporated to give the crude product, which was purified by repeated precipitation 
from 
methanol with acetone. This reaction has been carried out three times with 
91.87 and 
95 % yields. This showed that it is both high yielding and easily repeatable. 
In addition, 
due to omission of the HPLC step, and a number of other time consuming step`. 
the 
whole sequence requires about a days work, as opposed to the earlier procedure 
that 
took around a week. HPLC analysis (see trace in Appendix 
A) indicates that the product 
is 90 % hexapeptide after purification in this fashion, which was 
deemed sufficient for 
use in the coupling reactions. 
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3.2.4 Aglucovancomycin 
The preparation of aglucovancomycin (52) and aglucohexapeptide (53) were examined 
while optimisation of the Edman degradation of vancomycin was underway. The 
removal of the sugars from the peptide core was considered to be a useful option as they 
could potentially cause problems in the synthesis of new vancomycin analogues. 
These potential problems stem from the presence of a free amine in the vanco. amine 
sugar moiety; this amine introduced a synthetic challenge, because it necessitate,, 
distinguishing between two amine centres, the N-terminus and the sugar amine. 
The first instance where this could have caused a problem wwas the Edman degradation, 
because the sugar amine (A in Figure 3.7) may have reacted with the phenyl 
isothiocyanate, instead of the N-methyl leucine terminus (B in Figure 3.7). Indeed, this 
side-product was observed in some of the attempted Edman degradations on 
vancomycin, but only in trace amounts. Considering the environments of these two 
amines this is not surprising, the N-terminal amine (B in Figure 3.7) is both 
electronically favoured, because it is a secondary amine, and it is sterically favoured 
because it is adjacent to a secondary carbon centre, whereas the primary amine of the 
sugar (A in Figure 3.7) is adjacent to a tertiary carbon centre. 
NH2 O 
OH N-H 
R 
H 
OO '' 
(A) (B) 
Where R= The remainder of the vancomycin skeleton 
Figure 3.7. Comparison of amine environments during phenyl isothiocyanate addition. 
The second potential problem in the synthesis was the selective acylation of the N- 
terminus of the hexapeptide with piperazine extending groups. Here the outcome was a 
lot less clear because both amine centres are primary amines and both are in very 
sterically hindered environments. The sugar amine (A in Figure 3.8) i, adjacent to a 
tertiary carbon centre and one bond away from a secondary carbon centre. The 
hexapeptide N-terminus (B in Figure 3.8) is adjacent to a secondary carbon centre, but 
is further hindered by being only one bond a" ay from another secondary carbon centre. 
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In addition, the N-terminal amine (B in Figure 3.8) is within a macrocyclic ring, which 
places it in close proximity to an aromatic ring further hindering this centre. The 
experiments described in Section 3 of this Chapter, in which coupling of the extending 
fragments and vancomycin hexapeptide was attempted, showed that this was a real 
problem as in most of the reactions a side-product from double acylation (one at each 
amine) was observed. 
NH2 HOH 
OH Cl", H -- ýý I 
'NHz 
OO 
RRR 
(A) (B) 
Where R= The remainder of the vancomycin skeleton 
Figure 3.8. Comparison of amine environments during coupling to the piperazine extender. 
There were two further factors to consider; firstly, the removal of the sugar groups will 
greatly simplify NMR-based spectral analysis, and secondly, the removal of the sugar's 
would remove a large number of hydrophilic groups that promote water solubility. 
Water solubility is a potent advantage for a drug and it is reflected by the lower affinitv 
of the aglucovancomycin, 2 as compared to vancomycin, for all bacterial species. There 
is also evidence to suggest that the sugars are involved in the dimerization process and 
thus affect the binding to the cell wall, which further explains the loss of affinity in 
aglucovancomycin. 32 
Following consideration of these points it was decided to explore both conversion to 
aglucovancomycin and the further degradation to its hexapeptide. The first stage of this 
exploration was the synthesis of aglucovancomycin (Scheme 3.20). 
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Scheme 3.20. 
Aglucovancomycin (52) was prepared according to the literature method. 33 The reaction 
to remove the sugars is relatively simple and involves heating for two minutes in 
aqueous IM HCI, followed by purification using reverse phase HPLC. The initial 
attempt used 300 mg of vancomycin (47) and yielded 30 mg of product (52). (13 hic 
yield). A second attempt using 500 mg yielded 192.9 mg, (50 9c yield). Improvements 
in the yield for the second attempt were gained using the experience from the Edman 
degradations, i. e. recovery of the product after HPLC by rotary evaporation and then 
freeze-drying. This reduces the handling steps, improving the yield. 
The Edman degradation was attempted on agluco\ ancomycin (52) using the base 
catalysed cleavage of the thiourea (Scheme 3.21). 
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Scheme 3.21. 
The initial reaction with phenyl isothiocyanate (48) produced the aglucothiourea (56) 
and the second stage produced the desired product (53), as observed in the crude `IS. 
However the reaction was not left long enough and therefore the product was impure, 
containing aglucothiourea (56). The product was not purified, as conditions that would 
avoid HPLC were being sought. 
3.2.5 Direct conversion to aglucohexapeptide 
Research by Nagarajan, 34 at Lilly, showed that it was possible to cleave the sugars from 
vancomycin selectively using TFA. Below -10 "C the predominant product was loss of 
vancosamine (54), but above that temperature both sugars were lost. The observations 
in this work led to the idea that a combined reaction could be achieved. The combined 
synthesis would perform both the Edman degradation and the sugar clea\ age in one pot, 
reducing the number of reactions needed to produce the product. Purification by 
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precipitation was also used, thus removing the need for HPLC purification in the 
synthesis of the aglucohexapeptide. This synthesis is set out in Scheme 3.22. 
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Where R= The remainder of the peptide skeleton 
Scheme 3.22. 
This reaction replicated the conditions used for the Edman degradation of v ancomycin 
with the exception that neat TFA was used in the second step and the 
cyclisation/cleavage was stirred overnight. The neat TFA caused both the 
cyclisation/cleava``e and hydrolysis of the sugars, producing the aglucohexapeptide 
(53), the thiohydantoin (51) and both sugars. glucose (55) and vancosamine (54). The 
reaction was carried out on a 250 mg scale and purification by repeated wa'hing with 
acetonitrile produced 104 mg of product (53) (61 9c yield). 
3.2.6 Conclusions from the attempts to improve the Edman 
degradation 
Significant progress has been made in the application of the Edman degradation to 
vancomycin since its initial use in this project. The development of the degradation 
catalysed by aqueous base increased the yield, but at the cost of increased reaction time. 
Thorough examination of the conditions in both step., of the reaction hay e led to a 
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method that is both fast and high yielding, but also does not need HPLC purification to 
furnish product in sufficient purity for use in the coupling reactions. 
The techniques developed in the Edman degradation of vancomv cin were then applied 
to the formation of the aglucohexapeptide. This allowed the development of a combined 
degradation and sugar cleavage, which produced the aglucohexapeptide from 
vancomycin without the need for HPLC. 
These advances have allowed a sufficient quantity of hexapeptide skeletons to be made 
available to explore the key stage of this project, the coupling of the extending 
fragments synthesised in Section 3.1, to the hexapeptide skeletons synthesised in this 
section. 
3.3 Coupling of vancomycin hexapeptide and the piperazine- 
based extender fragments 
This section details the key step in the synthesis of the extended vancomycin analogues: 
the coupling reaction between the hexapeptide skeleton and the piperazine extenders. 
This was attempted with the hexapeptide that still carried the sugars, because if 
selectivity could be achieved in this acylation step, this would yield vancomycin 
analogues as opposed to analogues of aglucovancomvýcin. This was preferred as the 
sugars are involved in the binding event and have implications on the biological activity 
of the compound, as discussed in detail in Section 3.2.4. 
3.3.1 Synthesis of the glycine containing analogue (58) 
The first attempt at the synthesis of the vancomycin analogue (58) used 1-ethyl-3-( 
dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and hydroxybenzatriazole 
(HOBt) as the coupling agents as detailed in Scheme 3.23. The choice of EDC and 
HOBt followed their successful use in the piperazine synthesis (Section 3.1) and the 
tripeptide synthesis (Section 3.4), where they replaced the use of dicyclohexyl 
carbodiimide (DCC) and HOBt. resulting in improved yields and eliminating the 
production of a troublesome by-product dicyclohexy lurea (DCU), \ý hich proved 
difficult to remove from the products of the reactions. 
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In the first step the tert-butyl ester (35) was cleaved in neat TFA yielding (32 , as 
indicated by LCMS analysis of the reaction mixture. Product (2 was then isolated via 
evaporation and any excess TFA removed under high vacuum. The crude product of 
this reaction was then treated with EDC and HOBt to pre-form an activated 
benzatriazole ester (57). The pre-formed activated ester was then added to the 
hexapeptide (50). Treatment with 1.2 equivalents of the activated ester did not consume 
all the hexapeptide, so a further 0.6 equivalents were added. LCMS showed that 
addition of further quantities of the benzatriazole ester (57) did not drive the reaction to 
completion. 
When samples of the reaction mixture were diluted with CH3CN to prepare samples for 
LCMS a precipitate was observed; this re-dissolved with addition of water, thus 
allowing the LCMS to be recorded. Following this observation, a small quantity of the 
reaction mixture was diluted with CH3CN and the resultant precipitate was collected via 
filtration under reduced pressure, to see if this offered a method of purification. LCMS 
analysis of the CH3CN solution indicated that the reagents (EDC, HOBt and the 
piperazine extender) were present alongside only a trace of product. NIS analysis of the 
solid showed the presence of the desired product, un-reacted hexapeptide and only 
traces of the other reagents. 
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This isolation procedure was therefore used on the remaining reaction mixture and the 
solid collected via filtration. This was followed by purification via LCMS, but this 
produced only 2 mg of the vancomycin analogue (58), a3 '7c yield. MS analysis of the 
product showed that significantly the sugars of the acylated product were lost by 
fragmentation under the MS conditions. The fragmentation pattern (Figure 3.9) shows 
that alkylation must have occurred on the N-terminal amine of the hexapeptide as the 
peaks at 1432.9 m/z and 1270.9 m/z corresponded to (58) minus the vancosamine sugar 
and (58) minus both sugars (see Figure 3.9). 
SA 1 mini is 
This did not conclusively prove that acylation occurred at only the N-terminus though. 
as peaks at 1177.8 m/z and 1015.8 m/z could have been derived from hexapeptide that 
had been acylated on the amine of the vancosamine sugar and then fragmented. These 
fragments could also have resulted from fragmentation of the hexapeptide by MS: thus 
it is difficult to know if this is from fragmentation of hexapeptide acylated at the 'sugar 
amine, or from traces of unreacted hexapeptide in the product. There was little evidence 
of a peak at 1321 m/z, resulting from un-fragmented hexapeptide, so it seemed likely 
that these fragments were derived by acylation at the sugar amine. A comparison of the 
ratio of peak heights for the two types of fragment shows that the predominant product 
resulted from acylation on the N-terminal amine of the hexapeptide. Despite the poor 
yield, this was a significant result at this stage of the project and indicated that there was 
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Figure 3.9. MS spectra of product (58). 
a preference towards acylation at the N-terminus as was desired for the production of 
(58); and the hexapeptide with the sugars intact could be used in these coupling 
reactions instead of the aglucohexapeptide. 
There still remained the problem of the very low yield to overcome. Some possible 
explanations for the poor yield were: 
" Not all of the acid (32) was converted to the HOBt ester (57) and some still 
remained in the solution transferred to treat the hexapeptide. This may have had 
some effect on the coupling, but there was still EDC and HOBt in the mixture so 
this should have converted the acid to the activated ester as the ester was 
consumed. 
" Not all the hexapeptide was consumed in this reaction, as some \k as evident in 
the MS analysis of the reaction mixture and the crude product; this maybe 
overcome by allowing longer reaction times. 
" The attempt to purify the product i'ia precipitation with CH; C N, then filtration, 
may have introduced losses. Although the CH3CN did not contain significant 
amounts of product, as indicated by LCMS, some material might have been lost 
on the filter paper. This precipitation technique is valuable though, as it allows 
the facile removal of HOBt, which has a very similar retention time to the 
desired product. To avoid the problems of potential loss via filtration it should 
be possible to recover the fine precipitate by centrifugation. 
In order to address these problems the literature was searched to find alternative 
conditions for this coupling reaction. A paper by Nicolaou et x1.31 was discovered that 
detailed the production of vancomycin derivatives from the hexapeptide and used 0- 
benzotriazol-l-yl-N, N, N', N'-tetramethyluronium hexafluorophosphate (HBTU) to add 
an amino acid to both the C and N terminus of the hexapeptide. This was substantially 
different from the attempted coupling reaction because the hexapeptide used in their 
study was alkylated on the sugar amine with substituted benzyl groups and the synthesis 
was carried out partially on solid-phase, but the conditions allowed them to produce 66 
analogues of vancomycin. It was therefore decided that attempts should be made to 
utilise these conditions to see if they could be adapted to increase the yield in the 
coupling step required for the synthesis of (58). 
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This paper3' also contained a purification technique similar to the CHICN method 
utilised above. It involved concentration of the reaction mixture and then re-dioIý ing 
the crude solid in MeOH and precipitating the glycopeptides by addition of Et, O. This 
procedure had been used in the preparation of the hexapeptides, not in the coupling 'step, 
but was none the less of significant interest. These conditions utilising HBTU were 
incorporated into the synthesis of analogue (58). as shown in Scheme 3.24. 
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HO NH, H1 DH 
HIC 
CH. O 
0 Cl 
HO 
Hý O 
HHH 
1ý H 
0HN JH 
HO O 
HO2C H, N 
«O 
HO 
I 
OH 
OH 
0 
CNJ 
H 
CN 
O 
(58) 
For this second attempt at the synthesis of (58), ester (35) was again hydrolysed to acid 
(32) in neat TFA, as confirmed by MS. The resultant residue was treated with HBTU in 
the presence of the hexapeptide. MS analysis of the reaction mixture revealed that thi,, 
coupling again did not fully consume the starting materials despite stirring overnight. 
There was however a number of un-recognised impurities detected by this MS, so the 
reaction mixture was evaporated to a paste and then the glycopeptides were precipitated 
with McOHIEt7O, and then collected via centrifugation. The resultant solid contained 
desired product (58), hexapeptide (50) and traces of the other reagents as shovk n by 
LCMS. The McOH/Et, O solution was shown by LCMS analysis not to contain any 
glycopeptides. The mixture of compounds in the crude solid indicated by the LCMS 
was evident in the prep HPLC trace of the test injection as shown in Figure 3.10. 
146 
10 
5 
ti 
E 
rdin,. t- 
Figure 3.10. HPLC trace of the crude solid. 
The three peaks A, B and D corresponded to the reagents and starting materials: 1lOBt, 
acid (32) and hexapeptide (50) respectively. C was not identifiable by MS and neither 
were F or G as the samples from this test injection were too weak to gke a good N1S 
spectrum. Peak E was interesting as its retention time was close to that of the 
hexapeptide and the observed parent ion (13-t8.9 m/z) in the MS of a sample from this 
peak was very close in weight to the hexapeptide, a difference of 26 mass units. Peak C 
was too weak to correspond to the desired product as the intensity of the peaks for the 
hexapeptide and its fragment ions were of almost equal intensity to the peaks of the 
product and its fragment ions in the MS of the crude solid. Therefore peaks D-G were 
collected by preparative HPLC using a C- 18 reverse phase column and a gradient 0 -10 
c// acetonitrile over 30 minutes, followed by a 10 minute 98 C/c acetonitrile wash. 
After prep HPLC, the fractions for each peak were combined and evaporated. MS and 
LCMS confirmed that the peak D sample was the hexapeptide and that the peak E 
sample showed the mass (1348.9 m/z) found during the test HPLC purification of the 
precipitated solid. It is surmised that this compound was produced via reaction of the 
hexapeptide with CO2 present in the reaction mixture and the HBTU then causes a 
further reaction, which forms a carbonate between the N-terminal amine and the 
adjacent alcohol, this leads to the formation of compound (59) (Scheme 3.25. change, 
highlighted by the boxes). 
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Scheme 3.25. 
The sample obtained of peak F after preparative HPLC contained the desired product 
(58) as shown by MS and LCMS, but these techniques and further HPLC analysis 
showed that the product was impure. The sample from peak G also contained the 
desired product (58) and was significantly purer than peak F, as indicated by MS, 
LCMS and HPLC, but still was not entirely pure. The material recovered in the peak G 
fractions was freeze-dried and yielded 11.2 mg of compound that was predominantly 
product (58), (19 % yield). The presence of the desired compound in two separate peaks 
was an interesting observation. It is believed that this is an artefact of the rapidly 
changing gradient, which increases substantially from 10 % to 98 % CH3CN over 
minutes. It is likely that some material has moved with the solvent front as the eluent 
with higher CH3CN content moved down the column, resulting in peak F; while the rest 
of the material has moved through the column normally, resulting in peak G. This 
provides an explanation of why neither sample of material is pure; therefore better 
column conditions were sought after the next reaction. 
This last result still gave a low yield, but observation of the supposed compound (59) in 
the reaction mixture and the likelihood that it was derived from addition of CO2 to the 
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hexapeptide offered a partial explanation for this low yield. It was decided to repeat the 
reaction under conditions that should eliminate the presence of CO'; the steps necessary 
for this would also exclude water and oxygen rigorously from the reaction mixture and 
it was hoped these factors combined would increase the yield. To achieve this it «a' 
necessary to understand where H2O or CO? could be entering the reaction, considering 
each of the reagents in turn: 
" The DIPEA and DMF were both commercially obtained as anhydrous liquid; in 
sure-seal bottles and kept under a positive pressure of nitrogen, it seems unlikely 
that the CO2 came from these. However the DMF bottle was a few months old 
and therefore fresh dry DMF was sourced. 
" The acid (32) was left under high vacuum for at least 12 hrs to remove any 
excess of TFA from the cleavage reaction; this therefore also seems an unlikely 
source for the CO-) or H2O. 
" The HBTU was commercially obtained, but was not stored under N,, so this is a 
possibility for the introduction of the CO2. It was stored in a para-film sealed 
container at -18 "C and allowed to warm to room temperature before weighing, 
so was unlikely to contain any water. 
" The hexapeptide was stored under N2 at -18 "C after synthesis, but contains a 
number of nucleophilic groups that could trap CO2, so it i also a potential 
source of CO-,. 
" There is also the possibility that flushing the flask the N, is not sufficient to 
force all the atmospheric CO2 , or moisture from the reaction vessel. 
These considerations combined to produce the following modifications to the reactions 
laid out in Scheme 3.24, thus giving the conditions for the third attempt at the synthesis 
of analogue (58). They were: TFA cleavage of ester (35); followed by storage overnight 
under high vacuum; then the solids, HBTU and the hexapeptide, were added to the 
residue of (32). These solids were than exposed to high vacuum for 10 minutes, then 
flushed with N2, this was repeated twice and then the fresh DMF and DIPEA introduced 
without opening to the atmosphere, whilst maintaining the N, environment. 
After 3 hours stirring under N. MS of the reaction mixture showed all of hexapeptide 
(50) had been consumed. The reaction mixture was diluted with CH; CN to precipitate 
the glycopeptides, which were then collected by centrifugation. The crude solid (, see 
Figure 3.11 for crude HPLC) was purified by HPLC. New conditions ww ere established 
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as the earlier conditions resulted in the product being collected during the steep ramping 
of the acetonitrile concentration that precedes the wash and it was believed that this \\a" 
the reason for the reduced purity of the product in the earlier purification attempt. The 
new conditions still used a C-18 reverse phase column, but the gradient was now 5- 10 
% over 10 minutes, followed by 10- 15 '/(over twenty minutes and then the 98 cc ýý a. h 
for 10 minutes. 
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Figure 3.11. HPLC trace of crude solid. 
The material corresponding to the two major peaks, marked A and B, was collected. 
MS analysis of a sample of peak A from a test injection did not indicate any product 
(58). MS analysis of a sample of peak B indicated the desired product, compound (58) 
was present. The fractions from peak B were combined and freeze-dried and HPLC 
analysis indicated that it was a single compound, as only one peak was observed in the 
HPLC trace. The compound was returned in 29 11c yield based on the amount of 
hexapeptide used. 
MS analysis of the solid from peak B shows the desired product (58) at 1577.9 m/z as 
the singly charged ion and at 789.2 m/z as the doubly charged ion, (58) minu' the 
vancosamine sugar at 1432.9 m/z and (58) minus both sugars at 1270.9 m/z. 
There was 
no indication of peaks at 1177.8 m/z and 1015.8 m/z that would result 
from 
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fragmentation of the compound acylated on the amine of the sugar. it therefore can be 
concluded that this is the desired compound (58), see Figure 3.12. 
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The hexapeptide used in the above reactions had been purified by prep HPLC after 
synthesis. As discussed previously, progress in the development of the Edman 
degradation reaction has yielded hexapeptide that has been purified by precipitation. It 
was decided to repeat the synthesis of (58) using hexapeptide prepared this way to 
ensure that it did not lower the yields in this reaction. 
The reaction was repeated as above but the coupling reaction took - ?6 hrs to consume 
all the hexapeptide. Purification was also as above and returned product (58) that was 
shown to have a minor impurity by HPLC analysis (see Figure 3.13). The material 
recovered represents a -1? 
c'c yield based on the amount of hexapeptide used, but is -- 90 
11c pure. Further purification of this product was not attempted. MS fragmentation of the 
product again shows that synthesis of analogue (58) was achieved. 
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Figure 3.12. NIS spectra for product (5S) in peak B. 
Figure 3.13. HPLC trace of' compound (58) from the repeat reaction. 
3.3.2 Synthesis of the D-phenylalanine containing analogue (61) 
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TFA cleavage was carried on piperazine (38) to yield acid (60). This was coupled to 
hexapeptide purified by precipitation, as in the synthesis of analogue (58). However, 
acid (60) was treated for 15 minutes with the HBTU, DIPEA and DMF to pre-form the 
active ester, which was then transferred by cannular into the reaction vessel where the 
hexapeptide had been held under vacuum and then flushed with N, repeatedly to 
remove any CO2. It was hoped that pre-forming the active ester would increase the 
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yield. The crude product was recovered by CH3CN precipitation. MS (Figure 3.14) of 
this crude product shows a mixture of acid (60) as the M+H ion at 364.4 m/z, product 
(61) as the M+2H ion at 835.1 m/z and the doubly acylated by-product as the M+2H ion 
at 1007.5 m/z. 
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Figure 3.14. NIS of the crude product in the synthesis of compound (61). 
The ratio of product to the combined by-product peak heights is -- 3: 2. This crude 
material then underwent final purification 0. a prep HPLC to Live the desired product 
(61) in 22 c/c yield. Apparently, pre-forming the activated ester had no effect on the 
yield. The product purity was confirmed by HPLC analysis (single peak), and MS 
fragmentation (see Figure 3.15) shows that the terminal amine was acylated. Unusually 
this product preferred to exist as the doubly protonated 2+ ion under the MS condition,, 
and the level of fragmentation is reduced. A six fold expansion of the area for the singly 
protonated ions does reveal their presence. 
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Figure 3.15. NIS of the purified product in the synthesis of compound (61). 
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3.3.3 Synthesis of the D-phenylglycine containing analogue (63) 
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Scheme 3.27. 
The reaction conditions developed for analogue (61) were repeated on piperazine (40), 
again using hexapeptide purified by precipitation. Only 1.5 equivalents of acid (62) and 
1.4 equivalents of HBTU were used in contrast to the synthesis of (61) where 2 
equivalents of acid (60) and 2 equivalents of HBTU were used. It was hoped that 
reducing the amount of acid and HBTU would reduce the production of the di-acylated 
by-product and thus increase the yield of the desired product (63). Double acylation was 
not observed and the product was therefore purified by CH, CN precipitation and HPLC, 
to give product (63) in 28 (4 yield, based on the amount of hexapeptide used. I IPLC 
analysis (Figure 3.16) showed that the material recovered was - 90 pure with two 
minor impurities. 
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Figure 3.16. HPLC trace of product (63). 
MS indicated product (63) at 1655.3 m/z as the M+H ion and at 827.2 m/z as the M+2H 
ion, (63) minus vancosamine at 1510.1 m/z and (63) minus both sugars at 1347.9 m/z, 
thus showing acylation occurred on the N-terminus (Figure 3.17). 
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Figure 3.17. The NIS spectra of the purified compound (63). 
3.3.4 Attempted coupling of the rigid analogue 
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Scheme 3.28. 
This reaction was attempted twice, in each case using lithium hydroxide to cleave the 
ethyl ester of (46), followed by neutralisation with conc. HCI and evaporation to yield 
acid (64). The first attempt used the one pot method used for the glycine analogue (58), 
where hexapeptide and HBTU were added to the residue from the first stage and 
evacuated and flushed with N,, before addition of the solvents. However, only starting 
materials were observed in the reaction mixture. The acid of the rigid analogue was 
poorly soluble in DMF, and this seems to result in the failure to generate an product 
in 
this reaction. 
155 
The second attempt at the coupling used the method previously used for analogue (61). 
The ester was pre-formed but it was decided to attempt the reaction in DCCI. in the 
hope that it would be a better solvent for the acid. It was also decided to change the 
coupling agent to HATU, which is more reactive than HBTU. However, HATL? «as 
poorly soluble in DCM, so DMF was added to this reaction in order to solubilise the 
HATU. 
Again, only unreacted starting materials were observed and no product was formed 
These experiments exhausted the supply of intermediate (46); therefore no further 
attempts were made at the synthesis of analogue (65). 
3.3.5 Conclusions on coupling reactions 
Selectivity for the N-terminus has been established and stepp have been made to 
improve the low yielding nature of these reactions. Double acylation was observed in 
some couplings but conditions were modified to minimise formation of this by-product. 
These improvements in the methodology encorporated insights gained in the synthesis 
of the hexapeptide skeletons, and relied on observations during the reactions and 
purification to fine-tune this synthesis. Removal of CO2 was proven to be of significant 
importance in these reactions and necessitates that the hexapeptide must be put under 
vacuum directly before the coupling and that atmospheric moisture and CO2 must be 
rigorously excluded from the reaction vessel. 
The failure to form the rigid analogue is particularly disappointing, because of the dual 
benefits this scaffold offered, namely lower entropic penalties on binding and the abilit\ 
to offer hydrophilic groups to solvent. Though, this failure may be overcome if a 
suitable solvent could be found to sufficiently solubilise the hexapeptide, acid (64) and 
the coupling agent, and this would be a good starting point for any future investigation,,. 
The results of the coupling reactions with the piperazine methyl esters were gratifying 
as they have proved that coupling of the hexapeptide and these extenders can be 
achieved, thus validating the key step of the synthetic pathway. which completed the 
synthesis of three designed extensions of the vancomycin core. This is the first instance 
where a fragment designed to offer extra hydrogen bonding and lipophilic interaction. 
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with the tripeptide target had been successfully synthesised, coupled to the hexapeptide 
core and purified, and is thus the first instance of the rational design of semi-ynthetic 
analogues of a natural-product drug like vancomycin. 
3.4 The tripeptide for binding studies 
There have been a number of studies to elucidate and quantify the nature cif the binding 
between vancomycin and either the bacterial cell wall or peptides that mimic it. A range 
of peptides have been used and indeed there is a degree of diversity in the natural 
terminus of the cell wall peptide, as mentioned in the introduction (Chapter 1, Section 
1.4). However, the crystal structure (PDB code 1FVM)35 used for the design stage 
contained diacetyl-L-lys-D-ala-D-ala (Ac2KAA, 66) as the cell wall mimic. 
OH0 
ýN\ 
lN 
OH 
OHH 
ö- 
N 
H 
(66) 
This was considered a close mimic of the natural substrate, because although the cell 
wall building blocks, lipid I and II, contain a pentapeptide; only the three terminal 
residues are involved in the formation of the hydrogen bond network with vancomycin. 
It was therefore decided to use Ac2KAA in our binding studies, thus it became 
necessary to synthesise this compound. It was hoped that an increase in the binding 
affinity to Ac-KAA could be achieved in the initial stage of this investigation, but it was 
a further aim that the modified vancomycin analogues produced would also have an 
increased affinity to the variants of this compound that mimic the terminus of the 
peptides used by resistant bacteria. As discussed in Chapter 1, there are two different 
alterations to the C-terminal amino acid that confer resistance. Replacement of the 
terminal D-alanine with D-serine, which is less frequently observed, and replacement 
with D-lactate, which is the most common form of resistance. To mimic these 
replacements the sequences needed would be: diacetyl-L-lys-D-ala-D-ser (Ac-2KAS. 67) 
and diacetyl-L-lys-D-ala-D-lactate (Ac, KAlac, 68). The differences from . Ac4LA: \ are 
circled in the diagram. 
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Neito and Perkins36 reported the synthesis of Ac2KAA. However, they performed the 
synthesis from the C- to the N-terminus, and this was considered to be undesirable for 
this case, as a separate synthesis would have to be undertaken to furnish each of the 
desired analogues (67 - 68). A more efficient synthesis of all three peptides would be 
achieved if the synthesis began at the N-terminus. 
The use of tert-butoxycarbonyl (BOC) protecting groups to protect both nitrogen, of the 
lysine amino acid was considered desirable because they are known to be stable in the 
conditions used for the peptide coupling reactions and are frequently used within this 
context. Thay have a further advantage that they are also lipophilic and it was believed 
that this would aid purification of these compounds. The acid groups were protected as 
methyl esters because conditions were known for the formation of these eýterý. Also, 
work by Horton, 4 from this research group, had developed conditions for the cleavage 
of methyl esters in high yield. This led to a synthetic sequence which would begin with 
the protection of both nitrogens of lysine with BOC groups and then the sequential 
coupling of D-alanine methyl ester, methyl ester cleavage with lithium hydroxide, 
followed by a further coupling of the methyl ester of D-alanine. D-serine or D-lactate, 
depending on the analogue required. After the final coupling the BOC groups could be 
cleaved, the amino groups acetylated and the terminal methyl ester cleaved to give the 
free acids (67 - 68). This route is outlined in Scheme 
3.29. 
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Scheme 3.29. 
3.4.1 Tripeptide synthesis 
Due to the fact that this synthetic path was untested it was considered logical to test it 
on a small scale and furnish compound (66) and then repeat the synthesis on a larger 
scale to furnish a sufficient quantity of intermediate (73) to yield the required analogues 
(66-68). 
The first stage of this process was the protection of the main amino acid building 
blocks, L-lysine (69) and D-alanine (71). L-lysine was obtained as the free amino acid 
and BOC protected with BOC anhydride using the conditions of Tsuchida et cal. 
37 Thi. 
reaction was relatively inefficient; the first attempt gave the BOC protected compound 
(70) in a 28 % yield. Repeating the reaction gave (71) in a 58 Y- `ield, which ww as 
acceptable but still low for such a trivial protection step. 
159 
D-alanine was also acquired as the free amino acid and was reacted with methanol in 
the presence of acetyl chloride, following the conditions of Hulme, 15 as used in Section 
3.1. This again proceeded smoothly yielding (72) as the HCl salt. As a large quantity of 
this intermediate was required, this reaction was performed tvt ice on ß. 5g of D-alanine. 
From one reaction 2.6 g of the methyl ester (72) was isolated (65 9ý) and 3.9 R for the 
other (94 ý/c ). 
Dicyclohexyl carbodiimide (DCC) was used to couple (70) and (7-1) in the presence of 
hydroxybenzatriazole (HOBt) and triethylamine using the conditions of Rees et al. 3 
This reaction proceeded smoothly and afforded the desired product, intermediate (73) in 
82 % yield after filtration to remove the solid dicyclohexylurea (DCU) by-product and 
an aqueous work-up. This reaction was repeated but purification was achieved by 
column chromatography on silica gel. The yield was lower (-t I (/C), but the product ýý as 
purer, as trace amounts of DCU were observed when the product purified by aqueous 
work-up was used in subsequent reactions, whereas this was not observed in the product 
purified by silica column. 
The protected dipeptide (73) was partially deprotected by hydrolysis of the methyl ester 
using lithium hydroxide. 4 A trial of this reaction on 100 mg of the material purified by 
aqueous work-up yielded 87 mg (90 C/c), which was clean except for DCU remaining 
from the previous reaction as a minor impurity. Repetition on a large scale with the 
remaining 840 mg of material from the reaction purified by aqueous wash produced 768 
mg of the free acid (95 '/c), again with DCU as an impurity and a trace of HOBt. The 
HOBt signal was weaker, so this was probably present in the small-scale reaction but 
just not observed. The product from the large-scale reaction was taken on without 
further purification and coupled to D-alanine methyl ester (72) to yield the protected 
tripeptide (74). This coupling again used DCC, HOBt and triethylamine. However, 
purification required an aqueous work-up and two subsequent purifications by silica gel 
column chromatography to yield material of sufficient purity. As a result of this 
involved purification the yield for this reaction ýý, as low, only 27 7c. 
Repeating the ester cleavage on dipeptide (73) that had been purified by column 
chromatography was very successful. The hydrolysis progressed smoothly. consuming 
all the starting material and partitioning the product between base and EtOAc, and then 
acidifying the base and extraction with DCM gave the desired free acid 
in 97 ý< yield 
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and good purity. Taking this, material and performing the DCC, HOBt and triethylamine 
mediated coupling to (72), yielded (74). Purification by aqueous work-up and 
preparative LCMS gave the desired compound in high purity ww ith 32 YYc ' field 
In the first attempt to convert (74) to (66), the conversion to the acyl-protected 
tripeptide (75) was performed as a separate step, followed by the methyl ester cleava-_e. 
To convert (74) to (75) the two amino groups of the lysine from compound (74 were 
deprotected using a solution of 25 c/c TFA in DCM under the conditions of Fairlie et 
ell. 38 No attempt was made to purify at this stage and the material was simply 
concentrated under vacuum and then any remaining TFA removed under high vacuum. 
This was taken on and treated with DMAP, Hunigs base and acetic anhydride in THE 
The reaction mixture was concentrated and it was hoped that the di-acylated tripeptide 
(75) could be isolated by aqueous work up. However, this was unsuccessful and it was 
necessary to concentrate the aqueous layers in order to recover the product. This crude 
mixture was taken on without further purification. The MS and LCNIS data suggested 
that the methyl ester had partially hydrolysed. This was not viewed as a significant 
problem as the next step involved the hydrolysis of this ester. 
The attempted cleavage of the methyl ester using the conditions that had been 
established earlier yielded only a small amount of acid (66). The presence of a large 
amount of impurities within the crude sample of the precursor (75) may account for this 
low yield. After LCMS purification, only 16 mg of compound (66) was recovered and 
this was still slightly impure. Based on the 100 mg of (74) used in these reactions this 
is 
only a 22 c/o yield. 
It was decided that the remaining material would converted from the BOC protected 
tripeptide ester (7 I) to the N-acyl tripeptide with a free acid (66) without any 
purification. To this end, the diisopropylethylamine in the acylation step was replaced 
with triethylamine, this meant that it could be more easily removed 
by concentration in 
vacuro. It was hoped that this would reduce the number of 
impurities carried through the 
reactions and improve the yield. 
Ester (7-I) was treated with 25 cl(- TFA in DCM and after 
3.5 hrs analvsi, s using LCNIS 
indicated that there was still some mono-BOC compound present. 
The compound ýýas 
therefore treated with neat TFA overnight. Despite a significant reduction 
in this 
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impurity, some still remained even with these forcing conditions. The material was 
therefore taken on with this minor impurity. The acylation proceeded smoothly and took 
only 2 hrs. The mixture was then hydrolysed using LiOH in H2O and CHCN, then 
purified using LCMS to give 30 mg of the desired product (66), a 23 Yk yield. 
3.4.2 The repeat synthesis of tripeptide 
The above route did not furnish sufficient quantities of Ac2KAA (72) and none of the 
key intermediate (73) remained, which would allow the production of Ac, KAlac or 
Ac2KAS. There were three significant problems that caused this: the Boc protection of 
lysine from the free amino acid was low yielding, only 58 Y/-: the peptide couplings 
were low yielding (41 and 32 %) and conversion to the di-acylated. free acid (66) was 
low yielding (23 9c). It was necessary to solve these problems in order to progress with 
this synthesis, dealing with each of them in turn produced the following su`Tgestions: 
" Only small amounts of starting material were observed in the crude reaction 
mixture of the BOC protection. Therefore the product was probably being lost to 
side-reactions or during the purification steps. As the free acid on lysine was a 
likely cause of any side-reactions and also made purification more difficult. it 
was thought that protection of this group prior to the BOC protection would 
increase the yield for this step. As the formation of methyl esters was quick and 
high yielding and their hydrolysis seemed equally efficient in the earlier 
synthesis, this seemed the most appropriate strategy. 
" The low yield of the peptide couplings was a significant problem and also the 
prevalence of a persistent impurity, dicyclohexyl urea, from the coupling agent 
suggested a solution to this problem. This was the use of an alternate coupling 
agent I -ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride (EDC). 
EDC is water soluble, as is the urea by-product produced by using it in these 
coupling reactions, and it was hoped that this would both increase the yield of 
the reaction and allow easier purification. 
" The conversion from (74) to (66) utilised three reactions that were all 
individually high yielding and should produce the minimum of by-product', and 
thus simplify purification. There was a minor problem in the TFA hydrolysis of 
the BOC carbamates, but this could be overcome by using fresh TFA. This 
problem was insufficient to explain the lo\\ Meld though: this suggested that 
there were problems with the purification, as no problems were observed in the 
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two other reactions. This led to two possible causes; impurities in the starting 
materials or reagents being carried through the reaction and losses due to poor 
purification techniques. Eliminating any sources of impurities would make 
purification simpler, improving yields. There were also problems injecting the 
crude product dissolved in neat MeOH during the LCMS purification, which 
may have introduced losses and could be avoided. 
With these changes it was hoped that sufficient quantities of the tripeptide (66) could be 
achieved to cover all of our testing needs and also leave sufficient quantities of 
intermediate (73) to synthesize both Ac2KAlac and Ac2KAS if needed. The synthesis is 
set out in Scheme 3.30. 
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Scheme 3.30. 
Sufficient quantities of (72) remained from the earlier synthesis, so it was not nece"sar 
to synthesis this again. This synthesis therefore began with the production of lysine 
methyl ester, this utilised the same methods used to produce glycine, D-alanine and 
phenylalanine methyl ester. 15 It was performed on 5.0 g of lysine hydrochloride and 
produced 6.4 g of lysine methyl ester dihydrochloride, a quantitive conversion. 
The lysine methyl ester was protected by treatment with three equivalents of BOC 
anhydride in the presence of sodium hydroxide to afford amino acid (80). 
This used 
6.1 g of the methyl ester and yielded 6.0 g of di-BOC lysine methyl ester (80). as a 
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white solid after purification by column chromatography, a yield of 64 9c. This is only a 
marginal increase in yield for this BOC protection, but the product achieved is 
significantly purer than the BOC-protected free acid in the first synthesis and passed 
microanalysis. 
Hydrolysis of (80) using lithium hydroxide proceeded smoothly, showing complete 
conversion to product after 90 min, as indicated by LCMS analysis. The free acid was 
then coupled to D-alanine methyl ester (72) using water-soluble carbodiimide (EDC) 
and HOBt in DMF. 7'8'16 This produced 6.3 g of product (73) as a white solid. following 
aqueous work-up, a 90 c/c yield. This was pure enough to pass microanalysis without 
any further purification. 
Only 4.0 g of the material produced was taken on to produce the di-BOC tripeptide (74). 
The first step was again hydrolysis with lithium hydroxide, this reaction was successful 
and MS analysis showed only product after 1 hr. The yield of the subsequent peptide 
coupling reaction was low, only 1.59 2 (34 %) of (74) was isolated after the aqueous 
work-up. The low yield was the result of failing to neutralise the reaction mixture before 
the solvent was removed under vacuum in the lithium hydroxide cleavage. This meant 
that the excess lithium hydroxide was carried into the coupling reaction and appears to 
have reacted with the coupling agent and resulted in a poor conversion in the peptide 
coupling. Analysis of the aqueous waste by MS found the acid present as both the 
sodium and lithium salts. The solutions were acidified and extracted and thus 2.1? g of 
the acid were recovered; this is the equivalent of 2.19 g of methyl ester (73). Taking this 
recovered starting material into account the yield is 75 %. 
Conversion of the di-BOC methyl ester (74) to the di-acylated free acid (66) wk as 
performed in three stages. In the first stage the BOC protecting groups were removed 
using neat TFA, the reaction was complete after 80 minutes, as indicated by NIS. The 
TFA was removed under vacuum and any excess removed by leaving the sample under 
high vacuum. The residue from this reaction was then used directly in the second stage, 
where acetic anhydride, DMAP and triethylamine were used to acylate the free amine" 
of the tripeptide. An aqueous wash was attempted to purify the crude product. 
however 
it appears that the saturated sodium hydrogen carbonate, used in the work-up, wNas 
sufficiently basic enough to induce partial hydrolysis of the methyl ester. 
It wa" possible 
to isolate both the acid and the remaining methyl ester from the aqueous solvents and 
164 
proceed with the reaction. Despite attempts to purify this product by aqueous extraction, 
column chromatography and re-crystallisation a sample which would pass 
microanalysis could not be achieved. Conditions were therefore sought that would allow 
purification by prep LCMS and during this process it was observed that compound with 
the correct mass for the di-acyl free acid (66) was present in three of the peaks in the 
total ion count trace. This is presumably caused by the presence of diastereoisome rN 
resulting from the base-induced epimerisation at one or more of the chiral centres in the 
tripeptide; purification was therefore stopped at this point. 
3.4.3 The tripeptide synthesis via solid-phase 
Following the problems with the above synthesis and its failure to yield the tripeptide 
needed for the testing phase of this project, it was decided to synthesise the tripeptide on 
solid-phase. The synthesis was carried out via standard Fmoc chemistry as described in 
the Novabiochem catalogue'`' and began with Fmoc D-alanine already attached to a 
Wang resin. The Fmoc deprotection was achieved with 20 % piperidine in DMF and the 
peptide couplings used HATU. Conversion from the di-Fmoc protected tripeptide to the 
di-acyl tripeptide was performed on the resin, using piperidine deprotection followed by 
capping with acetic anhydride in the presence of pyridine. The final cleavage was 
carried out using freshly distilled TFA. This differed from standard cleavage conditions 
as no scavengers were employed. None of the side-chains required protecting ``roups 
and therefore no by-products from protecting group cleavage were present to be 
scavenged, thus the scavengers were unnecessary. 
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Scheme 3.31. 
The synthesis was performed on 500 mg of pre-loaded resin (0.8 mmol/g loading) and 
was monitored by both Kaiser test and a test cleavage of small samples from the resin 
for LCMS analysis, by both measures the synthetic scheme appeared successful. A 
small-scale cleavage on 1 17 mg of resin yielded 31 mg of tripeptide (66) as a glassy 
solid. Repeating this step on the bulk of the compound yielded a further 98 mfg. 
However, LCMS analysis of these samples showed the presence of a peak at 387 m/z, 
which corresponds to the methyl ester. This was present in both samples but was 
stronger in the large scale cleavage. The 1H NMR spectra did not agree with the LCNIS 
analysis, as the methyl ester was not observed in the small sample, but was present as a 
minor impurity in the large sample. HPLC analysis showed two major components in 
each sample, the samples were therefore combined and purified by preparative HPLC. 
and then the resulting product fractions were freeze-dried, yielding 31 mg. 21 ý'(. The 
presence of the methyl ester impurity is not understood at this point, but it is possibly 
derived by inadvertent acid catalysed esterification, where residual TFA from the 
cleavage step catalyses a reaction with the methanol that was added to the sample to 
prepare aliquots for analysis. 
166 
3.4.4 Conclusions on the tripeptide synthesis 
The failure of the designed route to produce the desired compound was a significant 
setback, particularly after the efforts to improve the synthesis had been so successful. 
Use of the methyl ester of lysine increased the yield and improved the purity of the 
product and replacing DDC with EDC gave both better yields and eased the 
purification. 
It is believed that the racemisation of the chiral centres was the result of the u; e of an 
excess of lithium hydroxide in the cleavage of the methyl esters. Three equivalents were 
used, as this was a procedure that had been successfully employed within the group 
before. However the earlier use did not highlight this problem. One equivalent should 
be sufficient to cleave the methyl esters and this might limit any racemisation, or the use 
of methyl esters could be revised and an alternative acid protecting group used: benzyl 
esters maybe a good choice as they would offer a chromophore that would aid 
purification on silica column. 
The solid-phase synthesis has provided sufficient material to test the analogues . r`ain't 
Ac2KAA (66); unfortunately neither Ac2KAS (67) nor Ac, KAlac (68) have been 
synthesised. 
3.5 Testing 
There are a great many ways to establish the association constants for the analogues 
produced during this project, UV difference spectroscopy, nanoelectrospray ioni, ation - 
mass spectrometry (nano ESI-MS), measurement of shifting signals in 
'H NNIR on 
complex formation and surface plasmon resonance (SPR) are examples of the numerous 
techniques available. There are also biological methods to asses if the analogue" hav e 
increased affinity to the complete peptide wall, minimum inhibitory concentration 
measurements for example, although most of the biological methods are not 
direct 
measures of affinity as they are dependant upon other factors like adsorption, solubility 
and lack of resistance in the target organism. 
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3.5.1 Nanoelectrospray ionisation - mass spectrometry (nano ESI-i\IS ) 
3.5.1.1 The precedent 
Jorgensen, Roepstorff and Heck40 established nano ESI-MS aa technique to directly 
quantify the binding interactions of glycopeptides and cell wall precursor. wk without the 
need to use titration curves. The first step in establishing this technique was to prove the 
solution phase stereospecificity for sequences terminating in D-ala-D-ala is preserved 
when the ionisation under nanoflow conditions occurs. They did this by analysing the 
region for the doubly charged complex of the MS produced by injecting an equimolar 
mixture of diacetyl-L-lys-D-ala-D-ala; diacetyl-L-lys-L-ala-L-ala d6 and vancom` cin in 
ammonium acetate buffer. The complex for the D-isomer was observed but the L- 
isomer was not, which is consistent with the results determined in solution. 36 
The presence of the deuterium label enables the two complexes to be distinguished, as 
complexes of the same molecular weight are indistinguishable by this technique. To 
ensure that the deuterium label did not have an effect on the complex formation they 
performed another experiment with equimolar amounts of acetyl-D-ala-D-ala-D-ala, 
acetyl-D-ala-D-ala-D-ala d3 and vancomycin and found that there was no difference in 
the abundance of the deuterated and non- deuterated complexes. 
They then went on to derive the association constants of vancomycin and ristocetin with 
five cell wall peptide analogues at three different concentrations. They found that the 
constants obtained at each concentration were in agreement with each other and with the 
published results of Neito et al. 4' obtained using different techniques. Thus showing 
that this technique is a valid way to directly quantify the solution binding properties of 
glycopeptides of the vancomycin family. 
Heck and van de Kerk-van Hoof 2 used nano ESI-MS to calculate the association 
constants of a- and P- avoparcin and interestingly in this paper they also quote the ESI 
MS derived constant of vancomycin and compare it to the literature \ alues, the ES[ `IS 
derived constant is 7.3 x 105 and the literature values quoted are 1.5 x 106 from Neito 
and Perkins, 36 4.1 x 105 from Allen et al. 4" and 3.0 x 105 from Popieniek and Pratt. 
'-' 
Numerous other papers have been produced that have used nano ESI-NIS to analye 
complexes of many variants of the cell wall mimicking peptide, 
4'-48 including a water 
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soluble variant of lipid II49 and a range of glycopeptides. In addition, the proce,,,, o 
dimerisation in glycopeptide binding has been investigated with this technique., " 
3.5.1.2 The theory 
The calculation of ligand binding affinity by nano ESI-MS involves measuring the ions 
produced by the free glycopeptide and its non-covalent complexes with the peptide 
ligand. The method relies on the assumption that the ion abundance is equivalent to the 
solution concentration, when applied to vancomycin this assumption means that the 
technique relies on vancomycin (1447 Da) ionising to the same degree as the non- 
covalent complex (- 1700-1900 Da, dependant on peptide ligand). It also assumes that 
complex formation does not significantly alter the physcio-chemical properties like 
hydrophobicity and polarity that are also important in ionisation . 
4, S However, the work 
of Heck et aI. 4U substantiated this assumption by deriving association constants that 
were comparable to those present in the literature obtained by other means, but they also 
showed that the conditions for ionisation must be sufficient to de-solvate the species as 
they are introduced to the machine and ionise them without destroying the complex and 
that the stability of the complex was dependant on pH, so the solution', must therefore 
be buffered. 
3.5.1.3 The testing in practice 
The nano ESI-MS testing was performed in the laboratory of Dr Alison Ashcroft, 
Astbury Centre for Structural Molecular Biology, Department of Biochemistry and 
Microbiology, University of Leeds. 
The technique used in this project was based on that of Jorgensen, Roepstorff and 
Heck, 40 but this work simplified the process by considering equimolar mixture,, of each 
glycopeptide and the Ac-, KAA tripeptide separately, as opposed to using three 
different 
cell wall mimics as they did. The three analogues, vancomycin and the hexapeptide 
were each separately prepared in equimolar mixtures with Ac, KAA. Vancomycin and 
the hexapeptide were run as controls to validate the results achieved. 
Each of the glycopeptides was run three times using equimolar (200 µN1) mixtures of 
Ac, KAA and the glycopeptide, results were recorded over 50 scans. the scans were 
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summed and the profile data was centred by mass. Both 1+ and 2+ ions were observed. 
Figure 3.18 shows a typical MS trace achieved. 
Wn 
100 
'a 
91203 
Complex 
2+ ion 
911. `. 5 
AML+Y ONM ereity of Leeds 01-ag-200611: 4e: 49 
The MassLynx software was used to convert the total ion counts spectra to a list of mass 
versus peak area, and for each injection the abundance of each type of ion was 
calculated by summing the peak area for all the mass centred peaks from each ion type, 
then the ions (e. g. I+ and 2+) for the complex were added together and all the ions for 
the free glycopeptide were added together. 
This agave two abundances one for the complex (c) and one for the free glycopeptide 
(fg), adding these together gives the total response for all the glycopeptide injected (tg). 
As the initial solution injected was prepared by mixing equal volumes of two 200 µM 
solution we know that the initial concentration of the glycopeptide in the solution must 
have been 100 [M. The concentration of complex [c] can be calculated in µ1e1 by: 
[c] _c 
tRI100 
To get the concentration of the complex in M, the equation would be: 
_ 
c/ 1000000 [ý] 
tg/100 
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Figure 3.18. NIS trace achieved with a 1: 1 ration of vancumvcin and Ac KAA. 
Which can be simplified to: 
C/10000 
tg 
The corresponding equation to obtain the molar concentration of the free glycopeptide 
would be: 
lfg] fg/10000 
to 
Where c= complex abundance, fg = free glycopeptide abundance and tg = total 
glycopeptide abundance. 
The equation to calculate the association constant is: 
K_ 
[c] 
a [f`ý]x [ft] 
Where [c] = complex concentration, [fg] = free glycopeptide concentration and I ft] = 
free tripeptide concentration. 
We have two of the three values needed to calculate the association constant, the 
remaining missing value [ft] can not be calculated directly in this experiment, as the 
tripeptide is much smaller and has completely different physico-chemical properties to 
the free glycopeptide and the complex, and would therefore ionise differently, but it can 
be easily inferred. 
The complex is a one to one complex, one glycopeptide and one tripeptide, the mixture 
is an equimolar combination of tripeptide and glycopeptide. Therefore for every 
glycopeptide molecule in the complex, there is one tripeptide molecule in the complex: 
but also for every free glycopeptide molecule, there is a free tripeptide. So, [fg] = [ftj 
and the equation to calculate the association constant can thus be simplified to: 
[C ], 
[fgY 
This was used to calculate the values in Table 3.4 below, which shows the association 
constant obtained for each injection, the avera``e association constant for the three 
injections and the ratio of the association constant for each gl}copeptide compared to 
vancomycin. The analogues are identified by the terminal amino acid of the extending 
fragment. 
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K. (M-1) from injection: I Avvrnap 
1 Z 3 K. (M) { vancomycin 
I 
I Ieyapeptitlc 0) 1.07L+U 3 1.1_I2E+U S. UUL+02 O. 6 )E+U' 0.0 16 
Vancomycin (47) 7.31E+04 6.25E+04 5.10E+04 6.22E+04 1 
Glycine 
Analogue (58) 
1.07E+05 8.98E+04 8.54E+04 9.41E+04 1.512 
Phenylglycine 
Analogue (63) 
9.24E+04 8.01E+04 8.11 E+04 8.45E+04 1.359 
Phenylalanine 
Analogue (61) 
1.74E+05 1.59E+05 1.63E+05 1.65E+05 2.658 
I ante s. 4. Ka data generated trom nano H: SI-MS runs. 
The association constant obtained for vancomycin (6.22 x 104) is lower than the 7.3 x 
IW reported by Jorgensen, Roepstorfff and Heck4 and is outside the literature range of 
3.0 x 10' to 1.5 x 106. However, the relationship between the values obtained for the 
hexapeptide and vancomycin confirm the technique is able to measure the relative 
affinity, as it is known that removing the terminal N-nmethyl-D-leucine residue destroy" 
the binding pocket and results in loss of antibacterial activýity. '4 Removal of this residue 
results in a 65-fold reduction in the observed binding affinity. This dramatic reduction 
in affinity were also observed in other glycopeptides by Allen et al. "' They found that 
converting LY264826 to its hexapeptide LY312607 produced aI I5-fold reduction in 
binding affinity and converting LY307599 to it's hexapeptide LY3 14015 produced a 
590-fold reduction in binding affinity, as measured by affinity capillary 
electrophoresis. `0 
The observation of increased association constants for every analogue, as compared to 
vancomycin under the same conditions, was a important accomplishment for this 
project. In particular the observation of greater than two-fold increase for the 
D-phenylalanine analogue was especially gratifying. These values are not necessarily 
the absolute values for the association constants of these glycopeptides, as the orders of 
magnitude are significantly different from the range previously quoted for vancomycin. 
The extending fragments are fulfilling their purpose and offer extra contacts to the 
tripeptide, increasing the affinity for the peptide sufficiently not only to compensate 
for 
the loss of the contribution from the N-methyl-D-leucine residue, but to exceed 
it and 
increase the affinity for the tripeptide as was designed. 
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3.5.2 Minimum inhibitory concentration (MIC) 
MIC measurements were performed on the hexapeptide, vancomycin and three 
analogues by Dr. Julieanne Bostock in the Institute for Molecular and Cellular Biology, 
Department of Biochemistry and Microbiology, University of Leeds. These were 
performed as a standard two-fold dilution series. The MIC determined is the lowest 
concentration required to inhibit bacterial growth. Growth was monitored by 
measurement of the optical density readings at 600nm, while the culture was incubated 
at 37 °C for 16 hrs. MIC were determined against E. coli 1441: an E. roli mutant. 
SM 1411, in which the drug efflux pump present in the outer membrane is disabled, and 
S. aurerrs 8325-4 as shown in Table 3.5. 
Compound E. coli 1441 
( ml) 
SM 1411 
( mI) 
aureus 8325-4 
mI) 
---- I Icxapeptidc (50) >51> >51> >51 2 
Vancomycin (47) 1 I 1 
Glycine Analogue (58) >512 >512 256 
Phenylglycine Analogue (65) >512 >512 64 
Phenylalanine Analogue (61) >512 >512 128 
Table 3.5. MIC data for vancom cin, vancomv cin hexapeptide and analogues. 
This showed that the hexapeptide was inactive as was expected, vancomycin was active 
against all strains and the analogues were only active against the Gram-positive 
S. aureirs. This was unusual, as vancomycin should not inhibit the growth of Gram- 
negative bacteria, as it should not pass through the outer membrane of the bacteria. This 
suggested that the vancomycin sample was contaminated with a broad spectrum m 
bactericidal agent and thus prompted the examination of the sample of vancomycin used 
in the MIC. The supply of vancomycin used was rated at > 95 C// purity by the supplier, 
but HPLC analysis (Appendix B) shows that the sample is far more impure than that (< 
75 %, as indicated by HPLC peak area). A sample of this has been purified 
by HPLC, 
but unfortunately it was not possible to repeat this testing before the submission of this 
document. 
Nicolaou31 reports the MIC of vancomycin against a different strain of 
S. aureirs, 4002, 
as 0.39 µg/ml and Kahne'' reports MIC's against three 
further strains of S. uurerrs; 
MB2985 as 0.5 µg/m1, CL3033 as I µg/ml and COL as I µg/ml. 
So it appears that the 
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anomalous activity of vancomycin in this assay only extends to it inhibiting growth in 
Gram-negative bacteria and the MIC value against S. aurerus is of an appropriate 
magnitude. 
It was disappointing that the MIC values for the analogues were lower than that 
expected for vancomycin and the increase in affinity demonstrated in the nano ESI-\IS 
study did not translate into biological activity. 
It was also unfortunate that there was not the opportunity to test the analogues against g 
S. aurreus strains resistant to vancomycin before the submission of this document. 
3.5.3 Conclusion on testing 
It was `gratifying to achieve increased affinity as measured in the nano ESI-. `lS, as this 
was the aim of the project. It was disappointing, but not entirely unexpected, that this 
did not translate into increased biological activity as measured by the NIIC assay. The 
lack of an increase in biological activity was considered possible because biological 
activity is dependant upon more than just the affinity for the target. There are factors 
which affect the biological activity of glycopeptides such as the dimerization, vý hich is 
important in their mode of action, and also subtle changes in the charge density around 
the molecule can play significant roles in determining the conformation of the 
compound. An example of this is the potential interactions between the positively 
charged piperazine ring and amino group of the sugar, this could introduce a repulsive 
interaction that changes the conformation of the sugar and which could have an 
implication for both the binding of the tripeptide and on the dimerization of the 
compound, and thus affect the biological activity. 
However, both the MIC and the nano ESI-MS show that the extending groups must be 
forming contacts to the peptide targets, as in both instances the analogues have better 
results than the hexapeptide and this validates the modelling results further, ruling out 
one possible result which could have the extending fragment adopting a conformation 
which rotated it away from the peptide and into solution and would has c thus given the 
analogues an affinity for the tripeptide around the same magnitude as that observed 
for 
the hexapeptide. 
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3.6 Conclusions and future work 
The project succeeded in its initial aims to design, synthesise and test analogues of 
vancomycin in order to produce increased affinity for the tripeptide mimic diacetý I-L- 
lys-D-ala-D-ala. This is the first example of rational drug design being applied to a 
complex natural product drug, like vancomycin, in order to produce semi-"ý nthetic 
derivatives with increased affinity for their targets. 
This work sets out a synthetic route to a series of analogues, which could be easilv 
exploited to create further analogues. It also offers the possibility of furnishing the 
rigidified analogue with further synthetic efforts. Further exploration of the cony ergent 
synthesis towards the piperazines protected with benzyl and tert-but\ I ester groups 
offers a route into a further series of analogues, which terminate in the free acid. 
It would also be interesting to test the analogues, produced and any further analogues 
created against mimics of the resistant cell walls and in %%hole cell a,, sav s against 
bacterial strains resistant to vancomycin. 
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4.1 General procedures and instrumentation 
Proton nuclear magnetic resonance spectra were recorded at 300 MHz on a Bruker 
DPX300 spectrometer, or at 500 MHz on a Bruker Avance 500 machine. Chemical 
shifts are expressed in parts per million (ppm) downfield of tetramethyl. ilane (singlet at 
0 ppm, TMS) for samples in CDCl . 
Carbon 13 spectra were recorded at either 7i %IHz 
or 125 MHz on the above spectrometers, respectively. Chemical shifts are expre'. ed in 
parts per million, referenced to the central peak of the triplet of CDC1 (77. Oppm). 
For 'H NMR or 13C NMR samples ran in alternative solvents the chemical shifts were 
calibrated such that the residual solvent peak matched published values. All coupling 
constants are quoted in Hertz (Hz). Multiplicities are as follows: s-singlet. d-doublet. t- 
triplet, q-quartet, quin-quintet, sept-septet, m-multiplet, obs-obscured. DEPT and 2- 
dimensional COSY and HMQC spectra were used to assist in the assignment of 
complex spectra. Where extensive overlapping of signals in 1-dimensional proton 
spectra was observed, multiplicities and coupling constants could not be resolv ed. 
Electrospray (ES) spectra were recorded on a Micromas,, LCT K1l1 spectrometer, a 
Waters ZMD spectrometer or a Bruker MicrOTOF spectrometer. Molecular ions are 
reported as mass with percentage abundance quoted in brackets. 
Optical rotations were recorded on an Optical Activity AA- 1000 polarimeter and are 
quoted in units of 10-1 deg cm2 9-1 as a solution in CHCI3 or MeOH with the 
concentration quoted in brackets (g/100 ml) 
Elemental analysis was carried out by the Microanalysis laboratory, School of 
Chemistry, University of Leeds, using a Carlo Erba Elemental Analyser MOD 1106. 
Thin layer chromatography (TLC) was carried out using pre-coated glass-backed silica 
gel 60 F-,;. ý (Merck) plates, ývhich were visualised using ultraviolet 
light and 
permanganate. Silica gel used for column chromatography was 
Merck t1a,, h silica 60. 
37-70 [im particle -size. 
Analytical HPLC was carried out with CH; CN in water on a 
Dionex/Gý nkotek ' stem 
equipped with 250 x 4.6 mm analytical columns using 
full-spectrum UV detection. 
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Preparative HPLC was carried out with CH3CN and water on a Gilson preparatory 
system equipped with 250 x 21.2 mm preparatory columns using single-wt avelength LA' 
detection. 
LCMS was carried out on a Waters Micromass ZQ equipped with a XTerra `IS C18 
µm 4.6 x 50 mm analytical column and a XTerra Prep MS C 18 5 µm 19 x 50 mm 
preparatory column. Both methods use gradient elutions of water with 0.1 % formic 
acid and CH3CN with 0.1 % formic acid. The gradients are shown in Table 4.1. 
Time (minutes) Method I (% CH1CN) Method 2 (% CH, CN) 
0-3.5 0 0 
3.5-7.5 Oto50 Oto30 
7.5-8 50 to 95 30 to 95 
8-11 95 95 
11-12 95 to ?O 95 to 20 
12-14 20 20 
Table 4.1. LCSIS methods. 
Petrol refers to light petroleum (b. p. 40-60) and ether refers to diethyl ether. 
EtOAc and petrol were distilled before use. DCM was distilled over calcium hydride, 
THE was distilled over sodium and benzophenone, and McOH was distilled from 
methoxide generated from a mixture of magnesium and iodine in MeOH before use. All 
other reagents were used as received. 
Solvents were removed at reduced pressure using a Buchi rotary evaporator connected 
to a rotary oil pump, and followed by drying under high vacuum at 0.5 mmHg. 
In all cases, except those using aqueous conditions, reactions were carried out under a 
positive pressure of dry, oxygen free nitrogen and glassware was oven 
dried before use. 
C7 - 
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4.2 Computational design 
The computational designs in Section 2.3.1 were produced with version 3.4 of SPROUT 
on a Silicon Graphics machine, running a Unix operating system. The starting 
fragments and connecting fragments and results are described in Section 2.3.1. The 
structural variations (with altered amino acids, Section 2.4.1. and the rigidified 
structure. Section 2.4.2) were produced by editing structures in MOLOC. All the 
structures were re-scored using version 6.1 of SPROUT running on a Linux PC. The 
score data in all the figures in Sections 2.3.1,2.4.1 and 2.4.2 come from SPROUT 
version 6.1. 
4.3 Synthesis of extending fragments 
4.3.1 The first synthesis of piperazine (2) 
(4-tert-Butoxycarbonylmethyl-pipe razin-1-yl)-acetic acid ethyl ester (7) 
Conditions adapted from Witiak. l 
0 ýN 
0 Piperazin- l -yl-acetic acid ethyl ester (3). (1.00 g. 5.81 f 
tJJeog mmol) and K, C03 ( 2.01 g, 
14.52 mmol, 2.5 eq) were 
ýp 
d 
(7) dksolved in EtOH (25 ml). tert-Butyl 
bromoacetate 
(1.29 ml, 8.71 mmol, 1.5 eq) was then added and the reaction mixture was left stirring at 
room temperature for 50 hrs. The reaction mixture was concentrated in vac«o, then the 
residue dissolved in water (30 ml) and extracted with EtOAc (3 x 30 ml). The organic 
phases were then combined, dried with MC--S04, filtered and then concentrated in t'acuo 
to yield the title compound as an orange gum (1. -l. 2 g. 4.97 mmol, 86 c/c ); 
SH (CDCli, 
300 MHz) 4.18 (? H, q, J=7.1, He), 3.21 (2H, s. H,, ), 3.11 (? H, s. H", ý. ?. 65 (8H, bý,. 
Hd+e), 1.46 (9H, s, H, _), 1 27 (3H, t, j=7.1, 
Ha); be (CDCI 75 MHz) 170.7 (C). 169.9 
(C), 81.5 (C), 61.0 (CH2), 60.3 (CH, ). 59.9 (CH, ). 53.3 (CH, ). 53.2 (CH-), 28.4 (CH1). 
14.6 (CHF). 
Data consistent with sample made in Section 4.2.2. 
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(4- [(tert-Butoxycarbonylmethyl-carbamoyl) -methyll-piperazin- I -y 1) -acetic acid 
ethyl ester (5) 
Conditions adapted from Rees. 2 
0 
t 
Ng 
J< 
O rN hO 
N 
Je 
0 
acd 
(5) 
Piperazine (7) (0.92 " 3.21 mmol) was 
dissolved in TFA (20 ml) and stirred for 4.5 
hrs, before being concentrated in i-acuo. An` 
excess TFA was then removed by exposure to 
high vacuum for 12 hrs. HOBt (0.43 Q, 3.21 mmol, I eq). DCC (0.66 g. 3.21 mmol, I 
eq) and Et3N (0.49 ml, 3.53 mmol, 1.1 eq) were added to the resultant residue, ýý hich 
was then dissolved in anhydrous DCM (30 ml) and stirred for 15 minutes. tert-Butv I 
glycine (0.54 g, 3.21 mmol, 1 eq) was then added and stirring maintained for -')5 hr.. 
The reaction mixture was then placed in the freezer overnight to precipitate the DCU 
by-product. The by-product was removed via filtration under reduced pressure and the 
filtrate was concentrated in vucito. The resultant residue was then dissolved in I MI 
NaHCO3 (40 ml) and extracted with EtOAc (3 x 30 ruht the organic layer, were 
combined, dried with MgSO4, filtered and evaporated to dryneos. Final purification used 
preparative LCMS (method 1) and afforded the title compound as a brown oil (0.31 g. 
0.901 mmol, 28Y(-); 6H (CDCI 3,300 MHz) 7.59 ( EH, bs, H,, ). 4.19 (2H, q. J=7.1, Hh), 
3.97 (2H, d, J=5.6, HI1), 3.25 (2H, s. H, 11). 3.07 (21-1, ,, H,, 1). 2.67 (8H. hs, Hj+e), 1.47 
(9H, s, H; ), 1.28 (3H, t, J= 7.1, H,, ); 8c (CDCl3,75 MHz) 170.8 (C). 170.6 (C). 169.3 
(C), 82.6 (C), 61.6 (CH, ), 61.1 (CH, ), 59.6 (CH, ), 53.6 (CH-)), 53.3 (CH, ), 41.8 (CU2), 
28.5 (CH3), 14.7 (CH3): LCMS (method 1) ml,. 44.3, retention time 6.31 minutes. 
4.3.2 Synthesis of piperazine (2) via alternative protecting groups 
(4-tert-Butoxycarbonylmethyl-piperazin-l-y l)-acetic acid ethyl ester (7) 
Conditions adapted from Witiak. l 
0 ýN"7'y 
o Piperazin-l-yl-acetic acid ethyl ester (3). (6.73 g, 39.1 
Na05 mmol) and K2CO3 (13.51 R. 97.8 mmol, -1.5 eq) were 
(7) dissolved in EtOH (100 ml). tert-Butyl 
bromoacetate 
(8.66 ml. 58.7 mmol, 1.5 eq) was then added dropwise over 15 minutes, after which the 
solution was stirred at room temperature for 24 hrs. The reaction mixture was 
filtered to 
remove the solid by-products and concentrated in vacuro to yield the title compound a, 
an orange gum (10.10 g, 35.3 mmol, 90 %). 
SH (CDCI1,300 MHz) 4.18 (2H, q, J=7.1, 
Hh), 3.21 (2H, s. Hr). 3.11 (2H, s. H, t). _1.65 (8H, 
bs, H,, +e). 1.46 (9H. ". 
H, _). 1.27 (3H, 
185 
t, J=7.1, H); Sc (CDC] , 75 MHz) 170.5 (C). 169.8 (C). 81.3 (C), 60.9 (CH, ). 60.2 
(CH, ), 59.8 (CH2), 53.2 (CH, ), 53.0 (CH, ), 28.4 (CH_, ), 14.5 (CH3); m/, (ES) '87.4 
(M+H+, 100 %), 573.6 (2M+H+, 85 %); (Found: M+, 287.1955. C1 HN,, O4 require. ; t1, 
287.1965). 
Amino-acetic acid tert-butyl ester (14) 
o An excess of ammonia (70 ml) was condensed into a reaction \ e,, sel 
H2N 
o, -ýe cooled at - 40 "C and then diluted with THE (40 ml). tert-Butyl 
(14) bromoacetate (19.82 g. 102.0 mmol) way then added to thk solution 
over 15 minutes; the resulting solution was then stirred for two hours at - 40 C. The 
reaction mixture was then allowed to warm to room temperature whilst . timing for a 
further 14 hours. The solids were filtered off and the solution c%aporatcdi to dryness. 
This yielded the title compound as a pale yellow oil (4.22 g, 32.2 mmol, 3? Y ): bH 
(CDC13,300 MHz) 3.36 (? H, s, H), 2.45 (2H, b. ti, NH, ), 1. -18 (9H, s, Hh); 8c (CDC I,, 75 
MHz) 171.4 (C), 81.6 (C), 51.2 (CH, ), 28. -I (CH3). 
H NMR is consistent with that reported by Lugtenburg et al. 3 
(4-tert-Butoxycarbonylmethyl-piperazin-l-yl)-acetic acid benzyl ester (11) 
0 rN 
0,,, < Piperazine (7) (0.50 ý-,, 1.75 mmol) was 
d0eN 
J9 
0i dissolved in dry THE (10 ml). then benzyl 
ar (11) alcohol (0.72" ml, 6.99 mmol, 4 eq) and NaH (60 
b 
Y/r in mineral oil, ?0 mfg) were added to the 
stirred solution. The reaction was stirred at room temperature for 4.5 days, at ww 11 ich 
point MS indicated un-reacted piperazine (7) was still present. The reaction mixture was 
therefore concentrated under reduced pressure and then re-treated with bent} I alcohol 
(0.72 ml, 6.99 mmol, 4 eq) and NaH (60 Y/r in mineral oil, 20 mg) in dry THE (10 ml). 
After a further 24 hrs stirring at room temperature the reaction had gone to completion 
as judged by MS, and the reaction mixture was concentrated in i'aciro. The resultant 
solid was then dissolved in EtOAc (30 ml) and extracted with 0.25 M HCI solution (2 x 
50 ml). The aqueous layers were then combined and basified (pH 8-9) with solid 
Na'CO3, before being extracted with DCM (3 x 50 ml). The organic layers were 
combined, dried with MgSO4, concentrated in ivaciio and then purified by preparative 
LCMS (method 2) to yield the title compound as a pale yellow oil, (0.431 g, 1.24 mmol, 
71 SH (CDCI. i, 300 MHz) 7.33-7.20 (5H, m, H, -, 
), 5.16 (2H, s, HA , 
3.2 (2H, 
H, n, ), 3.17 (2H, s. Hen, ), -1.67 (8H, 
hs. H,,, ), 1.46 (9H, s. H, ): be (CDCh, 75 NIHz) 170.4 
186 
(C), 129.0 (CH), 128.8 (CH), 81.9 (C), 66.8 (CH, ), 60.2 (CH, ). 59.7 (CH, ). 53.1 (CH, ) 
28.5 (CH3). 
(4-tert-B utoxycarbonylmethyl-piperazin-1-yl)-acetic acid 2-trimethylsilaný I-ethyl 
ester 
Conditions adapted from Horton` and Mukaiyama. ' 
Io 
rN 
Io 
Piperazine (7) (0.20 Q, 0.70 mmol) ý\ aý di. ýol \ ed 
s" DI in CH3CN ( 2.5 ml) and a solution of lithium 1-1 
(9) hydroxide (88 mg, 2.10 mmol, 3 eq) in ýv ater 
(2.5 ml) was added. The solution was stirred for 40 minutes and then evaporated to 
dryness. The residue was dissolved in anhydrous DCM (10 ml) and Et, N (0.21 ml, 0.16 
mmol, 2.2 eq), 2-trimethylsilanyl-ethanol (83 mg, 0.70 mmol, I eq) and 2-chloro-l- 
methyl-pyridinium iodide (0.21 g, 0.84 mmol, 1.2 eq) were added and the solution ww a, 
stirred at room temperature. After -80 hrs stirring starting material , till remained, as 
indicated by MS. A further portion of 2-chloro-l-methyl-pyridinium iodide ((1.357 g. 
1.40 mmol) was added and the stirring continued for a further 72 hrs. The reaction 
mixture was diluted with DCM (40 ml) and then washed with water (4 x 50 ml), the 
aqueous layers were combined and extracted with DCM (50 ml), the organics were 
combined, dried with MgSO4, filtered and evaporated to dryness. This gave the title 
compound as a brown gum (0.043 g, 0.35 mmol, 17 C/C) 8H (CDCl3,300 MHz) 4.18 (2H, 
m, He ), 3.15 (2H, s, Hd/g), 3.09 (2H, s. Heg), 2.63 (8H, bs, He+F). 1.42 (9H, s, Hh ), 0.97 
(2H, m Hb), 0.00 (9H, s, Ha); nn/, (ES) 359.4 (M+H+, 100 ck ), 314.5 (M-`Bu+H+, 15 %). 
4.3.3 Piperazine (2) via the benzyl ester 
(4-Benzyloxycarbonylmethyl-pipe razin-1-yl)-acetic acid (16) 
OH Piperazine (7) (0.50 g, 1.75 mmol) ývas 
dissolved in 
o ýN9 
dry THE (10 ml), then benzyl alcohol (0.72 ml, 
f, 
"dýoýNJ9 O 
e' (16) 6.99 mmol, 4 eq) and 
NaH (60 % in mineral oil, 20 
b mg) were added to the stirred solution. The solution 
was stirred at room temperature for 40 hrs. LCMS analysis of the reaction mixture 
indicated that the reaction had still not gone to completion. The reaction mixture was 
therefore concentrated under reduced pressure and then re-treated with 
benzv l alcohol 
(0.72 ml, 6.99 mmol, 4 eq) and NaH (60 9/c in mineral oil, _10 mg) 
in drv THE (10 ml). 
After a further 40 hrs stirring at room temperature the reaction mixture 'ý as 
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concentrated in vacuo. Purification by column chromatography, using a gradient elution 
beginning with 2: 1 petrol to EtOAc moving to neat EtOAc, removed two o fast eluting Ztý 
impurities. The remaining material was removed from the column bý washing ww ith neat 
MeOH and the purified by LCMS (method 1). This afforded the title compound a,, an 
orange/brown solid (0.103 g, 20 1c). 8H (CDC13,300 MHz) 7.40-7.29 (5H. m, H,, ). S. 15 
(2H, s, HA 3.52 (2H, bs, Hh), 3.45 (4H, bs, Hg), 3.33 (2H, bs, Hz), 2.89 (-114, bs, Hr): O( 
(CDC13,75 MHz) 170.1 (C), 169.5 (C), 135.8 (C), 129.0 (CH), 128.9 (CH), 128.8 CU ), 
67.0 (CH2), 59.3 (CH-, ), 58.7 (CHF), 52.7 (CHF), 50.5 (CH, ): ml, -. (ES) ? 93.3 (Nl+H+, 
100 %), 201.0 (M-tBu+H+, 75 c/c): (Found: M+, 293.1501. C15H2,, N204 requires . I/. 
293.1516). 
4-[(tert-Butoxycarbonylmethyl-carbamoyl)-methyl]-piperazin-l-yI)-acetic acid 
benzyl ester (12) 
Conditions adapted from Nozaki et al. 6'7 
NhNv Oý 
d OýNJ9 
O 
ef 
a /c 
(12) 
b 
Piperazine (16) (50 mg, 0.17 mmol ), 
glycine tert-butyl ester hydrochloride 
(29 mg. 0.17 mmol, 1 ccl ). Et3N (0.024 
ml, 0.17 mmol, I c(l) and HOBt (23 
mg, 0.17 mmol, I eq) were dissolved in 1,2-dichloroethane (10 ml). EDC (33 mg, 0.17 
mmol, I eq) and water (4 ml) were then added and the biphasic mixture was stirred for 
2.5 hrs at room temperature. The mixture was concentrated in vac«o and partitioned 
between ether (3 x 20 ml) and 0.5 M Na'C03 solution (20 ml). The combined organics 
were dried with MgSO4 and concentrated to give the title compound as a yellow oil (41 
mg, 0.1 1 mmol, 60 %); SH (CDCh, 300 MHz) 7.62-7.58 (IH, m, H; ), 7.45-7.31 (5H, m, 
Hj, 5.20 (2H, s, Hd), 3.99 (2H, d, J=5.6, H; ), 3.31 (2H, s, Hz). 3.09 (_' H, s. Hh ). 2.68 
(8H, bs, H, +_), 1.48 (9H, s, Hk); 
8c (CDCl3,75 MHz) 169.4 (C), 169.0 (C), 167.9. (C), 
134.7 (C), 127.6 (CH), 127.4 (CH), 81.1 (C), 65.4 (CH, ), 60.3 (CH, ). 58.1 (CH2). 52.3 
(CH, ), 51.9 (CH, ), 40.4 (CHF), 27.1 (CH, ), LCMS (method 1) in!: 406.2, retention time 
7.30 minutes, in! (ES) 833.4 (M-7+Na+, 14 cl/ ), 811.5 (M2+H+, 56 c/c), 406.2 (NI+H'. 
100 -/c), (Found: M+, 406.2336. C, IH32N305 requires M, 406.2336). 
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4.3.4 Convergent synthesis of piperazine (2) 
Piperazin-1-yl-acetic acid benzyl ester (22) 
Conditions adapted from Parker. 8 
0 NH Anhydrous piperazine (0.50 g, 4.37 mmol, 2 eq) and k_CO3 
d0e Nß%9 (0.75 g, 5.46 mmol, 2.5 eq) were stirred in dry CI1: Cti ýO 
aI (22) ml) at room temperature. Benzyl bromoacetate (0.35 ml. b 
2.18 mmol) was added slowly over ten minutes, stirring was maintained for a further 3 
hrs and then the reaction mixture was concentrated under reduced pressure. LONIS 
(method I) showed the desired product (retention time: 6.13 minn; mass found: 235.1 
nn/, ) and the dialkylated by-product (retention time: 7.53 minn; mass found: 383.1 nv. ý. 
The crude product was purified via silica Egel chromatography (gradient elution. 10 - 50 
McOH in CHCI3 ). This gave the title compound as pale yellow solid (0.19 g, 0.81 
mmol, 37 C/0; 8H (CDCI1,300 MHz) 7.45-7.31 (5H. m, H;, _, ). 
5.20 (214. ,. H,, ), 3.29 (214, 
s, He), 2.98 (4H, t, J=4.9, Hl/,, ), 2.60 (4H, t, J=4.9, Hti_). 8c (CDC1I, 75 MHz) 170.6 
(C), 136.1 (C). 129.0 (CH), 127.8 (CH). 127.8 (CH), 66.8 1C11 . 
60.3 SCH, ), 54.4 
(CH, ), 46.2 (CHF): LCMS (method 1) m/: 235.3, retention time 6.17 minutes: 'iV: (f `, S) 
235.1 (M+H+, 100 c/c); (Found: M. 235.1432. C13H19N, O2 requires, 11,215.1441). 
(2-Chloro-acetylamino) -acetic acid tert-butyl ester (31) 
o tert-Butyl glycine hydrochloride ( 1.00 g, 5.97 mmol) and 
CI a 
Nbý 'a d DIPEA (3.12 ml, 
17.91 mmol, 3 eq) were dissolved in dr' 
0 (31) DCM (5 ml) and stirred at room temperature.. solution of 
chloroacetylchloride (0.48 ml. 5.97 mmol, I eq) in DCM (10 mi) was added sloww Iy to 
the reaction mixture over approximately 1 hr, whilst stirring wwas maintained. The 
colourless solution turned amber on addition of the chloroacetylchloride and darkened 
to browniblack by the time the addition was complete. The reaction mixture was stirred 
for a further 14 hr at room temperature and then evaporated to dryness. 
The crude solid 
was partitioned between EtOAc (200 ml) and water (300 ml). 
The aqueous layer Asa, 
then extracted with a further portion of EtOAc (200 ml). The organics were then 
combined, dried with MgSO4, filtered and evaporated. 
The resultant oily solid was 
purified via silica gel chromatography using a 15 1/ ether 
in CHCI, as the eluent. which 
afforded the title compound as a yellow crystalline solid (0.90 g. 
4.34 mmol, 73 
(Found: C, 46.4: H, 6.65: N, 6.5: Cl, 17.2: C8H14C1N03 requires: 
C. 46.3: H. 6.80; N. 
6.8; Cl, 17.1 %), 6H (CDCII. 300 MHz) 7.02 (1H, m, Hb), 4.02 (2H. s. H. 3.91 (2H, 
d. 
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J=5.1, Ha), 1.50 (9H, s, Hd); Sc(CDCl3,75 MHz) 168.7(C), 166.4 (C). Sý. 2 (Cý. 42.8 
(CH2), 42.6 (CH, ), 28.4 (CH3); LCMS (method 1) fn/; 208.4. retention time 8.06 
minutes; iii/ (ES) (Found: M+, 152.0110. C4H7NO3CI requires ; t-1,152.0114). 
4.3.5 Piperazine methyl esters 
2-Amino-propionic acid methyl ester hydrochloride (34)9 
0 Acetyl chloride (7.10 ml, 100 mmol, 3 eq) was added dropwise to 
H2N", 
Aoe 
stirred dry MeOH (40 ml) at 0C and stirring maintained for 15 minutes 
(34) 
after completion of the addition. Glycine (2.5O g, 33 mmol) was then 
added in small portions with vigorous stirring. This solution was refluxed for 3 hrs. The 
reaction mixture was then concentrated under vacuum and afforded the title compound 
as a white powdery solid (4.15 g. 33 mmol, 99 9c): (Found: C. 28.5: H. 6.30; N, 11.0-, 
Cl, 28.1; C3H8CINO2 requires: C, 28.7; H, 6.42: N, 11.2. Cl. 28.2 9c): SH (DO, 300 
MHz) 3.89 (2H, s. Ha), 3.79 (3H, s, flh): Sc (D2O, 75 MHz) 169.1 (C), 53.7 (CH3), 4O. 4 
(CH, ). 
'H NMR is consistent with that reported by Caballero et al. 10 and Stammer et All 
{4-[(Methoxycarbonylmethyl-carbamoyl)-methyl]-piperazin-l-yl}-acetic acid tert- 
butyl ester (35) 
Conditions adapted from Horton4 and Nozaki. 
'2 
Ho 
Piperazine (7) (0.50 g. 1.75 mmol) wa,, 
f 
0Ng ooh dissolved in CH, CN (5 ml) and a solution of 
N 
Jd 
0 (35) lithium hydroxide monohydrate (0.22 g. 5.25 
mmol, 3 eq) in water (5 ml) was added and the resultant solution was strired at room 
temperature for 45 min and then concentrated under reduced pressure. Glycine methyl 
ester hydrochloride (34) (0.33 g, 2.63 mmol, 1.5 eq), Et3N (0.37 ml, 
2.63 mmol, 1.5 eq), 
HOBt (0.36 163 mmol, 1.5 eq) and EDC (0.50 g. 2.63 mmol, 1.5 eq) were added to 
this residue, which was then dissolved in anhydrous DMF (25 ml). 
The mixture \ýaý 
stirred for 44 hrs at room temperature and then diluted with water (100 ml). 
The 
solution was saturated with solid NaCl, then made 
basic (pH 7.5 - 8) with saturated 
NaHCO, solution. This was then extracted with ether (5 x 
100 ml). The organics ýý ere 
then combined, dried (MgSO4), filtered and concentrated 
in vacuo. This afforded the 
title compound as an orange/brown oil (0.30 a. 
0.91 mmol, H (CDCI ;. 300 
MHz) 7.67 OH, m, Hf), 4.11 (2H, d, J=5.1, H_). 3.80 (3H. s. 
Hh), ). 17 (2H. ,. Hh). 3.10 
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(2H, s, He), 2.69 (8H, bs, He+d), 1.51 (9H, s, H;, ); Sc (CDC13,75 MHz) 171.1 (C). 170.9 
(C), 169.9. (C), 81.7 (C), 61.6 (CH, ), 60.1 (CH2), 53.7 (CH, ), 53.2 (CH, ), 5" .8 (C11 . 
41.0 (CH, ), 28.5 (CH3): LCMS (method 1) m/: 330.3, retention time 5.91 minute.: in!: 
(ES) (Found: M+, 330.2036. C15H-, gN305 requires Al, 330 2029). 
2-Amino-3-phenyl-propionic acid methyl ester hydrochloride (37)9 
re Acetyl chloride (1.29 ml, 18.0 mmol, 3 eq) was added dropwke to 
d dry MeOH (15 ml) at 0ýC and stirring maintained for 10 minutes b 
ýo H 
o"'f after completion of the addition. D-Phenylalanine (1.00 g. 6.1 3N 
0 (37) mmol) was then added in small portions with vigorous stirring. 
This solution was refluxed for 3 hrs. The reaction mixture ww as then concentrated under 
d dry MeOH (15 ml) at 0ýC and stirring maintained for 10 minutes b 
ýo HDOf after completion of the addition. D-Phenylalanine (1.00 g. 6.1 3N II 
0 (37) mmol) was then added in small portions with vigorous stirring. 
vacuum to afford the title compound as a white powdery solid (I. 2k) g. 5.99 mmol, 99 
%); mp 157-159 "C (lit. '3 159-161 "C); [aID27 -? 5.6 (c 1.00 in %lCOHº: (lit. 
13 
-16.5 in 
MeOH); 8H (D, O, 300 MHz) 7.43-7.26 (3H, m, Hj+r), 7. _15 (3H, 
d, J=6.7, He), 4.39 
(I H, dd, J=7.6,5.8, H), 3.80 (3H, ,,, Hf), 3.30 (1 H, dd, J= 14.5.5.8, Hh), 3.18 (I H, dd, 
J= 14.5,7.6, HO, 6c (D2O, 75 MHz) 170.4 (C), 134.1 (C), 1-9.8 CH), 1'19.7 (CH), 
128.5 (CH), 54.5 (CH), 54.0 (CH3), 36.0 (CH, ). 8H (DMSO, 300 MHz) 8.85 (3H,.,,, 
NH3), 7.40-7.16 (5H, m, H, _, ), 
4.27-4.15 (1H, m, H. 3.64 (3H,,,,,, H, ), 3.31-3.18 (111, 
m, Hh), 3.10 (1H, dd, J= 14.5,7.6, He-). 
'H NMR in DMSO is consistent with that reported by Gardossi et al. '4 
2-[2-(4-tert-Butoxycarbonylmethyl-piperazin-1-yl)-acetylaminol-3-pheny'I- 
propionic acid methyl ester (38) 
Conditions adapted from Horton4 and Nozaki. ý' 
O Hf 
N 
O 
ýNý 
q LNG. 
/ d 
IOI 
k 
aýbci 
iý / r, (38) 
Piperazine (7) (1.33 g, 4.64 mmol) was 
dissolved in CH3CN (2.5 ml) and a solution of 
lithium hydroxide monohydrate (0.58 g. 13.92 
mmol, 3 eq) in water (2.5 ml) was added. The 
resultant solution was stirred at room 
temperature for 1 hr and then concentrated under reduced pressure. 2-Phen` lalanine 
methyl ester hydrochloride (37) (1.00 fig. -1.64 mmol, I eq), Et; N (0.97 ml, 6.96 mmol, 
1.5 eq ), HOBt (0.75 g, 5.57 mmol, 1.1 eq) and EDC (0.98 Q, 5.10 mmol, 
1.1 eq) ere 
added to the residue and then dissolved in anhydrous DMF (9.5 ml). 
The mixture as 
stirred for 25 firs at room temperature, at which point 
LCNIS indicated the starting 
material had been consummed. The reaction mixture ýý as evaporated to clr\ ne' and 
the 
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product purified by silica gel column, eluting with neat EtOAc. LCNIS indicated minor 
impurities and the crude material was therefore columned on alumina using 30 % petrol 
in EtOAc as the eluent. This afforded the title compound as a brown oil (0.28 Q, 0.66 
mmol, 15 %); [a]027 -16.4 (c 1.00 in CHCL); SH (CDC13,300 MHz) 7.55 (1H, d, J= 
8.1, Hf), 7.35-7.19 (3H, m, Hh+; ), 7.12 (2H. d, J=6.4, HI), 4.89 (1H, ddd, J=8.1.6.9, 
5.5, Hg), 4.75 (3H, s, HI), 3.19 (1 H, dd, J=14.1,5.5. Hk), 3.10 (1 H, dd, J= 14.1.6.9, 
HO, 3.08 (2H, s, Hb), 3.01 (2H, d, J= 16.4, He), 2.93 (2H, d, J= 16.4. H,. ). 2.60-2.39 
(8H, m, Hc+a), 1.47 (9H. s, Ha) 6c (CDC13,75 MHz) 172.5 (C), 170.5 (C). 169.9 ý C). 
136.3 (C), 129.6 (CH), 129.1 (CH), 127.6 (CH), 81.6 (C), 61.5 (CH, ). 60. (CH, ). 53.5 
(CH-2), 53.3 (CH, ), 52.8 (CH), 52.7 (CH3), 38.1 (CH2). 28.5 (CHF): in! (ES) 420.1 
(M+H+, 100 c/c), 442.2 (M+Na+, 72 %), 420.1 (M-`Bu+H+, 51 (Found ill', 
420.2467. C22H34N305 requires M, 420.2498). 
[2-(4-tert-Butoxycarbonylmethyl-piperazin-l-yl)-acetylamino]-phenyl-acetic acid 
methyl ester (40) 
2 Conditions adapted from Horton4 and Nozaki. ' 
O Hf 
O NN O/n 
NdO 
abc 
(40) 
k 
Piperazine (7) (500 mg. 1.75 mmol) was 
dissolved in CH3CN (2 ml) and a solution of 
lithium hydroxide monohydrate (81 mg, 13.92 
mmol, 1.1 eq) in water (2 ml) was added. The 
resultant solution was strired at room 
temperature for 35 minutes and then concentrated under reduced pressure. D- 
Phenylglycine methyl ester hydrochloride (5 29 mg, ?. 62 mmol, 1.5 eq), Et,. N (1.22 ml, 
6.99 mmol, 4 eq), HOBt (283 mg, ?. 10 mmol, 1. -2 eq) and 
EDC (402 mg, 2.10 mmol, 
1.2 eq) were added and then the reactants were dissolved in anhydrous DNIF (9 ml). 
The 
mixture was stirred for 12 hrs at room temperature, at which point %IS indicated the 
starting material had been consummed. The reaction mixture was concentrated to a 
paste and then dissolved in CHCI3 (50 ml) and then washed with IM 
HCl (2 x 25 ml), 
saturated aqueous NaHCOj (2 x 25 ml) and water (2 x 25 ml). 
The aqueous layers were 
combined, made basic (pH -9.5) and extracted with ether (5 x 
50 ml). The organic", 
both ether and CHCI3, were combined, dried with MQSO4, filtered and e\ aporated 
to a 
yellow paste. The crude product was then purified 
by silica Lel column v. ith I << EtOH 
in EtOAc as the eluent, this afforded the title compound as an amber oil (0.224 g. 
5.42 
mmol, 32 %); [aID 
7 
-58.4 (c 1.00 in 
CHCI3); 6H (CDCI.;, 300 MIHz) 8.10 (1H. d, J= 
8.0, Ht), 7.40-7.29 (5H, m. Hi-k), 7.25 (21-1. d. J=8.0, H,, ), 3.73 (31-1. s. 
Hh). 3.14 (2H, 
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Hh), 3.05 (2H, s, He), 2.73-2.49 (8H, m, H, d), 1.47 (9H,,,. H,, ): bo (CDCh, 75 \IHz 
171.8 (C), 170.3 (C), 169.9 (C), 137.0 (C), 129.5 (CH), 129.0 (CH), 127.6 (('H). 81.6 
(C), 61.6 (CH1), 60.2 (CHF), 56.2 (CH), 53.7 (CH, ), 53.3 (CH1), 53. _2 (CH3). 28.6 (CH- 
Irv, (ES) 406.0 (M+H+, 100 %), 349.9 (M-`Bu+H+, 28 c/c), (Found NI+. 406.2312. 
C21H32N305 requires M, 406.2336. 
4.3.6 The rigid analogue synthesis 
1,3-Dimethyl-9-(2-trimethylsilanyl-ethoxymethyl)-3,9-dihydro-purine-2,6-dione 
(43) 
Condition adapted from Lovely et al. 15 
o Theophylline (100 mg, 0.56 mmol) was dissolved in THE (0 
N N-'9 ml) and the suspension was stirred and cooled to 0 U. NaH 3 
Nýo (60 % in mineral oil, ?4 mg, 
0.61 mmol, 1.1 eq) was added --Si N a 
bcodf in three portions and then the solution was allowed to stir 
(43) 
for 90 minutes as it warmed to room temperature. The 
mixture was again cooled to 0 -C and (2-chloromethoxv-ethyl)-trimethyl-silane (t)7.9 
µl, 0.56 mmol, I eq) was added drop wise over 5 minutes, stirring wa,, maintained and 
the mixture was allowed to warm to room temperature. After 15 hrs, MS indicated the 
starting materials had been consumed and the reaction mixture was quenched by 
addition of water (2 ml) and then concentrated under vacuum. The residue wa: 
dissolved in DCM (30 ml) and washed with water (2 x 20 ml) and brine (2 x 20 ml) and 
then dried with MgSO4, filtered and evaporated to dryness. The crude product was then 
purified via silica column using neat EtOAc as the eluent. This yielded the title 
compound as a yellow solid (0.102 g, 0.33 mmol, 59 %); (Found: C, 50.3; H, 7.25: N, 
17.9; C13H22N4O3Si requires: C. 50.3; H, 7.14: N, 18.1 Y/c) 8H (CDC13,300 MHz) 7.76 
(IH, s, He), 5.72 (2H, s, Hd), 3.66 (2H, m, H,, ), 3.63 (3H, ,, Hf), 3.44 (3H, ,, IL). 0.96 
(211, m, He), 0.00 (9H, s. Ha); Sc (CDCI3,75 MHz) 156.6 (C), 153.1 (C ). 150.3 (C), 
142.9 (CH), 108.3 (C), 76.6 (CH-, ), 68.6 (CH2). 31.3 (CH; ). 29.5 (CHF). 19.2 (CH, ). 
0.00 (CHo, LCMS (method 1) m/, 311.1, retention time 8.32 minutes. 
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[4-(1,3-Dimethyl-2,6-dioxo-2,3,6,9-tetrahydro-1 H-purin-8-ylmethyl)-piperazin-1- 
yl]-acetic acid ethyl ester (46) 
Condition adapted from Danila. 16 
oNNo 
Theophylline (0.50 g. 2.78 mmol º. piperazin- l- 
Ne 'N N_ 
y1-acetic acid ethyl ester (3) (0.48 g, 1.78 mmol, 
acdN 
-j I eq), formaldehyde (3717c in Hý_O, 0.68 ml, 8.33 O (46) 
n 
mmol, 3 eq) and acetic acid (32 . il, 0.56 rnmol. 
20 mol %) were dissolved in EtOH (10 ml) and heated to reflux. After 24 hr. LC\IS 
indicated starting materials were still present, a further portion of acetic acid (32 µl, 
0.56 mmol, 20 mol c/c) was added. TLC indicated theophylline was still present after a 
further 2 hrs, therefore solid para-formaldehyde (0.25 g, 8.33 mmol, 3 eq) and p)- 
toluene sulphonic acid (5 mg, cat. ) were added. MS after a further ?4 hrs stirring 
indicated no theophylline, the reaction mixture was concentrated under vacuum and the 
crude product was separated by silica gel column using 20 % EtOII in EtOAc as the 
eluent. The final impurities were removed by re-crystallisation from EtOH and hexane 
to yield the title compound as an off-white solid (123 mg. 0.34 mmol, 12 (Found: 
C, 52.7: H, 6.65: N, 23.1; C16H24N6O. ý requires: C. 52.7: H, 6.64: N, 23.1 ý/ý º: 6H 
(CDCl1,300 MHz) 4.19 (2H, q, J=7.1, Hb), 3.77 (2H, s. Hf), 3.62 (3H, ,, Hh), 3.45 
(3H, s, H; ), 3.23 (2H, s, He), 2.66 (8H, bs, Hd+e), 1.27 (3H, d, J=7.1,11., ): 8c (CDCI I, 75 
MHz) 170.6 (C), 154.5 (C), 152.0 (C), 151.9 (C), 149.6 (C). 107.2 (C). 61.1 (CH, ), 59.6 
(CH-7), 56.0 (CH, ), 53.5 (CH, ), 53.1 (CH, ), 30.6 (CHF), 28.8 (CH; ), 14.7 (CH3): ml: 
(ES) 365.2 (M+H+, 100 9c). 
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4.4 Synthesis of hexapeptide skeletons 
The hexapeptide skeletons are significantly more complex than the earlier compound. 
and therefore have been named with an alternative system according to the cony entions 
of Williams and co-workers. '7"8 
4.4.1 Vancomycin hexapeptide (47) synthesis 
OH 
H2N 
a `` 6 N" 
73V5 
2a, e Co 
1 OH 
0',, 3 OH 
z 
CGI 
Op5,, , 
OH 
e CI 
6 
O 
HO, 
Hb CI rl4be 
-fib H 
H z6 1HfZ: 
x_ , \Nl xa Op 
OH 
w6 c51 
', 
O C6 H w' xH H x5 ws 
cHN 
C3 x, z2 
N-IH 0H 
NW3 
WNH2 
H w7 brH 3a H 
HO C, X, eO Cs 
NH2 
0f7 OH 
OH 
d 
By the method of'Booth and 
Willicrnt. v. 17: Phenv I isothiocý anate 
(18µl, 148 pmol, 1.1 e(l) in DNlFF 
(200 µl) was added to a solution of 
vancomycin hydrochloride (200 mg, 
134 pmol) in pyridine (0.4 ml) and 
water (0.4 ml). The mixture was then 
stirred at room temperature. After 45 
hrs MS showed the vancoin`cin had 
been consumed and indicated the 
presence of the mass ion, I SS4 ml, -., 
which corresponds to the thiourea. The HO 
solution was therefore evaporated to a paste without heating. water (2 ml) added and the 
mixture lyophilised. The resultant pale brown powder was dissolved in DCM (2 ml) and 
TFA (2 ml, excess) added. This solution was stirred for two minutes, and then 
evaporated to dryness without heating. The resulting solid was then dissolved in MeOH 
and purified using HPLC, on a discovery C-18 reverse phase column, with a gradient 
elution of 0 to 10 c// CH3CN in water with a 0.1 17c TFA modifier. The resulting 
fractions containing vancomycin hexapeptide dissolved in dilute aqueous CH,, CN were 
then combined and concentrated in vacuo to yield a thick paste. This was then dissolved 
in water and lyophilised to afford the title compound as a colourless solid (72 mg, 
55 µmol, 39 %); SH (d6-DMSO, 500 MHz) 9.46 (IH, s, OH), 9.16 (1 H,,,,, OH), 9.06 
(1 H, s, OH), 8.80 (IH, br s, W; ), 8.74 (1 H, br s, Z2OH), 8.57 (1 H, d, J=5.3. \\7.8.53 
(l H, br s, W4), 7.87 (1 H, s, 6b), 7.65 (1 H, br s, W, ), 7.64 (1 H, s. 2b), 7.51 (1 H, d, J= 
8.2,2f), 7.46 OH, d, J=8.1,6f), 7.34 (1 H, d, J=8.1,6e). 7.33-7.16 (211. obs, CONH2). 
7.22(lH, d, J=8.2,2e), 7.16(1H, brs, 5b). 6.78(1H, d, J=8.9,5f). 6.72(1H, d, J= 
8.9,5e), 6.67 (1H, d, J=11.5, W(, ), 6.58 (1H, br s. \Vz), 6.41 (1H, d. J=1.7.7d), 6.27 
(l H, d, J=1.9,7f), 5.94 (1 H, d, J=5.1. Z(, OH), 5.83 (1 H, d, J=7.8.7., ). 5.64 (111, ,. 
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X4), 5.46 (1 H, d, J=5.4,4b), 5.36 (1 H, br S. V4OH), 5.29 (1 H. s, G3OH), 5.? 7 (1 H, br 
s, GI ), 5.23 (1 H, br s, V 1), 5.17 (1 H, br s, 40,5.13 (1 H, d, J= 5.1. Zh ). 5.09 (1 H, br 
G4OH), 4.68 (1 H, q, J=6.3, V5), 4.51 (1 H, br s, X, X. 4.46 (1 H. d, J=7.4. X: ). 4.44 
(1 H, d, J=5.3, X7), 4.19 (1 H, d, J= 11.5. X6), 4.07 (1 H, br s. G6OH). 3.70 (1 H. br d. J 
= 10.7, Gbd), 3.67-3.58 (1H, m, X, ), 3.59-3.50 (1H, m, G6a'), 3.54 HH, obs, G, ). 3.4( 
(IH, obs, G3), 3.28 (IH, obs, G4), 3.26 (IH, br s, G5), 3.20 (IH, br s. V4). 2.93-2.80 (IH, 
m, 3a), 2.13 (1 H, dd, J= 16.0,9.7,3a'), 1.91 (1H, br d, J 13.2. V,, ), 1.74 (1 H. br d, J= 
13.2, V, «, ), 1.31 (3H, s, VO, 1.07 (3H, d, J=6.3, V(, ). be (d6-DMSO, 75 %IHz) 172.5 
(C), 172.5 (C), 169.9 (C), 169.2 (C), 168.5 (C), 167.8 (C). 157.9 (C), 157.2 (C), 156.6 
(C), 155.1 (C), 152.7 (C), 151.2 (C), 149.7 (C). 148.3 (C). 142.6 (C), 139.1 (C). 130.0 
(C), 135.8 (CH). 135.3 (C), 131.8 (CH), 128.6 (CH). 1-17.4 (CH). 1-17.2 (CII). 127.2 
(CH), 126.9 (C), 126.4 (C), 126.1 (C), 125.4 (CH), 123.4 ((H), 1X1.6 (C). 118.1 (('). 
116.2 (CH), 116.2 (CH), 107.4 (CH), 105.7 (CH), 104.6 (CH), 102.4 (CH), 1O1.2 (('11). 
96.7 (CH), 78.1 (CH), 77.1 (CH), 76.8 (CH), 71.6 (CH), 70.6 (CH), 70.1 (CH). 63.1 
(CH), 61.8 (CH), 61.2 (CH, ), 56.7 (CH), 54.8 (CH). 53.9 (C). 53.7 (CH), 53.5 (CH), 
53.5 (CH), 51.4 (CH), 41.8 (CH, ). 33.2 (CII, ). 22.3 (CH, ), 16.9 (CH3). 
Data consistent with that reported in the William's paper and numbered as reported. '7 
BY base cvrlisation: Conditions for thiourea formation from Williams et al. , 
17 the 
cleavage and cyclisation adapted from the work of Törngvist et al. 19 
Phenyl isothiocyanate (9 µl, 74 limol, 1.1 eq) in DMF (100 pl) was added to a solution 
of vancomycin hydrochloride (100 mfg, 67 pmol) in pyridine (0.4 ml) and water (0.4 
ml). The mixture was then stirred at room temperature. After 24 hrs MS showed the 
vancomycin had been consumed and the mass ion, 1584 m/ which corresponds to the 
thiourea, was present. The solution was evaporated to a paste, then dissolved in IM 
NaHCO3 solution (30 ml, excess) and stirred for 4.5 hrs at room temperature under N. 
The reaction mixture was then washed with ether (2 x 10 ml) and evaporated to dr}ne"', 
using MeOH to azeotrope the water and prevent foaming. The resulting solid way then 
dissolved in McOH and purified using HPLC, on a Discovery C- 18 reverse phase 
column, with a gradient elution of 0 to 10 cl(- CH3CN in water with a 0.1 9/C TF. \ 
modifier. The fractions containing vancomycin hexapeptide dissol\ed in dilute aqueous 
CH3CN were then combined and concentrated in i'acuro to \ leid the title compound as 
an off-white solid (27 mgs, 20 µmol, 30 %): LCMS (method I) nVz 6621.2 (NI+2H` ion). 
retention time 5.20 minutes. NMR consistant with data from above experiment. 
196 
One pot production: Phenyl isothiocyanate (16 µl, 134 limol, 1 eq) in DIF (200 ph 
was added to a solution of vancomycin hydrochloride (200 mg, 134 pmol) in pyridine 
(0.8 ml) and water (0.8 ml). The mixture was then stirred at room temperature. 
Observations by MS over 120 hrs showed that the vancomycin had been consumed and 
converted to the hexapeptide (58) (M+H+ 1321 ifs/: ) l'ia the intermediate thiourea 
(M+H+ 1584 in ). The reaction mixture was diluted with NleOH (-4 ml) and then 
evaporated to dryness. The resultant paste was repeated azeotroped with MeOH (5 ml 
portions) to remove the remaining water. The crude solid was dissolved in DMSO and 
purified via HPLC, on a discovery C- 18 reverse phase column, with a gradient elution 
of 0 to 10 Yc CH3CN in water with a 0.1 % TFA modifier. The resulting fraction', 
containing vancomycin hexapeptide dissolved in dilute aqueous CH-, CN ýýere then 
combined and concentrated in i'acuo to afford the title compound as a thick ww hi tc (Turn 
(148 mg, 112 pmol, 83c/c); nil: (ES) 1323.5 (M+H+, 100 %). 1178.5 (iNl- 
vancosamine+H+, 15 Yc), 1016.4 (M-both sugars+H, 10 %). NMR con"istant ýýith data 
from above experiment. 
Without HPLC: Adapted from the conditions of Nicolaou. 1° 
Phenyl isothiocyanate (60 µl, 505 µmol. 1.5eq) was added to a solution of vancomycin 
hydrochloride (500 mg, 337 µmol) in pyridine (5 ml) and water (5 ml). The mixture was 
then stirred at room temperature. After 3 hrs MS showed the vancomycin had been 
consumed and the mass ion, 1584 which corresponds to the thiourea, was present. 
The solution was therefore evaporated to dryness. The resultant residue was dissolved 
in 
DCM (2.5 ml) and TFA (0.5 ml, 673 µmol, 20 eq) was added. The solution was stirred 
for 3 hrs, and then evaporated to dryness. The resultant solid was dissolved in McOH 
(-10 ml) and precipitated by the addition of acetone (-50 ml). The precipitate ww as 
collected via centri fu oration and the solids dissolved in water (-10 ml) and 
freeze-dried. 
This yielded the title compound as an off-white solid (389 mg, 
294 pmol, 87 c/c ). HPLC 
(composition indicated as a percentage by comparing relative peak areas) - peak 
l: 
retention time, 19.8 minutes, 9 (1c: peak 2: retention time, 
22.1 minutes, 78 I/-C-, peak 3: 
retention time, 26.5 minutes, 13 c/c (gradient 0- 15 c/ 
CH, CN over 30 minutes). m/Z 
(ES) 661.3 (M+2H, 100 (1c), 1323.1 (M+H+, 69 cc). 681.8 (unknown, 50 
647.3 
(unknown, 40 C/c ), 263.0 (thiohydantoin, 35 ci ). 1178.5 (Nl-v anco: amine+H+. -10 
(/c º. 
Used without further purification in coupling reactions. 
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50 mg purified via HPLC for use during the testing and afforded 32 mg of fluffy white 
solid after freeze-drying (64 % recovery, 56 % yield from vancomycin), HPLC (single 
peak) - retention time, 22.6 minutes (gradient 0- 15 % CH3CN over 30 minutes), 
retention time, 1 l. 1 minutes (gradient 0- 95 c/c CH3CN over 30 minutes): iii/, (ES) 
Found M+, 1321.3334. C59Hn3CI, NKO: 3 requires M, 1321.3378. 
4.5 Coupling of vancomycin hexapeptide and piperazine extenders 
The analogues are named based on the terminating amino acid of the extender group 
and are numbered with an extension of the numbering system used in Pearce and 
Williams. 18 
This system numbers the amino acids of vancomycin sequentially from the N-terminus 
I -7, and uses X to denote the a-protons and W to denote the protons on the amide 
nitrogens. Each proton of the residue is then denoted with the residue number and a 
letter. The extenders described here all have three amino acids (coloured red, blue and 
magenta in Figure 4.1) and are numbered sequentially from 8 to avoid confusion with 
the residues of vancomycin. The four methylenes of the piperazine ring have been 
numbered as substitutents of residue 8. 
H 
N 
0 r'Ný 
Hex N0HR 
H 
89 10 
Figure 4.1. Naming convention for extending fragments. 
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Glycine analogue (58) 
Coupling conditions adapted from Nicolaou. 20 
OH 
H2N 
46 
73 v/ 
2a, e O OH 
2 
pýpJs'ýý, ýOH 
e CI 
6 
p 
HO, _ 
Hb 
cl 
fl 
b 4eH \ 
H zs IHfz 
2 OH X. ``, N6 C5- Nc X4 p 
W, xH O C6 HH XS Ws N C3 X3 Ný2 O 
N--''H pHH` ßw3 wN 
H, w7 bfH 3a H 
HO c7 X7 eO C3. 
X8 
- NHz ýN 
Of 7 OH 8 'a 
OH O N-r, 
d 
HO 
X'° NHw 
O z 
4 
1 0Me/ 0 
Piperazine (35) (41.5 mg, 1-6 mmol) 
was dissolved in TF. -A (3 ml, e\ce ) 
and stirred for 4 hrs before being 
concentrated under vacuum and left 
under high vacuum for 14 hr to 
remove any residual TFA. 
Hexapeptide (50(83.3 mg, 63 
mmol, 0.5 eq) and HBTU (47.8 mg, 
126 mmol, 1 eq) were added to the 
residue and the solids were put under 
vacuum for 15 minutes. then flushed 
with N2, the exposure to vacuum and 
N2 flush were repeated twice more 
and then the DMF (5 nil) and D[PEA 
(58) 
(43.9 µl, -151 mmol, 
2 ey) were 
added and the solution stirred at room temperature for 3 hrs. The reaction mixture was 
diluted with CH3CN (50 ml); this precipitated the product, which was recovered is 
centrifuge. This solid was dissolved in water and purified by HPLC using a 
ThermoHypersil HyperPrep HS column and a gradient of 0- 15 % CH3CN over 30 
minutes. The product fractions were then combined and concentrated under reduced 
pressure, this yielded a paste that was freeze dried to give the title compound as a cream 
solid (28.4 mg, 29 
c/c ). bH (do-DMSO, 500 MHz) 9.45 (1 H, br s. OH), 9.16 (]H, s. OH). 
9.11 (1 H, s, OH), 8.69 (1 H, d, J=2.3, Wo, 8.46 (1H, d, J=5.2, AV7), 8.04 (1 H, ,. W4). 
7.82 (1H, s, 6b), 7.73-7.52 (3H. m, 2b, W-, Win). 7.46 (IH, d, J= 8.4.2f). 7.38-7.24 
(3H, m, 6e, 6f, CONHý), 7.20-7.11 (2H, m, 2e, 5b), 6.95 (I H, br s. W, ). 6.85 (1 H, br 
CONH2), 6.76(1H, d, J=8.5,5f), 6.70(1H, d, J=8.5,5e), 6.67(1H, d, J=11.6, Ax',, ). 
6.39 (1 H, d, J=1.8,7d), 6.24 (1 H, d, J=1.8,7f), 5.94 (2H, br s. Z2-OH, Z6-OH), 5.71 
(1 H, d, J=7.9, X4), 5.53 (1 H, s, 4b), 5.45 (1 H, br s, V4-OH), 5.34 (l H, br s. G4-OH), 
5.28-5.15 (5H, m, 4f, G. V1, Z,, G3-OH), 5.10 (1H, s, Z(, ), 4.83-4.74 ( IH, m, X, ). 4.67 
(IH, q, J=6.4, V.; ), -4.50-4.33 (3H, m, X3, X5, X7), 4.17 (IH, d, J=11.6, 
X(, ), 3.95-3.85 
(3H, m, Xio, G6-OH), 3.67 (1H, d, J= 10.7, G6a), 3.67 (2H, obi. X. X, ». 3.62' (3H, .. 
l 0Me), 3.60-2.52 (8H. m, 8a-b), 3.59-3.47 (3H. m, G6 . 
X, -. X, ). ), 3.37 OH. ohs. G. (i. 
G4), 3.27 (1 H, s, G; ). 3.17 (1 H, s. V4 ). 2.43-2.32 (1 H, m. 3a), 2.15 (I H. dd. J= 15.4. 
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4.4,3a'), 1.90 (1H, d, J= 11.1, V,, r), 1.72 (IH, d, J= 11.1, V,, y). 1.2180H.. ". A', ). 1.06 
(3H, d, J=6.4, V6); Sc (CDCI_i, 75 MHz) 172.5 (C), 172.5 (C). 171.2 (C). 170.5 C). 
170.5 (C), 170.1 (C), 170.1 (C), 169.6 (C), 169.1 (C), 167.8 (C). 167.2 (C), 157.2 (('i. 
156.6 (C), 155.1 (C), 152.3 (C), 151.3 (C), 150.1 (C), 148.3 (C). 142.5 (C). 139.5 (Cº. 
136.1 (C), 135.7 (CH), 134.6 (C), 132.0 (CH), 128.8 (CH), 127.4 (CH), 127.4 (CH). 
127.4 (CH), 126.3 (C), 126.3 (C), 126.1 (C), 125.6 (CH), 124.2 (CH). 1X3.4 (CH), 
121.6 (C), 118.0 (C), 116.3 (CH), 107.3 (CH), 105.7 (CH). 104.7 (CH). 10-1.4 (CH). 
101.3 (CH), 96.7 (CH), 78.2 (CH), 77.0 (CH), 76.7 (CH), 71.6 (CH), 70.7 (CH). 70.7 
(CH), 70.2 (CH), 63.1 (CH), 61.8 (CH), 61.3 (CH, ), 61.3 (CH, ), 61.3 (CH, ), 58.8 (CH). 
56.7 (CH), 54.9 (CH), 53.9 (C), 53.7 (CH), 51.8 (CH'j), 50.9 (CH). 40.5 (CH, ). 40.5 
(CH2), 33.2 (CH3), 22.2 (CH, ), 16.7 (CH3), (cross coupling in the HMQC also indicates 
presence of CH, signals obscured by solvent peak); HPLC (single peak) retention time, 
24.8 minutes (gradient 0- 15 CIS CH3CN over 30 minutes), in/,. (ES) 1432.9 (M- 
vancosamine+H+, 100 %), 789.2 (M+2H+, 69 (7c), 809.4 (unknown, 30 %), 127'_. 9 (Nl- 
both sugars+H+, 28 Y/c), 1577.9 (M+H+, 22 %); (Found M+, 1576.454, C,,, E1, (, CI, N110- 
requires M, 1576.4597. 
D-Phenylalanine analogue (61) 
Coupling conditions adapted from Nicolaou. 2° 
OH 
H2N 
a 
73v5 
2a. e O OH 11 
3 OH OflOH 
OO/ 
Cl' s 
OO 
HO ý2 b 
H Z6 1HbO 
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fjbeH 
1Hf O 
Z= OH 
x. , \N 
O 
wb CS 'Nc x4 
°% 
xz 
H 
0 
C, HH x5 w5 HNc, 
`x, 
Njwc2 HN 
O 
HWH b/ 
HH 
3a H 
W2 
x 
" x, eOc,. 
öa 
0f7 OH 
Cb 
NH2 
ONb O 
dd 10 
Z, 0 xý HO 
x wl 
NH 
, O 
10Me/ 
(s1) 
Piperazine (38) (127 mg, 303 µmol) 
was dissolved in TFA (4 ml. excess) 
and stirred for 3 hrs. The reaction 
mixture was then concentrated under 
vacuum and the sample left under 
high vacuum for 16 hr to remove any 
residual TFA. The residue and 
HBTU (115 mg. 303 tmol. I eq) 
were dissolved in DMF (4 ml). 
DIPEA (106 µl, 607 µmol, -1 eq) was 
added and the resultant solution was 
stirred for 15 minutes. The 
hexapeptide (50) (200 mg, 152 
mmol, 0.5 eq) ww aý put under vacuum 
for 15 minutes. while the aho\ e 
solution was stirred. The solution was then transferred via canular 
into the hexapeptide 
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and washed in with further DMF (3 ml). The resultant solution wwas stirred for ?9 hr,,, 
before being diluted with CH3CN (50 ml); this precipitated the product, ww hich 
recovered via centrifuge. This solid was washed with further CH , CN (2 x 50 ml), 
collecting via centrifuge each time. The crude solid was then dissolved in ýv ater and 
purified by HPLC using a ThermoHypersil HyperPrep HS column and a gradient of 0- 
40 % CH3CN over 30 minutes. The product fractions were then combined and freeze 
dried to give the title compound as an off-white solid (55 mg, 33. tmol. 22 %); SH (d,, - 
DMSO, 500 MHz) 9.46 (1 H, s, OH), 9.17 (1 H, s, OH ). 9.12 (1 H, ,. OH), 8.64 (1 H, br . 
WS), 8.47 (1H, br s, WO, 8.14 (1H, br s, W4). 7.83 (1H, s. 6b), 7.65 (? H. br s. AVIo, AV'=). 
7.46 (1 H, d, J=8.3,6f), 7.35 (1 H, obs, 2b), 7.34 (1 H, obs, 6e). 7.29 (1 H. obs, 1(ºd º. 
7.27 (2H, obs, l Oc), 7.21 (I H, obs, l Ob), 7.20 (1 H, obs, 2f), 7.16 (1 H, obs. 2e ), 7.16 
(1H, br s, 5b), 7.06 (IH, br s, CONH, ), 6.77 OH, br d, J=8.3,5f), 6.71 (IH, d, J=8.3, 
5e), 6.68 (1 H, br s, W(, ), 6.40 (lH, d, J=2.0,7d), 6.25 (1 H, d, J=2.0.7f), 5.94 (1 H, br 
s, Z6OH), 5.94 (1 H, br s, Z7OH), 5.70 (1 H, d, J=8.0, X4), 5.54 (1 H, s. 4b), 5.46 (111, br 
s, V4OH), 5.36 (1 H, br s. G3OH), 5.27 (1 H, obs, G4OH), 5.25 (114, obs. GI). 5.24 (114, 
obs, V 1), 5.21 (1 H, obs, 4f), 5.21 (1 H, obs, Z, ), 5.10 (1 H, br s, Z(, ), 4.79 (1 H, br ,, V), ). 
4.68 (1H, q, J=6.5, V; ), 4.61 (1H, td, J=8.5,5.1, X, ()). 4.44 (1H, obs. X; ). 4.43 (1H, 
obs, XA 4.42 (1 H, obs, X3), 4.18 (1 H, d, J= 10.7, X,, ), 4.01 (1 H, br s, G('OH), 3.72- 
3.60 (1 H, m, G(,,, ), 3.64 (3 H, s, I OMe ), 3.58-3.50 (I H, m, G61'). 3.50 (2 H, obs, Vº. 3.50 
(2H, obs, X5 ), 3.54 (1 H, obs, G, ), 3.43 (1 H, obs, Go, 3.26 (1 H, obs, G4), 3? 7 (1 H, br s. 
GS ), 3.16 (l H, br s, V4). 3.11 (1 H, dd, J= 13.7.5.1, Z 3.06-2.88 (1 H. m, Z,  ), 2.69- 
2.21 (8H, obs, 8a-b), 2.39 (1 H, obs, 3a), 2.15 (1 H, br d, J= 13.3.3a'), 1.91 (1 H, br d, J 
12.2, V,;,, ), 1.73 (1H, br d, J= 12 2, V,, y), 1.28 (3H, s, V; ), 1.07 (3H, 
d, J=6.5, V(, ): S(' 
(CDC13,75 MHz) 172.5 (C), 172.5 (C). 170.5 (C). 170.5 (C). 169.6 (C). 169.1 C. 
169.1 (C), 167.8 (C), 167.8 (C). 157.2 (C). 157.2 (C), 156.5 (C). 155.1 (C). 15'. 3 (C). 
151.3 (C), 150.1 (C). 148.3 (C). 142.5 (C). 139.5 (C). 136.9 (C). 136.1 (C), 136.1 )C). 
135.7 (CH), 134.6 (C), 132.0 (CH), 129.1 (CH). 129.1 (CH). 129.1 (CH). 1-8.8 (CH). 
128.3 (CH), 128.3 (CH), 127.4 (CH). 127.4 (CH), 126.7 (C). 1-6.7 (CH). 126.3 (C). 
126.1 (C), 125.5 (CH), 124.1 (CH), 123.4 (CH), 121.6 (C). 118.0 (C). 116.2 (CH). 
107.3 (CH), 105.7 (CH), 104.7 (CH), 102.4 (CH), 101.3 (CH). 96.7 (CH). 78.2 (CH), 
77.0 (CH). 76.7 (CH), 71.6 (CH), 70.7 (CH), 70.7 (CH). 70.2 (CH). 63.1 (CH), 61.8 
)C). (CH), 61.3 (CH-, ), 61.3 (CH, ). 61.3 (CH, ). 58.6 (CH). 56.6 (CH), 54.9 (CH). 53.9 
53.7 (CH), 52.8 (CH), 52.1 (CHF). 50.9 (CH). 36.4 (CH, ). 36.4 (CH, ), 33.2 (CH, ). 22.2 
(CH3), 16.7 (CH3), (cross coupling in the HMQC also indicates presence of CH, signal: 
obscured by solvent peak): HPLC (single peak) retention time, 
23.7 minutes (gradient 0 
201 
- 40 % CH3CN over 30 minutes), retention time, 14.9 minutes (gradient 0- 95 % 
CH3CN over 30 minutes); m/z (ES) 834.5 (M+2H, 100 %), 854.9 (unknown, 31 %), 
1668.2 (M+H+, 5 %), 1523.3 (M-vancosamine+H+, 4 %); (Found M+. 1666.5218. 
C77H86C12N11027 requires M 1666.5066. 
D-Phenylglycine analogue (63) 
Coupling conditions adapted from Nicolaou. 20 
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(63) 
Piperazine (40) (83.4 mg, 206. imol, 
1.5 eq) was dissolved in TFA (2 ml, 
excess) and stirred for 3 hrs. The 
reaction mixture was then 
concentrated and the sample left 
under high vacuum for 16 hr to 
remove any residual TFA. The 
hexapeptide (50) (181 mg, 137 
mmol) was put under vacuum for 1. S 
hrs. The residue from the TFA 
cleavage and HBTU (72.8 mg, 303 
limol, 1.4 eq) were dissolved in 
DMF (6 ml). DIPEA (96 µl, 548 
µmol, 4 eq) was added and the 
resultant solution was stirred for 45 
minutes, whilst the hexapeptide was still under vacuum. The solution was then 
transferred i'ia canular into the hexapeptide and washed in with further DMF (3 ml). 
The resultant solution was stirred for 19 hrs under N,. The reaction mixture was diluted 
with CH3CN (50 ml); this precipitated the crude product, which was recovered t'iu 
centrifuge. This solid was washed with further CH3CN (2 x 50 ml), collecting lvia 
centrifuge each time. The crude solid was then dissolved in water and purified by HPLC 
using a ThermoHypersil HyperPrep HS column and a gradient of 0- 40 c// CH3CN over 
30 minutes. The product fractions were then combined and freeze dried to give the title 
compound as an off-white solid (64 mg, 39 µmol, 28 9c ): 6H (d6-DMSO, 500 MHz) 9.46 
(IH, s, OH), 9.17 OH, s, OH), 9.15 (IH, s. OH), 8.62 (1 H, s, W; ), 8.46 (1 H, br d, J= 
4.8, W7), 8.19 (1H, S, W4), 7.83 (1H, s, 6b), 7.80-7.52 (2H, m, W. W, o). 7.57 (IH, d, J 
= 7.9,2f), 7.51 (1 H, obs, 2b). 7.46 (1 H, d, J=8.5,6f), 7.42-7.3? (5H, m, I Ob-d), 7.2 
(1H, d, J=8.5.6e). 7.21-7.13 (2H, m, 2e. 5b). 7.02 (IH, s. W; ). 6.85-6.74 (I H, m, Sf). 
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6.40 (1 H, s, 7d), 6.24 (l H, s, 7f), 5.95 (1 H, d, J=5.9, Z6-OH), 5.92 (1 H. s, Z-011). 
5.71 (1H, d, J= 7.8, X4), 5.53 (1H, s, 4b), 5.50-5.42 (2H. m, X1o, G1-OH), 5.35 (111. s, 
V4-OH), 5.30-5.16 (4H, m, 4f, G1, Vi, Z2), 5.13-5.05 (2H. M, Z6, G4-OH), 4.67 (1 H, q, J 
= 6.0, Vs), 4.52 (3H, m, X3, X5, X7), 4.18 (1H, d, J= 11. X(, ), 3.97 (1H, br ,. G6-OH). 
3.64 (3H, obs, G6a, X8, X9), 3.63 (3H, s, IOMe), 3.60-3.47 (3H, obs, G,,,,. X,. X ). 3.36 
(3H, obs, G2, G-i, G4), 3.27 (1 H, s, GS), 3.17 (1 H, d, J=6.0, V4 ), 2.98- 2.40 (8H. m, 8a- 
b), 2.37-2.25 (IH, m, 3a), 2.13 (IH, dd, J= 14.8,4.5,3a'), 1.90 (IH. dd, J= 11.2.3.5, 
V2;, x), 1.72 (1H, d, J= 11.2, V2eq), 1.28 (3H, s, VO, 1.06 (3H, d, J=6.0, V(, ); be (CD('I ;. 
75 MHz) 172.5 (C), 170.9 (C), 170.9 (C), 170.6 (C), 169.6 (C), 169.1 (C), 167.8 (C), 
167.4 (C), 157.2 (C), 156.6 (C), 155.1 (C), 152.2 (C). 1.51.2 (C). 150- (C). 148.3 (C). 
142.5 (C), 139.5 (C), 136.3 (C), 136.1 (C), 135.7 (CH), 134.6 (C), 132.0 WI 1), 128.8 
(CH), 128.8 (CH), 128.8 (CH), 128.3 (CH). 127.5 (CH), 127.5 (C11). 127.5 (CI 1). 127.4 
(CH), 127.4 (CH), 126.8 (C), 126.3 (C), 126.1 (C), 125.6 (CH), 124.0 (CH), 123.5 
(CH), 121.7 (C), 117.9(C). 116.3 (CH), 107.2 (CH), 105.8 (CH), 104.7 WI 1), 102.4 
CH), 101.3 (CH), 96.8 (CH), 78.2 (CH), 77.0 (CH), 76.7 (CI-1), 71.6 (CHº. 70.7(Cl1). 
70.7(CH), 70.2 (CH), 63.1 (CH), 61.8 (CH), 61.3 (C11, ), 61.3 (CH, ). 61.3 (CIS, ), 58.4 
(CH), 56.7 (CH), 55.8 (CH), 54.8 (CH), 53.9 (CH), 52.4 (C11 ). 51.0 (CH), 37.8 
33.2 (CH, ), 22.2 (CH3), 22.2 (CH33), 16.7 (CHF), (cross coupling in the HMQC also 
indicates presence of CH-) signals obscured by solvent peak); HPLC (single peak) 
retention time, 21.0 minutes (gradient 0- 40 % CH3CN over 30 minutes), retention 
time, 12.9 minutes (gradient 0- 95 11c CH3CN over 30 minutes); nil, (ES) 1510.1 (M- 
vancosamine+H+, 100 c/c), 827.2 (M+2H+, 67 SIC)11655.4 (M+H+. 45 c/c), 1347.9 (M- 
both sugars+H+, 17 c%c); (Found M+, 825.7420. C, (, H5, Cl2Ni 1O requires , 1.1,825.7424 
(2+ ions). 
'1U3 
4.6 Solid-phase synthesis of tripeptide (66) 
0 =d 0 Hý H 
N a°N 
bHe OH 
O9Of 
h 
rj (66) 
kýNH 
0 
Wang resin pre-loaded with FMOC D-alanine (500 
mg, 0.4 mmol) was coupled sequentially with 
FMOC D-alanine (249 mg, 0.8 mmol. 2 eq), then 
di-FMOC L-lysine (473 mg, 0.8 mmol, 2 eq ). 
Removal of the FMOC protecting groups ww as 
accomplished with 20 9c piperidine in DMIF and 
each coupling used HATU (297 mg, 0.78 mmol, 1.95 eq) and DIPEA (279 pl, 1.6 
mmol, 4 eq) dissolved in DMF. Conditions for the couplings, deprotections and kvashes 
as described in the Synthesis Notes section of the Novabiochem catolog. " After the 
final coupling the terminal amino groups of the lysine residue were deprotected ww ith 20 
C/c piperidine in DMF and then acylated by agitation with acetic anhydride (189 µl, 2 
mmol, 5 eq) and pyridine (16 RI, 0.2 mmol, 0.5 eq) dissol\ed in DMF (3 ml) for 1 hr. 
The solution was drained and washed with DMF (3 x3 ml). The resin then underwent a 
final wash with DCM (3x3 ml), 0.5 M aqueous acetic acid (3 x3 ml), DMF (3 x3 ml). 
DCM (3 x3 ml), MeOH (2 x3 ml) and was then dried over KOH under vacuum. 
The peptide was then cleaved from the resin by agitation with TFA (> ml) for 1 hr. 
followed by washing with TFA (2 x3 ml) for 2 minutes per portion. The TFA was 
collected, combined and evaporated to 0.5 ml and then pipetted into ether (5 ml), which 
produced a precipitate. The precipitate was collected and purified by HPLC using a C- 
18 reverse phase column and 0-20 % CH3CN gradient over 30 minutes. The resulting 
product fractions were combined and freeze-dried to give the title compound as an off- 
white solid (31 mg, 83 p. mol, 21 9c), HPLC (single peak) retention time, 17.3 minutes 
(gradient 0- 20 1/c CH3CN over 30 minutes), retention time, 9.4 minutes (gradient 0- 
95 % CH3CN over 30 minutes). SH (D-, O, 300 MHz) 4.21 (1 H, q, J=7.4, H, ). 4.18 (1 H. 
q, J=7 . 
2, He), 4.06 (1 H, t, J=7.2, Hh), 4.09 (1 H, t, J=6.8, Hj), 1.87 (3H, s, Ha ). 1.82 
(3H, s, Hk), 1.58 (lH, m, H. ), 1.37 (lH, quin, J=7.1, H), 1.28 (3H, 
d, J=7.4, Hd), 1.23 
(3H, d, J=7.2. He), 1.26-1.12 (1 H, m, Hh), 8c (CDCI,. 75 MHz) 176.6 (C). 174.9 (C). 
174.7 (C). 174.6 (C). 174.3 (C). 54.4 (CH). 49.8 (CH). 49.0 (CH), 39.5 (CH, ), 
30.9 
(CH, ), 28.2 (CHF). 22.7 (CHF), 22.2 (CHI). 22.0 (CHI). 16.8 (CH. ). 16.4 (CH, ): m/z 
(ES) (Found M+, 373.2076. C16Hý9N4O(, requires Al, 373.2082). 
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4.7 Testing 
4.7.1 Nanoelectrospray ionisation - mass spectrometry (nano ESI- 
MS)22 
The samples were analysed on an LCT Premier (Waters, Manchester, UK) equipped 
with a NanoMate (Advion Biosciences, Ithaca, NY. USA) automated injection and 
nano-electrospray ionisation interface. The solutions were prepared using HPLC grade 
solvents. Stock solutions (2 mM) were prepared and diluted 10-fold with 5m , %I 
ammonium acetate buffer (pH 5.1). Equal volumes of each of the five glycopeptide 
solutions were then mixed separately with the tripeptide, this produced five separate 
solutions that each contained 100 µM of glycopeptide and 100 µM of tripeptide. An 
aliquot (5 microlitres) of the sample was injected with an electrospray voltage of 2kV. 
Data were acquired over the range irr/,. 500-3000, for 50 scans at a can speed of 2.4 
seconds per scan. A separate introduction of horse heart niv oglobin ww a, used to 
calibrate the spectra. The data were processed using ylassLyn. x software by summing 
the 50 scans and producing a peak list with the profile data centred by mass. This list 
allowed the calculation of peak area as a measure of abundance for each ion. The peak 
areas for ions of each species were added together and used to calculate the 
concentration of each species, both peak area and concentration for each injection are 
shown in Table 4.2. 
2ftS 
Species Injection I Injection 2 Injection 3 
Glycopeptide Peak Conc. Peak Conc. Peak Conc. 
Area (M) Area (M) Area (M) 
I. OýS 1.06 I ý ý 
Free Drug 9.11 E-05 99.151: O5 . . )., ý I t: (l5 
E+05 E+05 E+U5 
hexapeptide 1.06 9.92 1.14 
Complex 8.88E-06 8.55E-06 6.93E-06 
E+04 E+03 E+04 
1.19 1.16 1.64 
Total Drug 1.00E-04 I. 00E-04 I. 00E-04 
E+05 E+05 [+O5 
8.40 9.90 1.05 
Free Drug 
E+04 3.08E-05 E+04 3.28E-05 E+05 3.55E-05 
1.89 2.03 1.91 
vancomycin Complex 
E+05 6.92E-05 E+05 6.72E-05 E+05 6.45E-05 
2.73 3.02 2.96 
Total Drug 
E+05 1.00E-04 E+05 1.00E-04 E+05 1.00E-04 
4.91 7.06 7.50 
Free Drug 
E+04 2.63E-05 E+04 2.83F-05 [+04 22.89E-U5 
Glycine 1.38 1.79 1.85 
Complex 
E+05 7.37E-05 E+05 7.17E-05 E+05 7.1 I E-05 
1.87 2.50 2.60 
Total Drug 
11+05 I. ()OE-O4 1-: +O5 I. 00E-04 [+05 I. ()OE-O4 
3.48 1.37 1.50 
Free Drug 
E+04 2.79E-05 E+05 2.96E-05 E+05 2.95E-05 
D-phenyl 8.97 3.25 3.59 
Complex 
glycine E+04 7.21 E-05 E+05 7.04E-05 E+05 7.05E-05 
1.24 4.62 5.09 
Total Drug 
E+05 1.00E-04 E+05 1.00E-04 E+05 I. 00E-04 
5.23 8.37 7.89 
Free Drug 
E+04 2.13E-05 E+04 2.22E-05 E+04 2.19E-05 
l D h -p eny 1.93 2.94 2.82 
alanine Complex E+05 7.87E-05 E+05 7.78E-05 E+05 7.81 E-05 
2.45 3.78 3.61 
Total Drug 
E+05 1.00E-04 E+05 1.00E-04 E+05 1.00E-04 
Cable 4. L. Data from nano C J1-ivLJ experuII IILN. 
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4.7.2 Minimum inhibitory concentration (MIC)23 
The MIC of antimicrobial agents were determined by broth microdilution in 
IsoSensitest broth (Oxoid, Basingstoke, UK) using and inoculum of 104 cells per ml for 
Escherichia coli or 106 cells per ml for Staphylococcus aureirs. Antimicrobial agents 
were prepared in a two-fold dilution series in 50Y1c DMSO (Sigma-Aldrich, Dorset, 
UK). Microwell plates with 96 wells (Nunc, Fisher Scientific, Loughborough, UK) 
containing the antimicrobial agent and bacterial suspension were incubated for 16h at 
37°C in a Spectramax 384 plus microwell plate reader (Molecular Devices. , Abingdon, 
UK), running SOFTmax PRO 3.1.1 software. Optical density readings (600nm) were 
taken at 10min intervals. Plates were shaken for 30 seconds before each reading. The 
MIC was taken as the lowest concentration of antimicrobial that prevented growth. 
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HPLC trace of hexapeptide purified by precipitation 
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Appendix B 
, I, 
HPLC trace of vancomycin before HPLC purification 
0 
M 
O 
M 
fV 
M 
O 
O 
M 
h 
N- 
N 
0 
'1 
47 
N 
N 
O 
O 
N 
Yi 
0 
h N 
0 
.^ 
0 e 
. 10 N 
_Lo 
-1o 
S N 
213 
OOOöööö0ö 
